			Occu	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Aton No.	nic Radionuclide	Class	ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
I	Hydrogen-3	Water, DAC includes skin absorption	8E+4	8E+4	2E-5	1E-7	1E-3	1E-2
		Gas (HT or T <sub>2</sub> ) Submersion <sup>1</sup>	: Use above v	alues as HT	and T <sub>2</sub> oxidize	in air and in	the body to H	ITO.
4	Beryllium-7	W, all compounds except those given for Y Y, oxides, halides, and	4E+4	2E+4	9E-6	3E-8	6E-4	6E-3
		nitrates	-	2E+4	8E-6	3E-8	-	-
4	Beryllium-10	W, see <sup>7</sup> Be	1E+3 LLI wall	2E+2	6E-8	2E-10	-	-
		Y, see <sup>7</sup> Be	(1E+3) -	- 1E+1	- 6E-9	- 2E-11	2E-5 -	2E-4 -
6	Carbon-11 <sup>2</sup>	Monoxide Dioxide	-	1E+6 6E+5	5E-4 3E-4	2E-6 9E-7	-	-
		Compounds	4E+5	4E+5	2E-4	6E-7	6E-3	6E-2
<u> </u>	Carbon-14	Monoxide Dioxide Compounds	- - 2E+3	2E+6 2E+5 2E+3	7E-4 9E-5 1E-6	2E-6 3E-7 3E-9	- - 3E-5	- - 3E-4
9	Fluorine-18 <sup>2</sup>	D, fluorides of H, Li,						
		Na, K, Rb, Cs, and Fr	5E+4 St wall	7E+4	3E-5	1E-7	-	-
		W, fluorides of Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, As, Sb, Bi, Fe, Ru, Os, Co, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, V, Nb,	(5E+4)	-	-	-	7E-4	7E-3
		Ta, Mn, Tc, and Re Y, lanthanum fluoride	-	9E+4 8E+4	4E-5 3E-5	1E-7 1E-7	-	-
11	Sodium-22	D, all compounds	4E+2	6E+2	3E-7	9E-10	6E-6	6E-5
11	Sodium-24	D, all compounds	4E+3	5E+3	2E-6	7E-9	5E-5	5E-4
12	Magnesium-28	D, all compounds except those given for W W, oxides, hydroxides,	7E+2	2E+3	7E-7	2E-9	9E-6	9E-5
$\subseteq$		carbides, halides, and nitrates	-	1E+3	5E-7	2E-9	-	-

			Осси	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (μCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
13	Aluminum-26	D, all compounds except those given for W	4E+2	6E+1	3E-8	9E-11	6E-6	6E-5
		W, oxides, hydroxides, carbides, halides, and nitrates	_	9E+1	4E-8	1E-10		
					41-0	16-10	-	-
14	Silicon-31	D, all compounds except those given for W and Y W, oxides, hydroxides,	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
		carbides, and nitrates Y, aluminosilicate glass	-	3E+4 3E+4	1E-5 1E-5	5E-8 4E-8	-	-
14	Silicon-32	D, see <sup>31</sup> Si	2E+3 LLI wall	2E+2	1E-7	3E-10	-	-
		W, see <sup>31</sup> Si	(3E+3)	- 1E+2	- 5E-8	- 2E-10	4E-5	4E-4
		Y, see <sup>31</sup> Si	-	5E+0	2E-9	7E-12	-	-
15	Phosphorus-32	D, all compounds except phosphates given for W W, phosphates of Zn <sup>2+</sup> , S <sup>3+</sup> , Mg <sup>2+</sup> , Fe <sup>3+</sup> , Bi <sup>3+</sup> ,	6E+2	9E+2	4E-7	1E-9	9E-6	9E-5
		and lanthanides	-	4E+2	2E-7	5E-10	-	•
15	Phosphorus-33	D, see <sup>32</sup> P W, see <sup>32</sup> P	6E+3 -	8E+3 3E+3	4E-6 1E-6	1E-8 4E-9	8E-5 -	8E-4 -
16	Sulfur-35	Vapor D, sulfides and sulfates	-	1E+4	6E-6	2E-8	-	-
		except those given for W	1E+4 LLI wall	2E+4	7E-6	2E-8	-	-
		W, elemental sulfur, sulfides of Sr, Ba, Ge, Sn, Pb, As, Sb, Bi, Cu, Ag, Au, Zn, Cd, Hg, W, ar Mo. Sulfates of Ca, Sr,	(8E+3) 6E+3 nd	-	-	-	1E-4	1E-3
		Ba, Ra, As, Sb, and Bi	-	2E+3	9E-7	3E-9	-	-
17	Chlorine-36	D, chlorides of H, Li, Na, K, Rb, Cs, and Fr W, chlorides of lantha- nides, Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, Ge, Sn, Pb, As, Sb, Bi,	2E+3	2E+3	1E-6	3E-9	2E-5	2E-4

			Occu	Occupational Values Effluent		Table II Effluent Concentrations		Table III Releases to Sewers
j		•	Col. 1 Oral Ingestion	Col. 2 Inhal	Col. 3	Col. 1	Col. 2	Monthly Average
Ator No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air Water (μCi/ml) (μCi/ml)		Concentration (µCi/ml)
		Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, W, Mn, Tc, and Re		2E+2	1E-7	3E-10	_	_
17	Chlorine-38 <sup>2</sup>	D, see <sup>36</sup> Cl	2E+4	4E+4	2E-5	6E-8	-	-
			St wall (3E+4)	_			3E-4	25.2
		W, see <sup>36</sup> Cl	•	5E+4	2E-5	- 6E-8	3E-4 -	3E-3 -
17	Chlorine-39 <sup>2</sup>	D, see <sup>36</sup> Cl	2E+4 St wall	5E+4	2E-5	7E-8	-	-
		W, see <sup>36</sup> Cl	(4E+4) -	- 6E+4	- 2E-5	- 8E-8	5E-4 -	5E-3 -
18	Argon-37	Submersion <sup>1</sup>	-	-	1E+0	6E-3	-	-
18	Argon-39	Submersion <sup>1</sup>	-	-	2E-4	8E-7	-	-
18	Argon-41	Submersion <sup>1</sup>	-	-	3E-6	1E-8	-	-
19	Potassium-40	D, all compounds	3E+2	4E+2	2E-7	6E-10	4E-6	4E-5
19	Potassium-42	D, all compounds	5E+3	5E+3	2E-6	7E-9	6E-5	6E-4
19	Potassium-43	D, all compounds	6E+3	9E+3	4E-6	1E-8	9E-5	9E-4
19	Potassium-44 <sup>2</sup>	D, all compounds	2E+4	7E+4	3E-5	9E-8	-	-
			St wall (4E+4)	-	-	-	5E-4	5E-3
19	Potassium-45 <sup>2</sup>	D, all compounds	3E+4	1E+5	5E-5	2E-7	-	-
			St wall (5E+4)	-	-	-	7E-4	7E-3
20	Calcium-41	W, all compounds	3E+3	4E+3	2E-6	-	-	-
			Bone surf (4E+3)	Bone surf (4E+3)	-	5E-9	6E-5	6E-4
20	Calcium-45	W, all compounds	2E+3	8E+2	4E-7	1E-9	2E-5	2E-4
20	Calcium-47	W, all compounds	8E+2	9E+2	4E-7	1E-9	1E-5	1E-4
21	Scandium-43	Y, all compounds	7E+3	2E+4	9E-6	3E-8	1E-4	1E-3

• 、

			Occu	Table I pational Valu	ies	Table Efflu Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Inhal	Col. 3 ation	Col. 1	Col. 2	Monthly Average
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
21	Scandium-44m	Y, all compounds	5E+2	7E+2	3E-7	1E-9	7E-6	7E-5
21	Scandium-44	Y, all compounds	4E+3	1E+4	5E-6	2E-8	5E-5	5E-4
21	Scandium-46	Y, all compounds	9E+2	2E+2	1E-7	3E-10	1E-5	1E-4
21	Scandium-47	Y, all compounds	2E+3 LLI wall	3E+3	1E-6	4E-9	-	-
			(3E+3)	-	-	-	4E-5	4E-4
21	Scandium-48	Y, all compounds	8E+2	1E+3	6E-7	2E-9	1E-5	1E-4
21	Scandium-49 <sup>2</sup>	Y, all compounds	2E+4	5E+4	2E-5	8E-8	3E-4	3E-3
22	Titanium-44	D, all compounds except those given for W and Y W, oxides, hydroxides, carbides, halides, and	3E+2	1E+1	5E-9	2E-11	4E-6	4E-5
		nitrates Y, SrTi0	-	3E+1 6E+0	1E-8 2E-9	4E-11 8E-12	-	: ~
22	Titanium-45	D, see <sup>44</sup> Ti W, see <sup>44</sup> Ti Y, see <sup>44</sup> Ti	9E+3 - -	3E+4 4E+4 3E+4	1E-5 1E-5 1E-5	3E-8 5E-8 4E-8	1E-4 - -	1E-3 - -
23	Vanadium-47 <sup>2</sup>	D, all compounds except those given for W	3E+4 St wall (3E+4)	8E+4 -	3E-5	1E-7 -	- 4E-4	- 4E-3
		W, oxides, hydroxides, carbides, and halides	-	1E+5	4E-5	1E-7	-	-
23	Vanadium-48	D, see <sup>47</sup> V W, see <sup>47</sup> V	6E+2 -	1E+3 6E+2	5E-7 3E-7	2E-9 9E-10	9E-6 -	9E-5 -
23	Vanadium-49	D, see <sup>47</sup> V	7E+4 LLI wall	3E+4 Bone surf	1E-5	-	-	-
		W, see <sup>47</sup> V	(9E+4) -	(3E+4) 2E+4	- 8E-6	5E-8 2E-8	1E-3 -	1E-2 -
24	Chromium-48	D, all compounds except those given for W and Y W, halides and nitrates Y, oxides and hydroxides	6E+3 - -	1E+4 7E+3 7E+3	5E-6 3E-6 3E-6	2E-8 1E-8 1E-8	8E-5 - -	8E-4 -
24	Chromium-49 <sup>2</sup>	D, see <sup>48</sup> Cr	3E+4	8E+4	4E-5	1E-7	4E-4	ب 4E-3

			Occup	Table I pational Valu	es	Table Efflue Concent	ent	Table III Releases to Sewers
_			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Ato No	mic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inhal</u> ALI (μCi)	ation DAC (µCi/ml)	Air (µCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
		W, see <sup>48</sup> Cr	-	1E+5	4E-5	1E-7	_	
		Y, see <sup>48</sup> Cr	-	9E+4	4E-5	1E-7	-	-
24	Chromium-51	D, see <sup>48</sup> Cr	4E+4	5E+4	2E-5	6E-8	5E-4	5E-3
		W, see <sup>48</sup> Cr	-	2E+4	1E-5	3E-8	-	-
		Y, see <sup>48</sup> Cr	-	2E+4	8E-6	3E-8	-	-
25	Manganese-51 <sup>2</sup>	those given for W	2E+4	5E+4	2E-5	7E-8	3E-4	3E-3
		W, oxides, hydroxides, halides, and nitrates	-	6E+4	3E-5	8E-8	-	-
25	Manganese-52m	1 <sup>2</sup>	D, see <sup>51</sup> Mn St wall	3E+4	9E+4	4E-5	1E-7	
		W, see <sup>51</sup> Mn	(4E+4) -	- 1E+5	- 4E-5	- 1E-7	5E-4	5E-3
								-
25	Manganese-52	D, see <sup>51</sup> Mn W, see <sup>51</sup> Mn	7E+2 -	1E+3 9E+2	5E-7 4E-7	2E-9 1E-9	1E-5 -	1E-4 -
25	Manganese-53	D, see <sup>51</sup> Mn	5E+4	1E+4 Bone surf	5E-6	-	7E-4	7E-3
			-	(2E+4)	-	3E-8	-	-
		W, see <sup>51</sup> Mn	-	1E+4	5E-6	2E-8	-	-
25	Manganese-54	D, see <sup>51</sup> Mn	2E+3	9E+2	4E-7	1E-9	3E-5	3E-4
		W, see <sup>51</sup> Mn	-	8E+2	3E-7	1E-9	-	-
25	Manganese-56	D, see <sup>51</sup> Mn	5E+3	2E+4	6E-6	2E-8	7E-5	7E-4
		W, see <sup>51</sup> Mn	-	2E+4	9E-6	3E-8	-	-
26	Iron-52	D, all compounds except						
		those given for W W, oxides, hydroxides,	9E+2	3E+3	1E-6	4E-9	1E-5	1E-4
		and halides		2E+3	1E-6	3E-9	-	-
26	Iron-55	D, see <sup>52</sup> Fe W, see <sup>52</sup> Fe	9E+3	2E+3	8E-7	3E-9	1E-4	1E-3
		W, SEE FE	-	4E+3	2E-6	6E-9	-	-
26	Iron-59	D, see <sup>52</sup> Fe W, see <sup>52</sup> Fe	8E+2 -	3E+2 5E+2	1E-7 2E-7	5E-10 7E-10	1E-5 -	1E-4 -
26	Iron-60	D, see <sup>52</sup> Fe W, see <sup>52</sup> Fe	3E+1 -	6E+0 2E+1	3E-9 8E-9	9E-12 3E-11	4E-7	4E-6 -
27	Cobalt-55	W, all compounds except		*		<i></i>		

.

			Осси	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers	
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly	
Atom No.	nic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inha</u> ALI (µCi)	llation DAC (μCi/ml)	Air (µCi/ml)	Water	Average Concentration	
			(µci)	(µCI)	(µC//III)	(µCi/mi)	(µCi/ml)	(µCi/ml)	
		those given for Y	1E+3	3E+3	1E-6	4E-9	2E-5	2E-4	
		Y, oxides, hydroxides, halides, and nitrates	-	3E+3	1E-6	4E-9	-	-	
27	Cobalt-56	W, see <sup>55</sup> Co	5E+2	3E+2	1E-7	4E-10	6E-6	6E-5	
		Y, see <sup>55</sup> Co	4E+2	2E+2	8E-8	3E-10	-	-	
27	Cobalt-57	W, see <sup>55</sup> Co	8E+3	3E+3	1E-6	4E-9	6E-5	6E-4	
		Y, see <sup>55</sup> Co	4E+3	7E+2	3E-7	9E-10	-	-	
27	Cobalt-58m	W, see <sup>55</sup> Co	6E+4	9E+4	4E-5	1E-7	8E-4	8E-3	
		Y, see <sup>55</sup> Co	-	6E+4	3E-5	9E-8	-	-	
27	Cobalt-58	W, see <sup>55</sup> Co	2E+3	1E+3	5E-7	2E-9	2E-5	2E-4	
		Y, see <sup>55</sup> Co	1E+3	7E+2	3E-7	1E-9	-	-	
27	Cobalt-60m <sup>2</sup>	W, see <sup>55</sup> Co	1E+6 St wall	4E+6	2E-3	6E-6	•	-	
		Y, see <sup>55</sup> Co	(1E+6) -	- 3E+6	- 1E-3	- 4E-6	2E-2 -	2E-1	
27	Cobalt-60	W, see <sup>55</sup> Co	5E+2	2E+2	7E-8	2E-10		25.6	
		Y, see <sup>55</sup> Co	2E+2	3E+1	1E-8	2E-10 5E-11	3E-6 -	3E-5 -	
27	Cobalt-61 <sup>2</sup>	W, see <sup>55</sup> Co	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3	
		Y, see <sup>55</sup> Co	2E+4	6E+4	2E-5	8E-8	-	-	
27	Cobalt-62m <sup>2</sup>	W, see <sup>55</sup> Co	4E+4 St wall	2E+5	7E-5	2E-7	-	-	
		Y, see <sup>55</sup> Co	(5E+4) -	- 2E+5	- 6E-5	- 2E-7	7E-4 -	7E-3 -	
28	Nickel-56	D, all compounds except							
		those given for W W, oxides, hydroxides,	1E+3	2E+3	8E-7	3E-9	2E-5	2E-4	
		and carbides Vapor	-	1E+3 1E+3	5E-7 5E-7	2E-9 2E-9	-	-	
28	Nickel-57	D, see <sup>56</sup> Ni	2E+3	5E+3	2E-6	7E-9	2E-5	2E-4	
		W, see <sup>56</sup> Ni Vapor	-	3E+3 6E+3	1E-6 3E-6	4E-9 9E 0	-	-	
		-				9E-9	-	-	
28	Nickel-59	D, see <sup>56</sup> Ni W, see <sup>56</sup> Ni	2E+4 -	4E+3 7E+3	2E-6 3E-6	5E-9 1E-8	3E-4	3E-3	
		Vapor	-	2E+3	3E-0 8E-7	1E-8 3E-9	-	- ``,	

No.	ic Radionuclide	Class	Col. 1 Oral Ingestion	Col. 2	Col. 3	<u> </u>		
No.	ic Radionuclide	Class		Inha	lation	Col. 1	Col. 2	Monthly Average
			ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
28	Nickel-63	D, see <sup>56</sup> Ni	9E+3	2E+3	7E-7	2E-9	1E-4	1E-3
		W, see <sup>56</sup> Ni Vapor	-	3E+3 8E+2	1E-6 3E-7	4E-9 1E-9	-	-
28	Nickel-65	D, see <sup>56</sup> Ni W, see <sup>56</sup> Ni	8E+3	2E+4 3E+4	1E-5 1E-5	3E-8 4E-8	1E-4 -	1E-3 -
		Vapor	-	2E+4	7E-6	2E-8	-	-
28	Nickel-66	D, see <sup>56</sup> Ni	4E+2 LLI wall	2E+3	7E-7	2E-9	-	-
		W. see <sup>56</sup> Ni	(5E+2)	- 6E+2	- 3E-7	- 9E-10	6E-6	6E-5
		Vapor	-	3E+3	1E-6	9E-10 4E-9	-	-
29	Copper-60 <sup>2</sup>	D, all compounds except those given for W and Y	3E+4 St wall	9E+4	4E-5	1E-7	-	-
		W, sulfides, halides,	(3E+4)	-	-	-	4E-4	4E-3
_		and nitrates Y, oxides and hydroxides	-	1E+5 1E+5	5E-5 4E-5	2E-7 1E-7	-	-
29	Copper-61	D, see <sup>60</sup> Cu W, see <sup>60</sup> Cu	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3
		Y, see <sup>60</sup> Cu	-	4E+4 4E+4	2E-5 1E-5	6E-8 5E-8	-	-
29	Copper-64	D, see <sup>60</sup> Cu W, see <sup>60</sup> Cu	1E+4 -	3E+4 2E+4	1E-5 1E-5	4E-8 3E-8	2E-4 -	2E-3
		Y, see <sup>60</sup> Cu	-	2E+4	9E-6	3E-8	-	-
29	Copper-67	D, see <sup>60</sup> Cu W, see <sup>60</sup> Cu	5E+3	8E+3 5E+3	3E-6 2E-6	1E-8 7E-9	6E-5	6E-4
		Y, see <sup>60</sup> Cu	-	5E+3	2E-6	6E-9	-	-
30	Zinc-62	Y, all compounds	1E+3	3E+3	1E-6	4E-9	2E-5	2E-4
30	Zinc-63 <sup>2</sup>	Y, all compounds	2E+4 St wall (3E+4)	7E+4 -	3E-5 -	9E-8 -	- 3E-4	- 3E-3
30	Zinc-65	Y, all compounds	4E+2	3E+2	1E-7	4E-10	5E-6	5E-5
30	Zinc-69m	Y, all compounds	4E+3	7E+3	3 <b>E-</b> 6	1E-8	6E-5	6E-4
30	Zinc-69 <sup>2</sup>	Y, all compounds	6E+4	1E+5	6E-5	2E-7	8E-4	8E-3

			Occu	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers	
		- -	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average	
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)	
30	Zinc-71m	Y, all compounds	6E+3	2E+4	7E-6	2E-8	8E-5	8E-4	
30	Zinc-72	Y, all compounds	1E+3	1E+3	5E-7	2E-9	1E-5	1E-4	
31	Gallium-65 <sup>2</sup>	D, all compounds except those given for W	5E+4 St wall	2E+5	7E-5	2E-7	-	-	
		W, oxides, hydroxides, carbides, halides, and	(6E+4)	-	-	-	9E-4	9E-3	
		nitrates	-	2E+5	8E-5	3E-7	-	-	
31	Gallium-66	D, see <sup>65</sup> Ga W, see <sup>65</sup> Ga	1E+3 -	4E+3 3E+3	1E-6 1E-6	5E-9 4E-9	1E-5 -	1E-4 -	
31	Gallium-67	D, see <sup>65</sup> Ga W, see <sup>65</sup> Ga	7E+3 -	1E+4 1E+4	6E-6 4E-6	2E-8 1E-8	1E-4 -	1E-3 -	
31	Gallium-68 <sup>2</sup>	D, see <sup>65</sup> Ga W, see <sup>65</sup> Ga	2E+4 -	4E+4 5E+4	2E-5 2E-5	6E-8 7E-8	2E-4 -	2E-3	
31	Gallium-70 <sup>2</sup>	D, see <sup>65</sup> Ga	5E+4 St wall	2E+5	7E-5	2E-7	-	-	
		W, see 65Ga	(7E+4) -	- 2E+5	- 8E-5	- 3E-7	1E-3 -	1E-2 -	
31	Gallium-72	D, see <sup>65</sup> Ga W, see <sup>65</sup> Ga	1E+3 -	4E+3 3E+3	1E-6 1E-6	5E-9 4E-9	2E-5	2E-4	
31	Gallium-73	D, see <sup>65</sup> Ga W, see <sup>65</sup> Ga	5E+3 -	2E+4 2E+4	6E-6 6E-6	2E-8 2E-8	7E-5	7E-4	
32	Germanium-66	D, all compounds except those given for W	2E+4	3E+4	1E-5	4E-8	3E-4	3E-3	
		W, oxides, sulfides, and halides	-	2E+4	<b>8E-</b> 6	3E-8	-	-	
32	Germanium-67 <sup>2</sup>	D, see <sup>66</sup> Ge	3E+4 St wall	9E+4	4E-5	1E-7	-	-	
		W, see <sup>66</sup> Ge	(4E+4) -	- 1E+5	- 4E-5	- 1E-7	6E-4 -	6E-3 -	
32	Germanium-68	D, see <sup>66</sup> Ge	5012						
20	Jermannum-08	D, see <sup>66</sup> Ge	5E+3 -	4E+3 1E+2	2E-6 4E-8	5E-9 1E-10	6E-5 -	6E-4 -	
32	Germanium-69	D, see <sup>66</sup> Ge	1E+4	2E+4	6E-6	2E-8	2E-4	2E-3	

· \* -

			Occu	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Aton No.	nic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inha</u> ALI (μCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		W, see <sup>66</sup> Ge	-	8E+3	3E-6	1E-8	-	-
32	Germanium-71	D, see <sup>66</sup> Ge	5E+5	4E+5	2E-4	6E-7	7E-3	7E-2
		W, see <sup>66</sup> Ge	-	4E+4	2E-5	6E-8	-	-
32	Germanium-75 <sup>2</sup>	D, see <sup>66</sup> Ge	4E+4 St wall	8E+4	3E-5	1E-7	-	-
		W, see <sup>66</sup> Ge	(7E+4) -	- 8E+4	- 4E-5	- 1E-7	9E-4 -	9E-3 -
32	Germanium-77	D, see <sup>66</sup> Ge W, see <sup>66</sup> Ge	9E+3 -	1E+4 6E+3	4E-6 2E-6	1E-8 8E-9	1E-4 -	1E-3 -
32	Germanium-78 <sup>2</sup>	D, see <sup>66</sup> Ge	2E+4 St wall	2E+4	9E-6	3E-8	-	-
		W, see 66Ge	(2E+4) -	- 2E+4	- 9E-6	- 3E-8	3E-4 -	3E-3 -
· <u> </u>	Arsenic-69 <sup>2</sup>	W, all compounds	3E+4 St wall	1E+5	5E-5	2E-7	-	-
			(4E+4)	-	-	-	6E-4	6E-3
33	Arsenic-70 <sup>2</sup>	W, all compounds	1E+4	5E+4	2E-5	7E-8	2E-4	2E-3
33	Arsenic-71	W, all compounds	4E+3	5E+3	2E-6	6E-9	5E-5	5E-4
33	Arsenic-72	W, all compounds	9E+2	1E+3	6E-7	2E-9	1E-5	1E-4
33	Arsenic-73	W, all compounds	8E+3	2E+3	7E-7	2E-9	1E-4	1E-3
33	Arsenic-74	W, all compounds	1E+3	8E+2	3E-7	1E-9	2E-5	2E-4
33	Arsenic-76	W, all compounds	1E+3	1E+3	6E-7	2E-9	1E-5	1E-4
33	Arsenic-77	W, all compounds	4E+3 LLI wall	5E+3	2E-6	7E-9	-	-
			(5E+3)	-	-	-	6E-5	6E-4
33	Arsenic-78 <sup>2</sup>	W, all compounds	8E+3	2E+4	9E-6	3E-8	1E-4	1E-3
34	Selenium-70 <sup>2</sup>	D, all compounds except those given for W W, oxides, hydroxides, carbides, and	2E+4	4E+4	2E-5	5E-8	1E-4	1E-3
$\subseteq$		elemental Se	1E+4	4E+4	2E-5	6E-8	-	-

			Occu	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inha</u> ALI (µCi)	l <u>lation</u> DAC (μCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
34	Selenium-73m <sup>2</sup>	D, see <sup>70</sup> Se W, see <sup>70</sup> Se	6E+4 3E+4	2E+5 1E+5	6E-5 6E-5	2E-7 2E-7	4E-4 -	4E-3
34	Selenium-73	D, see <sup>70</sup> Se W, see <sup>70</sup> Se	3E+3 -	1E+4 2E+4	5E-6 7E-6	2E-8 2E-8	4E-5	4E-4 -
34	Selenium-75	D, see <sup>70</sup> Se W, see <sup>70</sup> Se	5E+2 -	7E+2 6E+2	3E-7 3E-7	1E-9 8E-10	7E-6	7E-5 -
34	Selenium-79	D, see <sup>70</sup> Se W, see <sup>70</sup> Se	6E+2 -	8E+2 6E+2	3E-7 2E-7	1E-9 8E-10	8E-6 -	8E-5 -
34	Selenium-81m <sup>2</sup>	D, see <sup>70</sup> Se W, see <sup>70</sup> Se	4E+4 2E+4	7E+4 7E+4	3E-5 3E-5	9 <b>E-8</b> 1E-7	3E-4 -	3E-3 -
34	Selenium-81 <sup>2</sup>	D, see <sup>70</sup> Se	6E+4 St wall	2E+5	9E-5	3E-7	-	-
		W, see <sup>70</sup> Se	(8E+4) -	- 2E+5	- 1E-4	- 3E-7	1E-3 -	1E-2 -
34	Selenium-83 <sup>2</sup>	D, see <sup>70</sup> Se W, see <sup>70</sup> Se	4E+4 3E+4	1E+5 1E+5	5E-5 5E-5	2E-7 2E-7	4E-4 -	4E-3 -
35	Bromine-74m <sup>2</sup>	D, bromides of H, Li, Na, K, Rb, Cs, and Fr	1E+4 St wall	4E+4	2E-5	5E-8	-	-
		W, bromides of lantha- nides, Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, Ge, Sn, Pb, As, Sb, Bi, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Mn,	(2E+4)	-	-	-	3E-4	3E-3
		Tc, and Re	-	4E+4	2E-5	6E-8	-	-
35	Bromine-74 <sup>2</sup>	D, see <sup>74m</sup> Br	2E+4 St wall (4E+4)	7E+4 -	3E-5	1E-7	- 5E-4	- 5E-3
		W, see <sup>74m</sup> Br	-	- 8E+4	- 4E-5	- 1E-7	-	- -

ار \_

			Occu	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers	
			Col. 1 Oral Ingestion	Col. 2		Col. 1	Col. 2	Monthly Average	
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)	
35	Bromine-75 <sup>2</sup>	D, see <sup>74m</sup> Br	3E+4 St wall	5E+4	2E-5	7E-8	-	-	
		W, see <sup>74m</sup> Br	(4E+4) -	- 5E+4	- 2E-5	- 7E-8	5E-4 -	5E-3 -	
35	Bromine-76	D, see <sup>74m</sup> Br W, see <sup>74m</sup> Br	4E+3 -	5E+3 4E+3	2E-6 2E-6	7E-9 6E-9	5E-5 -	5E-4 -	
35	Bromine-77	D, see <sup>74m</sup> Br W, see <sup>74m</sup> Br	2E+4 -	2E+4 2E+4	1E-5 8E-6	3E-8 3E-8	2E-4 -	2E-3 -	
35	Bromine-80m	D, see <sup>74m</sup> Br W, see <sup>74m</sup> Br	2E+4 -	2E+4 1E+4	7E-6 6E-6	2E-8 2E-8	3E-4 -	3E-3 -	
35	Bromine-80 <sup>2</sup>	D, see <sup>74m</sup> Br	5E+4 St wall	2E+5	8E-5	3E-7	-	-	
		W, see <sup>74m</sup> Br	(9E+4) -	- 2E+5	- 9E-5	- 3E-7	1E-3 -	1E-2 -	
- 35	Bromine-82	D, see <sup>74m</sup> Br W, see <sup>74m</sup> Br	3E+3 -	4E+3 4E+3	2E-6 2E-6	6E-9 5E-9	4E-5 -	4E-4 -	
35	Bromine-83	D, see <sup>74m</sup> Br	5E+4 St wall	6E+4	3E-5	9E-8	-	-	
		W, see <sup>74m</sup> Br	(7E+4) -	- 6E+4	- 3E-5	- 9E-8	9E-4 -	9E-3 -	
35	Bromine-84 <sup>2</sup>	D, see <sup>74m</sup> Br	2E+4 St wall	6E+4	2E-5	8E-8	-	-	
		W, see <sup>74m</sup> Br	(3E+4) -	- 6E+4	- 3E-5	- 9E-8	4E-4 -	4E-3 -	
36	Krypton-74 <sup>2</sup>	Submersion <sup>1</sup>	-	-	3E-6	1E-8	-	-	
36	Krypton-76	Submersion <sup>1</sup>	-	-	9E-6	4E-8	-	-	
36	Krypton-77 <sup>2</sup>	Submersion <sup>1</sup>	-	-	4E-6	2E-8	-	-	
36	Krypton-79	Submersion <sup>1</sup>	-	-	2E-5	7E-8	-	-	
36	Krypton-81	Submersion <sup>1</sup>	-	-	7E-4	3E-6	-	-	
36	Krypton-83m <sup>2</sup>	Submersion <sup>1</sup>	-	-	1E-2	5E-5	-	-	
36	Krypton-85m	Submersion <sup>1</sup>	-	-	2E-5	1E-7	-	-	

			Осси	Table I pational Val	ues	Table Efflu Concen	ent	Table III Releases to Sewers
		-	Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ΑLΙ (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
36	Krypton-85	Submersion	-	-	1E-4	7E-7	-	-
36	Krypton-87 <sup>2</sup>	Submersion <sup>1</sup>	-	-	5E-6	2E-8	-	-
36	Krypton-88	Submersion <sup>1</sup>	-	-	2E-6	9E-9	-	-
37	Rubidium-79 <sup>2</sup>	D, all compounds	4E+4 St wall	1E+5	5E-5	2E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3
37	Rubidium-81m <sup>2</sup>	D, all compounds	2E+5 St wall	3E+5	1E-4	5E-7	-	-
			(3E+5)	-	-	-	4E-3	4E-2
37	Rubidium-81	D, all compounds	4E+4	5E+4	2E-5	7E-8	5E-4	5E-3
37	Rubidium-82m	D, all compounds	1E+4	2E+4	7E-6	2E-8	2E-4	2E-3
37	Rubidium-83	D, all compounds	6E+2	1E+3	4E-7	1E-9	9E-6	9E-5
37	Rubidium-84	D, all compounds	5E+2	8E+2	3E-7	1E-9	7E-6	7E-5
37	Rubidium-86	D, all compounds	5E+2	8E+2	3E-7	1E-9	7E-6	7E-5
37	Rubidium-87	D, all compounds	1E+3	2E+3	6E-7	2E-9	1E-5	1E-4
37	Rubidium-88 <sup>2</sup>	D, all compounds	2E+4 St wall	6E+4	3E-5	9E-8	-	-
			(3E+4) <sup>-</sup>	-	-	-	4E-4	4E-3
37	Rubidium-89 <sup>2</sup>	D, all compounds	4E+4 St wall	1E+5	6E-5	2E-7	-	-
			(6E+4)	-	-	-	9E-4	9E-3
38	Strontium-80 <sup>2</sup>	D, all soluble compounds except SrTiO Y, all insoluble com-	4E+3	1E+4	5E-6	2E-8	6E-5	6E-4
		pounds and SrTi0	-	1E+4	5E-6	2E-8	-	-
38	Strontium-81 <sup>2</sup>	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	3E+4 2E+4	8E+4 8E+4	3E-5 3E-5	1 <b>E-7</b> 1E-7	3E-4 -	3E-3 -
38	Strontium-82	D, see <sup>80</sup> Sr	3E+2 LLI wall	4E+2	2E-7	6E-10	-	-
		Y, see <sup>80</sup> Sr	(2E+2) 2E+2	- 9E+1	- 4E-8	- 1E-10	3E-6 -	3E-5 🤍

				Occu	Table I pational Valu	es	Table Efflue Concent	ent	Table III Releases to Sewers
				Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
	tom No.	ic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inhal:</u> ALI (µCi)	ation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
					<del></del>				
	38	Strontium-83	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	3E+3 2E+3	7E+3 4E+3	3E-6 1E-6	1E-8 5E-9	3E-5 -	3E-4 -
:	38	Strontium-85m <sup>2</sup>	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	2E+5 -	6E+5 8E+5	3E-4 4E-4	9E-7 1E-6	3E-3 -	3E-2
-	38	Strontium-85	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	3E+3 -	3E+3 2E+3	1E-6 6E-7	4E-9 2E-9	4E-5 -	4E-4 -
2	38	Strontium-87m	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	5E+4 4E+4	1E+5 2E+5	5E-5 6E-5	2E-7 2E-7	6E-4	6E-3 -
3	38	Strontium-89	D, see <sup>80</sup> Sr	6E+2 LLI wall	8E+2	4E-7	1E-9	-	-
			Y, see <sup>80</sup> Sr	(6E+2) 5E+2	- 1E+2	- 6E-8	- 2E-10	8E-6 -	8E-5 -
3	38	Strontium-90	D, see <sup>80</sup> Sr	3E+1 Bone surf	2E+1 Bone surf	8E-9	-	-	-
$\smile$			Y, see <sup>80</sup> Sr	(4E+1) -	(2E+1) 4E+0	- 2E-9	3E-11 6E-12	5E-7 -	5E-6 -
3	38	Strontium-91	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	2E+3	6E+3 4E+3	2E-6 1E-6	8E-9 5E-9	2E-5	2E-4 -
3	38	Strontium-92	D, see <sup>80</sup> Sr Y, see <sup>80</sup> Sr	3E+3 -	9E+3 7E+3	4E-6 3E-6	1E-8 9E-9	4E-5 -	4E-4 -
3	39	Yttrium-86m <sup>2</sup>	W, all compounds except those given for Y Y, oxides and hydroxides	2E+4 -	6E+4 5E+4	2E-5 2E-5	8E-8 8E-8	3E-4 -	3E-3 -
3	39	Yttrium-86	W, see <sup>86m</sup> Y Y, see <sup>86m</sup> Y	1E+3 -	3E+3 3E+3	1E-6 1E-6	5E-9 5E-9	2E-5 -	2E-4 -
3	39	Yttrium-87	W, see <sup>86m</sup> Y Y, see <sup>86m</sup> Y	2E+3 -	3E+3 3E+3	1E-6 1E-6	5E-9 5E-9	3E-5 -	3E-4 -
3	39	Yttrium-88	W, see <sup>86m</sup> Y Y, see <sup>86m</sup> Y	1E+3 -	3E+2 2E+2	1E-7 1E-7	3E-10 3E-10	1E-5 -	1E-4
3	39	Yttrium-90m	W, see <sup>86m</sup> Y Y, see <sup>86m</sup> Y	8E+3 -	1E+4 1E+4	5E-6 5E-6	2E-8 2E-8	1E-4 -	1E-3 -
_ <sup>3</sup>	39	Yttrium-90	W, see <sup>86m</sup> Y	4E+2 LLI wall	7E+2	3E-7	9E-10	-	-

			Occu	Table I pational Valu	es	Table Efflu Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomi No.	ic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inhal</u> ALI (µCi)	ation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentratior (µCi/ml)
							(	
			(5E+2)	-	_	_	7E-6	7E-5
		Y, see <sup>86m</sup> Y	-	6E+2	3E-7	9E-10	-	- -
39	Yttrium-91m <sup>2</sup>	W, see <sup>86m</sup> Y	1E+5	2E+5	1E-4	3E-7	2E-3	2E-2
		Y, see <sup>86m</sup> Y	-	2E+5	7E-5	2E-7	-	- -
39	Yttrium-91	W, see <sup>86m</sup> Y	5E+2 LLI wall	2E+2	7E-8	<b>2E-</b> 10	-	-
		3.7 Sóma 7	(6E+2)	-	-	-	8E-6	8E-5
		Y, see <sup>86m</sup> Y	-	1E+2	5E-8	2E-10	-	-
39	Yttrium-92	W, see <sup>86m</sup> Y	3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
		Y, see <sup>86m</sup> Y	-	8E+3	3E-6	1E-8	-	-
39	Yttrium-93	W, see <sup>86m</sup> Y	1E+3	3E+3	1E-6	4E-9	2E-5	2E-4
		Y, see <sup>86m</sup> Y	-	2E+3	1E-6	3E-9	-	-
39	Yttrium-94 <sup>2</sup>	W, see <sup>86m</sup> Y	2E+4 St wall	8E+4	3E-5	1E-7	-	-
		Y, see <sup>86m</sup> Y	(3E+4)	-	-	-	4E-4	4E-3
		I, see and Y	-	8E+4	3E-5	1E-7	-	-
39	Yttrium-95 <sup>2</sup>	W, see <sup>86m</sup> Y	4E+4 St wall	2E+5	6E-5	2E-7	-	-
		Y, see <sup>86m</sup> Y	(5E+4) -	- 1E+5	- 6E-5	- 2E-7	7E-4 -	7E-3
10	Zirconium-86							
+0	Zircolium-86	D, all compounds except those given for W and Y W, oxides, hydroxides.	1E+3	4E+3	2E-6	6E-9	2E-5	2E-4
		halides, and nitrates	-	3E+3	1E-6	4E-9	-	-
		Y, carbide	-	2E+3	1E-6	3E-9	-	-
40	Zirconium-88	D, see <sup>86</sup> Zr	4E+3	2E+2	9E-8	3E-10	5E-5	5E-4
		W, see <sup>86</sup> Zr	-	5E+2	2E-7	7E-10	-	-
		Y, see <sup>86</sup> Zr	-	3E+2	1E-7	4E-10	-	-
10	Zirconium-89	D, see <sup>86</sup> Zr	2E+3	4E+3	1E-6	5E-9	2E-5	2E-4
		W, see ${}^{86}Zr$	-	2E+3	1E-6	3E-9	-	-
		Y, see <sup>86</sup> Zr	-	2E+3	1E-6	3E-9	-	-
40	Zirconium-93	D, see <sup>86</sup> Zr	1E+3 Bone surf	6E+0 Bone surf	3E-9	-	-	-
		W, see <sup>86</sup> Zr	(3E+3)	(2E+1) 2E+1	- 1E-8	2E-11	4E-5	4E-4
		11, 500 ZI	-	Bone surf	16-0	-	-	•

			Осси	Table I pational Value	es	Table Efflu Concent	ent	Table III Releases to Sewers
, 			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Releases to
Ator No.	nic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inhala</u> ALI (µCi)	ntion DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	
<del></del>	·····			······································	· · · · · · · · · · · · · · · · · · ·			<u> </u>
		Y, see <sup>86</sup> Zr	-	(6E+1) 6E+1	- 2E-8	9E-11	-	-
		1,500 21	-	Bone surf (7E+1)	-	- 9E-11	-	-
				(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		<i>JL</i> -11		-
40	Zirconium-95	D, see <sup>86</sup> Zr	1E+3	1E+2 Bone surf	5E-8	-	2E-5	2E-4
		*** 86-	-	(3E+2)	-	4E-10	-	-
		W, see <sup>86</sup> Zr	-	4E+2	2E-7	5E-10	-	-
		Y, see <sup>86</sup> Zr	-	3E+2	1E-7	4E-10	-	-
40	Zirconium-97	D, see <sup>86</sup> Zr	6E+2	2E+3	8E-7	3E-9	9E-6	9E-5
		W, see <sup>86</sup> Zr	-	1E+3	6E-7	2E-9	-	-
		Y, see <sup>86</sup> Zr	-	1E+3	5E-7	2E-9	-	-
41	Niobium-88 <sup>2</sup>	W, all compounds except						
••		those given for Y	5E+4	2E+5	9E-5	3E-7	-	-
			St wall (7E+4)	-	•	-	1E-3	
		Y, oxides and hydroxides	-	2E+5	9E-5	3E-7	-	-
41	Niobium-89 <sup>2</sup> (66 min)	W, see <sup>88</sup> Nb	1E+4	4E+4	2E-5	6E-8	1E-4	1E-3
		Y, see <sup>88</sup> Nb	-	4E+4	2E-5	5E-8	-	-
41	Niobium-89 (122 min)	W, see <sup>88</sup> Nb	5E+3	2E+4	8E-6	3E-8	7E-5	7E-4
	· · · ·	Y, see <sup>88</sup> Nb	-	2E+4	6E-6	2E-8	-	-
41	Niobium-90	W, see <sup>88</sup> Nb	1E+3	3E+3	1E-6	4E-9	1E-5	117.4
41	Nioonani-90	Y, see <sup>88</sup> Nb	-	2E+3	1E-6	4E-9 3E-9	1E-3	
41	Niobium-93m	W, see <sup>88</sup> Nb	9E+3	2E+3	8E-7	3E-9	-	
		,	LLI wall	20.5	OL-7	512-7	-	_
			(1E+4)	-	-	-	2E-4	2E-3
		Y, see <sup>88</sup> Nb	-	2E+2	7E-8	2E-10	-	-
41	Niobium-94	W, see <sup>88</sup> Nb	9E+2	2E+2	8E-8	3E-10	1E-5	1E-4
		Y, see <sup>88</sup> Nb	-	2E+1	6E-9	2E-11	-	-
41	Niobium-95m	W, see <sup>88</sup> Nb	2E+3	3673	15 4	412 0		
41	1110010111-7.3111	TY, SEC IND	LLI wall	3E+3	1E-6	4E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
		Y, see <sup>88</sup> Nb	-	2E+3	9E-7	3E-9	-	-
ـــــــــــــــــــــــــــــــــــــ	Niobium-95	W, see <sup>88</sup> Nb	ንፑታ2	16-12	50 7	250	28 5	25.4
41	111001001-73	w, sec inu	2E+3	1E+3	5E-7	2E-9	3E-5	3E-4

•

			Occuj	Table I pational Val	ues	Table Efflu Concent	ent       H         trations $\overline{Col. 2}$ Water $C         (µCi/ml)       C         2E-5       2         3E-4       3         -       2         3E-4       2         -       2         3E-5       31         -       2         3E-5       31         -       -         2E-8       61         -       2         2E-5       51         -       -         2E-7       -         2E-7       -         7E-4       7         1E-3       11         -       -         4E-4       4         -       -         6E-8       31   $	Table III Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral	T 1				Monthly
Δ tor	Atomic Radionuclide Class		Ingestion		lation			Average
No.	the Radionuclide	Class	ALI	ALI	DAC	Air		Concentration
110.			(µCi)	(µCi)	(µCi/ml)	(µCi/ml)	(µCi/ml)	(µCi/ml)
		Y, see <sup>88</sup> Nb	-	1E+3	5E-7	2E-9	-	-
41	Niobium-96	W, see <sup>88</sup> Nb	1E+3	3E+3	1E-6	4E-9	2F-5	2E-4
		Y, see <sup>88</sup> Nb	-	2E+3	1E-6	3E-9		212-4
						02 /		
41	Niobium-97 <sup>2</sup>	W, see <sup>88</sup> Nb	2E+4	8E+4	3E-5	1E-7	3E-4	3E-3
		Y, see <sup>88</sup> Nb	-	7E+4	3E-5	1E-7		-
41	Niobium-98 <sup>2</sup>	W/ 200 88b TL	15.4					
41	191001 <b>011-98</b> -	W, see <sup>88</sup> Nb Y, see <sup>88</sup> Nb	1E+4	5E+4	2E-5	8E-8	2E-4	2E-3
		I, SEE INU	-	5E+4	2E-5	7E-8	-	-
42	Molvbdenum-90	D, all compounds except						
	<i>j</i>	those given for Y	4E+3	7E+3	3E-6	1E-8	255	3E-4
		Y, oxides, hydroxides,	0	1010	52-0	12-0	51-5	3E-4
		and MoS	2E+3	5E+3	2E-6	6E-9	-	-
42	Molybdenum-93	m	D, see <sup>90</sup> Mo	9E+3	2E+4	7E-6	15 0	
	2	Y, see <sup>90</sup> Mo	4E+3	1E+4	6E-6	2E-8		6E-56E-4
		, · · ·		12.1	OL U	21-0	-	-
42	Molybdenum-93	D, see <sup>90</sup> Mo	4E+3	5E+3	2E-6	8E-9	5E-5	5E-4
		Y, see <sup>90</sup> Mo	2E+4	2E+2	8E-8	2E-10	-	-
42	Molybdenum-99	D cao 90Ma	217 1 2	25.12		17 0		
τ2	worybuchum-99	D, see 1010	2E+3 LLI wall	3E+3	1E-6	4E-9	-	-
			(1E+3)				ar -	
		Y, see <sup>90</sup> Mo	1E+3	- 1E+3	- 6E-7	- 2E-9	2E-5	2E-4
		1,000 110	112.5	112+5	0E-7	26-9	-	-
42	Molybdenum-101	L <sup>2</sup>	D, see <sup>90</sup> Mo	4E+4	1E+5	6E-5	2E-7	
			St wall			020	22, 7	
			(5E+4)	-	-	-	7E-4	7E-3
		Y, see <sup>90</sup> Mo	-	1E+5	6E-5	2E-7	-	
12	Technotium 02-2	1	<b>.</b>					
43	Technetium-93m <sup>2</sup>		D, all comp	-		AT -		
		those given for W W, oxides, hydroxides,	7E+4	2E+5	6E-5	2E-7	1E-3	1E-2
		halides, and nitrates	-	3E+5	16 4	48 7		
		minues, and minales	-	JETJ	1E-4	4E-7	-	-
43	Technetium-93	D, see <sup>93m</sup> Tc	3E+4	7E+4	3E-5	1E-7	4 <b>F</b> -4	4E-3
		W, see <sup>93m</sup> Tc	-	1E+5	4E-5	1E-7 1E-7	-	
						•		
3	Technetium-94m <sup>2</sup>		D, see <sup>93m</sup> Tc	2E+4	4E+4	2E-5	6E-8	3E-43E-3
		W, see <sup>93m</sup> Tc	-	6E+4	2E-5	8E-8		
~	Tashast	<b>D</b> 03mm						
-3	Technetium-94	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	9E+3	2E+4	8E-6	3E-8	1E-4	1E-3
		M/ 600		2E+4	1E-5	3E-8		

			Table I Occupational Values		Table Efflue Concent	ent	Table III Releases to Sewers	
1			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
43	Technetium-95m	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	4E+3 -	5E+3 2E+3	2E-6 8E-7	8E-9 3E-9	5E-5 -	5E-4 -
43	Technetium-95	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	1E+4 -	2E+4 2E+4	9E-6 8E-6	3E-8 3E-8	1E-4 -	1E-3 -
43	Technetium-96m <sup>2</sup>	W, see <sup>93m</sup> Tc	D, see <sup>93m</sup> Tc	2E+5 2E+5	3E+5 1E-4	1E-4 3E-7	4E-7 -	2E-32E-2 -
43	Technetium-96	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	2E+3 -	3E+3 2E+3	1E-6 9E-7	5E-9 3E-9	3E-5 -	3E-4
43	Technetium-97m	I.	D, see <sup>93m</sup> Tc St wall	5E+3	7E+3	3E-6	-	6E-56E-4
		W, see 93mTc	-	(7E+3) 1E+3	- 5E-7	1E-8 2E-9	-	-
43	Technetium-97	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	4E+4 -	5E+4 6E+3	2E-5 2E-6	7E-8 8E-9	5E-4 -	5E-3 -
43	Technetium-98	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	1E+3 -	2E+3 3E+2	7E-7 1E-7	2E-9 4E-10	1E-5 -	1E-4 -
43	Technetium-99m	D, see <sup>93m</sup> Tc W, see <sup>93m</sup> Tc	8E+4 -	2E+5 2E+5	6E-5 1E-4	2E-7 3E-7	1E-3 -	1E-2
43	Technetium-99	D, see <sup>93m</sup> Tc	4E+3	5E+3 St wall	2E-6	-	6E-5	6E-4
		W, see <sup>93m</sup> Tc	-	(6E+3) 7E+2	- 3E-7	8E-9 9E-10	-	-
43	Technetium-101 <sup>2</sup>	D, see 93mTc	9E+4 St wall	3E+5	1E-4	5E-7	-	-
		W, see <sup>93m</sup> Tc	(1E+5) -	- 4E+5	- 2E-4	- 5E-7	2E-3 -	2E-2 -
43	Technetium-104 <sup>2</sup>	D, see <sup>93m</sup> Tc	2E+4 St wall	7E+4	3E-5	1E-7	-	-
		W, see <sup>93m</sup> Tc	(3E+4) -	- 9E+4	- 4E-5	- 1E-7	4E-4 -	4E-3 -
44	Ruthenium-94 <sup>2</sup>	D, all compounds except those given for W and Y W, halides	2E+4 -	4E+4 6E+4	2E-5 3E-5	6E-8 9E-8	2E-4 -	2E-3
		Y, oxides and hydroxides	-	6E+4	2E-5	8E-8	-	-

.

			Осси	Table I pational Va	lues	Table Efflu Concen	ent	Table III Releases to Sewers	)
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly	 
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)	
44	Ruthenium-97	D, see <sup>94</sup> Ru	8E+3	2E+4	8E-6	3E-8	1E-4	1E-3	
		W. see <sup>94</sup> Ru	-	1E+4	5E-6	2E-8	12-4	1E-5	
		Y, see <sup>94</sup> Ru	-	1E+4	5E-6	2E-8	-	-	
44	Ruthenium-103	D, see <sup>94</sup> Ru	2E+3	2E+3	<b>7</b> E-7	2E-9	3E-5	25.4	
		W, see <sup>94</sup> Ru	-	1E+3	4E-7	1E-9	52-5	3E-4	
		Y, see $^{94}$ Ru	-	6E+2	4E-7 3E-7	9E-10	-	-	
				5	i −يدر.	26-IV	-	-	
44	Ruthenium-105	D, see <sup>94</sup> Ru	5E+3	1E+4	6E-6	2E-8	7E-5	7E-4	
		W, see <sup>94</sup> Ru	-	1E+4	6E-6	2E-8	-	-	
		Y, see <sup>94</sup> Ru	-	1E+4	5E-6	2E-8	-	-	
44	Ruthenium-106	D, see <sup>94</sup> Ru	2E+2 LLI wall	9E+1	4E-8	1E-10	-	-	
		11/ and 94D	(2E+2)	-	-	-	3E-6	3E-5	
		W, see <sup>94</sup> Ru Y, see <sup>94</sup> Ru	-	5E+1 1E+1	2E-8 5E-9	8E-11 2E-11	-	-	
15									
45	Rhodium-99m	D, all compounds except those given for W and Y	2E+4	6E+4	2E-5	8E-8	2E 4	0E 2	$\cup$
		W, halides	-	8E+4	3E-5	1E-7	2E-4	2E-3	
		Y, oxides and hydroxides	-	7E+4	3E-5	9E-8	-	-	
45	Rhodium-99	D, see <sup>99m</sup> Rh		25.12					
		W, see <sup>99m</sup> Rh	2E+3	3E+3 2E+3	1E-6	4E-9	3E-5	3E-4	
		Y, see <sup>99m</sup> Rh	-	2E+3 2E+3	9E-7 8E-7	3E-9 3E-9	-	-	
						5 <b>L</b> -7	-	-	
5	Rhodium-100	D, see <sup>99m</sup> Rh	2E+3	5E+3	2E-6	7E-9	2E-5	2E-4	
		W, see <sup>99m</sup> Rh	-	4E+3	2E-6	6E-9	-	-	
		Y, see <sup>99m</sup> Rh	-	4E+3	2E-6	5E-9	-	-	
5	Rhodium-101m	D, see 99mRh	6E+3	1E+4	5E-6	2E-8	8E-5	8E-4	
		W, see <sup>99m</sup> Rh	-	8E+3	4E-6	1E-8	-	-	
		Y, see <sup>99m</sup> Rh	-	8E+3	3E-6	1E-8	-	-	
15	Rhodium-101	D, see <sup>99m</sup> Rh	2E+3	5E+2	2E-7	7E-10	3E-5	3E-4	
	· _	W, see <sup>99m</sup> Rh	-	8E+2	3E-7	1E-9	- -		
		Y, see <sup>99m</sup> Rh	-	2E+2	6E-8	2E-10	-	-	
5	Rhodium-102m	D, see 99mRh	1E+3 LLI wall	5E+2	2E-7	7E-10	-	-	
			(1E+3)	-	-	-	2E-5	2E-4	
		W, see <sup>99m</sup> Rh	-	4E+2	2E-7	5E-10	-	-	
		Y, see <sup>99m</sup> Rh	-	1E+2	5E-8	2E-10	-	-	
15	Rhodium-102	D, see 99mRh	6E+2	9E+1	4E-8	1E-10	8E-6	8E-5	$\sim$

-----

			Occu	Table I pational Val	ues	Table II Effluent Concentrations		Table III Releases to Sewers
/		-	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Ator No.		Class	ALI (μCi)	ALI (µCi)	DAC (µCi/ml)		Water (µCi/ml)	Concentration (µCi/ml)
		W. see <sup>99m</sup> Rh	-	2E+2	7E-8	2E-10	-	-
		Y, see <sup>99m</sup> Rh	-	6E+1	2E-8	8E-11	-	-
45	Rhodium-103m <sup>2</sup>	D, see <sup>99m</sup> Rh	4E+5	1E+6	5E-4	2E-6	6E-3	6E-2
		W, see <sup>99m</sup> Rh	-	1E+6	5E-4	2E-6	-	-
		Y, see <sup>99m</sup> Rh	-	1E+6	5E-4	2E-6	-	-
45	Rhodium-105	D, see <sup>99m</sup> Rh	4E+3 LLI wall	1E+4	5E-6	2E-8	-	-
			(4E+3)	-	-	-	5E-5	5E-4
		W, see <sup>99m</sup> Rh	-	6E+3	3E-6	9E-9	-	-
		Y, see <sup>99m</sup> Rh	-	6E+3	2E-6	8E-9	-	-
45	Rhodium-106m	D, see <sup>99m</sup> Rh	8E+3	3E+4	1E-5	4E-8	1E-4	1E-3
		W, see <sup>99m</sup> Rh	-	4E+4	2E-5	5E-8	-	-
		Y, see <sup>99m</sup> Rh	-	4E+4	1E-5	5E-8	-	-
45	Rhodium-107 <sup>2</sup>	D, see <sup>99m</sup> Rh	7E+4 St wall	2E+5	1E-4	3E-7	-	-
/		VV 99mD1	(9E+4)	-	-	-	1E-3	1E-2
		W, see <sup>99m</sup> Rh Y, see <sup>99m</sup> Rh	-	3E+5 3E+5	1E-4 1E-4	4E-7 3E-7	-	-
46	Palladium-100	D, all compounds except	1012	11710		25.0	0F 6	a
		those given for W and Y W, nitrates	1E+3	1E+3 1E+3	6E-7 5E-7	2E-9	2E-5	2E-4
		Y, oxides and hydroxides	-	1E+3 1E+3	5E-7 6E-7	2E-9 2E-9	-	-
		r, onlues and hydromues			OL-7	219	-	-
46	Palladium-101	D, see <sup>100</sup> Pd	1E+4	3E+4	1E-5	5E-8	2E-4	2E-3
		W, see <sup>100</sup> Pd	-	3E+4	1E-5	5E-8	-	-
		Y, see <sup>100</sup> Pd	-	3E+4	1E-5	4E-8	-	-
46	Palladium-103	D, see <sup>100</sup> Pd	6E+3 LLI wall	6E+3	3E-6	9E-9	-	-
			(7E+3)	-	-	-	1E-4	1E-3
		W, see <sup>100</sup> Pd	-	4E+3	2E-6	6E-9	-	-
		Y, see <sup>100</sup> Pd	-	4E+3	1E-6	5E-9	-	-
46	Palladium-107	D, see <sup>100</sup> Pd	3E+4 LLI wall	2E+4 Kidneys	9E-6	-	-	-
		MI and 10075-4	(4E+4)	(2E+4)	-	3E-8	5E-4	5E-3
		W, see $^{100}$ Pd Y, see $^{100}$ Pd	-	7E+3	3E-6	1E-8	-	-
		1,500 FU	-	4E+2	2E-7	6E-10	-	-
46	Palladium-109	D, see <sup>100</sup> Pd	2E+3	6E+3	3E-6	9E-9	3E-5	3E-4
		W, see <sup>100</sup> Pd						

			Occu	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
			Ingestion		lation			Average
No.	Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Releases to Sewers 
		Y, see <sup>100</sup> Pd	-	5E+3	2E-6	6E-9	-	-
47 5	Silver-102 <sup>2</sup>	D, all compounds except						
		those given for W and Y	5E+4 St wall	2E+5	8E-5	2E-7	-	-
			(6E+4)	-	-	-	9E-4	9E-3
		W. nitrates and sulfides	-	2E+5	9E-5	3E-7	-	-
		Y, oxides and hydroxides	-	2E+5	8E-5	3E-7	-	-
47 5	Silver-103 <sup>2</sup>	D. see $^{102}$ Ag	4E+4	1E+5	4E-5	1E-7	5E-4	517.2
		W, see $^{102}$ Ag	-	1E+5	5E-5	2E-7	JE-4	5E-3
		Y, see <sup>102</sup> Ag	-	1E+5	5E-5	2E-7 2E-7	-	-
		-						-
<b>1</b> 7 S	Silver-104m <sup>2</sup>	D, see $^{102}$ Ag	3E+4	9E+4	4E-5	1E-7	4E-4	4E-3
		W, see $^{102}$ Ag	-	1E+5	5E-5	2E-7	-	-
		Y, see <sup>102</sup> Ag	-	1E+5	5E-5	2E-7	-	-
17 S	Silver-104 <sup>2</sup>	D, see <sup>102</sup> Ag	2E+4	7E+4	3E-5	1E-7	3E-4	25.2
		W, see $^{102}$ Ag	-	1E+5	6E-5	2E-7	JE-4	JE-3
		Y, see <sup>102</sup> Ag	-	1E+5	6E-5	2E-7 2E-7	-	
		- 102 .						
47 S	Silver-105	D, see $^{102}$ Ag	3E+3	1E+3	4E-7	1E-9	4E-5	4E-4
		W. see $^{102}$ Ag	-	2E+3	7E-7	2E-9	-	-
		Y, see <sup>102</sup> Ag	-	2E+3	7E-7	2E-9	-	-
17 S	ilver-106m	D, see <sup>102</sup> Ag	8E+2	7E+2	3E-7	1E-9	1E-5	
		W, see $^{102}$ Ag	-	9E+2	4E-7	1E-9 1E-9	112-5	16-4
		Y, see <sup>102</sup> Ag	-	9E+2	4E-7	1E-9 1E-9	-	-
	11 10 52	- 102 .						
17 S	ilver-106 <sup>2</sup>	D, see <sup>102</sup> Ag	6E+4 St. wall	2E+5	8E-5	3E-7	-	
		W, see <sup>102</sup> Ag	(6E+4)	-	-	-	9E-4	9E-3
		Y, see $^{102}$ Ag	-	2E+5 2E+5	9E-5 8E-5	3E-7 3E-7	-	-
						527		
17 S	ilver-108m	D, see ${}^{102}$ Ag	6E+2	2E+2	8E-8	3E-10	9E-6	9E-5
		W, see ${}^{102}$ Ag	-	3E+2	1E-7	4E-10	-	-
		Y, see <sup>102</sup> Ag	-	2E+1	1E-8	3E-11	-	-
17 S	ilver-110m	D, see $^{102}$ Ag	5E+2	1E+2	5E-8	2E-10	6E-6	6E-5
		W, see $^{102}$ Ag		2E+2	8E-8	3E-10		
		Y, see $^{102}$ Ag	-	9E+1	4E-8	1E-10	-	-
						**		
17 S	ilver-111	D, see $^{102}$ Ag	9E+2	2E+3	6E-7	-	-	-
			LLI wall	Liver				~
			(1E+3)	(2E+3)	-	2E-9	2E-5	2E-4

---- A

			Occuj	Table I pational Valu	ies	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
			Ingestion	Inha	lation			Average
Atomi No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
		W, see $^{102}$ Ag	-	9E+2	4E-7	1E-9	_	_
		Y, see <sup>102</sup> Ag	-	9E+2	4E-7	1E-9	-	-
47	Cilman 112	D 102 A	25.12		<b>AF</b> (			
47	Silver-112	D, see $^{102}$ Ag	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4
		W, see $^{102}$ Ag	-	1E+4	4E-6	1E-8	-	-
		Y, see $^{102}$ Ag	-	9E+3	4E-6	1E-8	-	-
47	Silver-115 <sup>2</sup>	D, see <sup>102</sup> Ag	3E+4	9E+4	4E-5	1E-7	-	-
			St wall					
			(3E+4)	-	-	-	4E-4	4E-3
		W, see <sup>102</sup> Ag	-	9E+4	4E-5	1E-7	-	-
		Y, see $^{102}$ Ag	-	8E+4	3E-5	1E-7	-	-
48	Cadmium-104 <sup>2</sup>	D, all compounds except						
	Quannan 101	those given for W and Y	2E+4	7E+4	3E-5	9E-8	3E-4	3E-3
		W, sulfides, halides,	2017	7214	52-5	72-0	512-4	512-5
		and nitrates	-	1E+5	5E-5	2E-7	_	_
		Y, oxides and hydroxides	-	1E+5	5E-5	2E-7 2E-7	-	-
/ 10	O. I	D 10401	05.4		AT 6	070 0	<b>AT 1</b>	
- 48	Cadmium-107	D, see ${}^{104}Cd$	2E+4	5E+4	2E-5	8E-8	3E-4	3E-3
		W, see ${}^{104}Cd$	-	6E+4	2E-5	8E-8	-	-
		Y, see ${}^{104}Cd$	-	5E+4	2E-5	7E-8	-	-
48	Cadmium-109	D, see <sup>104</sup> Cd	3E+2	4E+1	1E-8	-	-	-
			Kidneys	Kidneys				
			(4E+2)	(5E+1)	-	7E-11	6E-6	6E-5
		W, see <sup>104</sup> Cd	-	1E+2	5E-8	-	-	-
				Kidneys				
			-	(1E+2)	-	2E-10	-	-
		Y, see <sup>104</sup> Cd	-	1E+2	5E-8	2E-10	-	-
48	Cadmium-113m	D see <sup>104</sup> Cd	2E+1	2E+0	1E-9	-	-	-
10	Cuumum 115m	2,500 Gu	Kidneys	Kidneys	12-7	-	-	-
			(4E+1)	(4E+0)	-	5E-12	5E-7	5E-6
		W, see <sup>104</sup> Cd	-	(4£+0) 8E+0	4E-9	-	JL-7	- -
		11, 500 Cu		Kidneys	412-2	-	-	-
			_	(IE+1)	-	2E-11		
		Y, see <sup>104</sup> Cd	-	(IE+1) 1E+1	- 5E-9	2E-11 2E-11	-	-
						••		
48	Cadmium-113	D, see <sup>104</sup> Cd	2E+1	2E+0	9E-10	-	-	-
			Kidneys	Kidneys				
			(3E+1)	(3E+0)	-	5E-12	4E-7	4E-6
		W, see <sup>104</sup> Cd	-	8E+0	3E-9	-	-	-
		,		Kidneys				
		Y, see <sup>104</sup> Cd	-	Kidneys (1E+1)	-	2E-11	-	-

		Occu	Table I pational Valu	Ies	Table Efflu Concent	ent	Table III Releases to Sewers
		Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
		Ingestion	Inhal	ation			•
Atomic Radionuclide No.	Class	ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
48 Cadmium-115m	D, see <sup>104</sup> Cd	3E+2	5E+1	2E-8	-	4E-6	4E-5
			Kidneys		15 10		
	W, see <sup>104</sup> Cd	-	(8E+1)	-	1E-10	-	-
		-	1E+2	5E-8	2E-10	-	-
	Y, see <sup>104</sup> Cd	-	1E+2	6E-8	2E-10	-	-
48 Cadmium-115	D, see <sup>104</sup> Cd	9E+2 LLI wall	1E+3	6E-7	2E-9	-	-
	104	(1E+3)	-	-	-	1E-5	1E-4
	W, see <sup>104</sup> Cd	-	1E+3	5E-7	2E-9	-	-
	Y, see <sup>104</sup> Cd	-	1E+3	6E-7	2E-9	-	-
48 Cadmium-117m	D see <sup>104</sup> Cd	5E+3	1E+4	5E-6	2E-8		
to caumam 11/m	W, see $^{104}$ Cd	5+11				6E-5	6E-4
		-	2E+4	7E-6	2E-8	-	-
	Y, see <sup>104</sup> Cd	-	1E+4	6E-6	2E-8	-	-
48 Cadmium-117	D, see <sup>104</sup> Cd	5E+3	1E+4	5E-6	2E-8	6E-5	6E-4
	W, see <sup>104</sup> Cd		2E+4	7E-6	2E-8	012-5	012-4
	Y, see $^{104}$ Cd	-	1E+4	6E-6	2E-8 2E-8	-	-
							<u>_</u>
49 Indium-109	D, all compounds except				<b>.</b>		
	those given for W	2E+4	4E+4	2E-5	6E-8	3E-4	3E-3
	W, oxides, hydroxides,						
	halides, and nitrates	-	6E+4	3E-5	9E-8	-	-
49 Indium-110 <sup>2</sup>	D, see <sup>109</sup> In	2E+4	4E+4	2E-5	6E-8	2E-4	
(69.1 min)	W, see <sup>109</sup> In	-	4E+4				2E-3
(0).1 mm)		-	0E74	2E-5	8E-8	-	-
49 Indium-110	D, see <sup>109</sup> In	5E+3	2E+4	7E-6	2E-8	7E-5	7E-4
(4.9 h)	W, see <sup>109</sup> In	-	2E+4	8E-6	3E-8	-	-
40 To 1	► 100 <del>-</del>						
49 Indium-111	D, see <sup>109</sup> In	4E+3	6E+3	3E-6	9E-9	6E-5	6E-4
	W, see <sup>109</sup> In	-	6E+3	3E-6	9E-9	-	-
49 Indium-112 <sup>2</sup>	D, see <sup>109</sup> In	2E+5	6E+5	217 4	05.7	<u> </u>	
• maran-112	W. see $^{109}$ In			3E-4	9E-7	2E-3	2E-2
	w, see "In	-	7E+5	3E-4	1E-6	-	-
49 Indium-113m <sup>2</sup>	D, see <sup>109</sup> In	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3
	W, see <sup>109</sup> In	-	2E+5	8E-5	3E-7	, L-4	-
	- 100						
49 Indium-114m	D, see <sup>109</sup> In	3E+2	6E+1	3E-8	9E-11	-	-
		LLI wall					
		(4E+2)	-	-	-	5E-6	5E-5
	W, see <sup>109</sup> In	-	1E+2	4E-8	1E-10	•	-
10 T-1	D 1007						-
יא indium-115m	D, see <sup>w</sup> in	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3
49 Indium-115m	D, see <sup>109</sup> In	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3

			Осси	Table I pational Valu	es	Table Efflu Concent	ent	Table III Releases to Sewers
j		-	Col. 1 Oral Ingestion	Col. 2 Inhali	Col. 3	Col. 1	Col. 2	Monthly Average
Atom No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)		Concentratior (µCi/ml)
		W, see <sup>109</sup> In	-	5E+4	2E-5	7E-8	-	-
49	Indium-115	D, see <sup>109</sup> In W, see <sup>109</sup> In	4E+1 -	1E+0 5E+0	6E-10 2E-9	2E-12 8E-12	5E-7 -	5E-6 -
49	Indium-116m <sup>2</sup>	D, see <sup>109</sup> In W, see <sup>109</sup> In	2E+4 -	8E+4 1E+5	3E-5 5E-5	1E-7 2E-7	3E-4 -	3E-3 -
49	Indium-117m <sup>2</sup>	D, see <sup>109</sup> In W, see <sup>109</sup> In	1E+4 -	3E+4 4E+4	1E-5 2E-5	5E-8 6E-8	2E-4 -	2E-3 -
49	Indium-117 <sup>2</sup>	D, see <sup>109</sup> In W, see <sup>109</sup> In	6E+4 -	2E+5 2E+5	7E-5 9E-5	2E-7 3E-7	8E-4 -	8E-3 -
49	Indium-119m <sup>2</sup>	D, see <sup>109</sup> In	4E+4 St wall	1E+5	5E-5	2E-7	-	-
		W, see <sup>109</sup> In	(5E+4) -	- 1E+5	- 6E-5	- 2E-7	7E-4 -	7E-3 -
50	Tin-110	D, all compounds except those given for W W, sulfides, oxides, hydroxides, halides, nitrates, and stancio	4E+3	1E+4	5E-6	2E-8	5E-5	5E-4
		nitrates, and stannic phosphate	-	1E+4	5E-6	2E-8	-	-
50	<b>Tin-111</b> <sup>2</sup>	D, see <sup>110</sup> Sn W, see <sup>110</sup> Sn	7E+4 -	2E+5 3E+5	9E-5 1E-4	3E-7 4E-7	1E-3 -	1E-2 -
50	Tin-113	D, see <sup>110</sup> Sn	2E+3 LLI wall	1E+3	5E-7	2E-9	-	-
		W, see <sup>110</sup> Sn	(2E+3) -	- 5E+2	- 2E-7	- 8E-10	3E-5 -	3E-4 -
50	Tin-117m	D, see <sup>110</sup> Sn	2E+3 LLI wall	1E+3 Bone surf	5E-7	-	-	-
		W, see <sup>110</sup> Sn	(2E+3) -	(2E+3) 1E+3	- 6E-7	3E-9 2E-9	3E-5 -	3E-4 -
50	Tin-119m	D, see <sup>110</sup> Sn	3E+3 LLI wall	2E+3	1E-6	3E-9	<u>-</u>	-
		W, see <sup>110</sup> Sn	(4E+3) -	- 1E+3	- 4E-7	- 1E-9	6E-5 -	6E-4
50	Tin-121m	D, see <sup>110</sup> Sn	3E+3 LLI wall	9E+2	4E-7	1E-9	-	-

~

			Occuj	Table I pational Val	ues	Table Efflu Concen	ent	Table III Releases to Sewers	
		-	Col. 1 Oral Ingestion	Dral		Col. 1 Col. 2		Monthly Average	
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water Concent		
			(4E+3)	-	-	-	5E-5	5E-4	
		W, see <sup>110</sup> Sn	-	5E+2	2E-7	8E-10	-	-	
50	Tin-121	D, see <sup>110</sup> Sn	6E+3 LLI wall	2E+4	6E-6	2E-8	-	-	
		W, see <sup>110</sup> Sn	(6E+3) -	- 1E+4	- 5E-6	- 2E-8	8E-5 -	8E-4	
50	Tim 100?	·	<b></b>					-	
50	Tin-123m <sup>2</sup>	D, see <sup>110</sup> Sn W, see <sup>110</sup> Sn	5E+4 -	1E+5 1E+5	5E-5 6E-5	2E-7 2E-7	7E-4 -	7E-3 -	
50	Tin-123	D, see <sup>110</sup> Sn	5E+2 LLI wall	6E+2	3E-7	9E-10	-	-	
		W, see <sup>110</sup> Sn	(6E+2) -	- 2E+2	- 7E-8	- 2E-10	9E-6 -	9E-5 -	
50	Tin-125	D, see <sup>110</sup> Sn	4E+2 LLI wall	9E+2	4E-7	1E-9	-	-	
		W, see <sup>110</sup> Sn	(5E+2) -	- 4E+2	- 1E-7	- 5E-10	6E-6 -	6E-5 -	
50	Tin-126	D, see <sup>110</sup> Sn W, see <sup>110</sup> Sn	3E+2 -	6E+1 7E+1	2E-8 3E-8	8E-11 9E-11	4E-6 -	4E-5 -	
50	Tin-127	D, see <sup>110</sup> Sn W, see <sup>110</sup> Sn	7E+3 -	2E+4 2E+4	8E-6 8E-6	3E-8 3E-8	9E-5 -	9E-4 -	
50	Tin-128 <sup>2</sup>	D, see <sup>110</sup> Sn W, see <sup>110</sup> Sn	9E+3 -	3E+4 4E+4	1E-5 1E-5	4E-8 5E-8	1E-4 -	1E-3 -	
51	Antimony-115 <sup>2</sup>	D, all compounds except those given for W W, oxides, hydroxides, halides, sulfides,	8E+4	2E+5	1E-4	3E-7	1E-3	1E-2	
		sulfates, and nitrates	-	3E+5	1E-4	4E-7	-	-	
51	Antimony-116m <sup>2</sup>	W, see <sup>115</sup> Sb	D, see <sup>115</sup> Sb	2E+4 1E+5	7E+4 6E-5	3E-5 2E-7	1E-7 -	3E-43E-3 -	
51	Antimony-116 <sup>2</sup>	D, see <sup>115</sup> Sb	7E+4 St wall	3E+5	1E-4	4E-7	-	-	
		W, see <sup>115</sup> Sb	(9E+4) -	- 3E+5	- 1E-4	- 5E-7	1E-3 -	1E-2	

				Table I ational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers Monthly Average Concentration (µCi/ml)
			Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	
51	Antimony-117	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	7E+4	2E+5 3E+5	9E-5 1E-4	3E-7 4E-7	9E-4 -	9E-3 -
51	Antimony-118m	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	6E+3 5E+3	2E+4 2E+4	8E-6 9E-6	3E-8 3E-8	7E-5 -	7E-4 -
51	Antimony-119	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	2E+4 2E+4	5E+4 3E+4	2E-5 1E-5	6E-8 4E-8	2E-4 -	2E-3
51	Antimony-120 <sup>2</sup> (16 min)	D, see <sup>115</sup> Sb	1E+5 St wall	4E+5	2E-4	6E-7	-	-
		W, see <sup>115</sup> Sb	(2E+5) -	- 5E+5	- 2E-4	- 7E-7	2E-3 -	2E-2 -
51	Antimony-120 (5.76 d)	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	1E+3 9E+2	2E+3 1E+3	9E-7 5E-7	3E-9 2E-9	1E-5 -	1E-4 -
51	A ntimony-122	D, see <sup>115</sup> Sb	8E+2 LLI wall	2E+3	1E-6	3E-9	-	-
/		W, see <sup>115</sup> Sb	(8E+2) 7E+2	- 1E+3	- 4E-7	- 2E-9	1E-5 -	1E-4 -
51	Antimony-124m <sup>2</sup>	W, see <sup>115</sup> Sb	D, see <sup>115</sup> Sb 2E+5	3E+5 6E+5	8E+5 2E-4	4E-4 8E-7	1E-6 -	3E-33E-2
51	Antimony-124	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	6E+2 5E+2	9E+2 2E+2	4E-7 1E-7	1E-9 3E-10	7E-6 -	7E-5
51	Antimony-125	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	2E+3 -	2E+3 5E+2	1E-6 2E-7	3E-9 7E-10	3E-5 -	3E-4
51	Antimony-126m <sup>2</sup>		D, see <sup>115</sup> Sb St wall	5E+4	2E+5	8E-5	3E-7	
		W, see <sup>115</sup> Sb	(7E+4) -	- 2E+5	- 8E-5	- 3E-7	9E-4 -	9E-3 -
51	Antimony-126	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	6E+2 5E+2	1E+3 5E+2	5E-7 2E-7	2E-9 7E-10	7E-6 -	7E-5 -
51	Antimony-127	D, see <sup>115</sup> Sb	8E+2 LLI wall	2E+3	9E-7	3E-9	-	-
		W, see <sup>115</sup> Sb	(8E+2) 7E+2	- 9E+2	- 4E-7	- 1E-9	1E-5 -	1E-4 -
51	Antimony-128 <sup>2</sup> (10.4 min)	D, see <sup>115</sup> Sb	8E+4 St wall	4E+5	2E-4	5E-7	-	-

			Occu	Table I pational Valu	ies	Table Efflu Concen	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Aton No.	nic Radionuclide	Class	ALI (µCi)	<u>Inhal</u> ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
			(1E+5)	-	-	-	1E-3	1E-2
		W, see <sup>115</sup> Sb	-	4E+5	2E-4	6E-7	-	-
51	Antimony-128	D, see <sup>115</sup> Sb	1E+3	4E+3	2E-6	6E-9	2E-5	2E-4
	(9.01 h)	W, see <sup>115</sup> Sb	-	3E+3	1E-6	5E-9	-	2£-4 -
51	Antimony-129	D, see <sup>115</sup> Sb	3E+3	9E+3		17.0	( <b>F</b> -	
	i mamony 12)	W, see $^{115}$ Sb	-	9E+3 9E+3	4E-6 4E-6	1E-8 1E-8	4E-5 -	4E-4 -
~ .		-				12 0		-
51	Antimony-130 <sup>2</sup>	D, see <sup>115</sup> Sb W, see <sup>115</sup> Sb	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		W, SEC 50	-	8E+4	3E-5	1E-7	-	-
51	Antimony-131 <sup>2</sup>	D, see <sup>115</sup> Sb	1E+4 Thyroid	2E+4 Thyroid	1E-5	-	-	-
		W, see <sup>115</sup> Sb	(2E+4)	(4E+4)	-	6E-8	2E-4	2E-3
		w, see 50	-	2E+4 Thyroid	1E-5		-	-
			-	(4E+4)	-	6E-8	-	-
52	Tellurium-116	D, all compounds except						
		those given for W W, oxides, hydroxides,	8E+3	2E+4	9E-6	3E-8	1E-4	1E-3
		and nitrates	-	3E+4	1E-5	4E-8	-	-
52	Tellurium-121m	D, see <sup>116</sup> Te	5E+2 Bone surf	2E+2 Bone surf	8E-8	-	-	-
		XX lióm	(7E+2)	(4E+2)	-	5E-10	1E-5	1E-4
		W, see <sup>116</sup> Te	-	4E+2	2E-7	6E-10	-	-
52	Tellurium-121	D, see <sup>116</sup> Te	3E+3	4E+3	2E-6	6E-9	4E-5	4E-4
		W, see <sup>116</sup> Te	-	3E+3	1E-6	4E-9	-	-
52	Tellurium-123m	D, see <sup>116</sup> Te	6E+2 Bone surf	2E+2 Bone surf	9E-8	-	-	-
			(1E+3)	(5E+2)	-	8E-10	1E-5	1E-4
		W, see <sup>116</sup> Te	-	5E+2	2E-7	8E-10	-	-
52	Tellurium-123	D, see <sup>116</sup> Te	5E+2 Bone surf	2E+2 Bone surf	8E-8	-	-	-
		W, see <sup>116</sup> Te	(1E+3)	(5E+2)	-	7E-10	2E-5	2E-4
		w, See 10	-	4E+2 Bone surf	2E-7	-	-	-
			-	(1E+3)	-	2E-9	-	-
52	Tellurium-125m	D, see <sup>116</sup> Te	1E+3 Bone surf	4E+2 Bone surf	2E-7	-	-	-

·

.

				Table I ational Value	es	Table Efflue Concent	ent	Table III Releases to Sewers
_		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	Ingestion ALI (µCi)	Inhala ALI (µCi)	ntion DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		W, see <sup>116</sup> Te	(1E+3) -	(1E+3) 7E+2	- 3E-7	1E-9 1E-9	2E-5 -	2E-4 -
52	Tellurium-127m	D, see <sup>116</sup> Te	6E+2	3E+2 Bone surf	1E-7	-	9 <b>E-</b> 6	9E-5
		W, see <sup>116</sup> Te	-	(4E+2) 3E+2	- 1E-7	6E-10 4E-10	-	-
52	Tellurium-127	D, see <sup>116</sup> Te W, see <sup>116</sup> Te	7E+3 -	2E+4 2E+4	9E-6 7E-6	3E-8 2E-8	1E-4 -	1E-3 -
52	Tellurium-129m	D, see <sup>116</sup> Te W, see <sup>116</sup> Te	5E+2	6E+2	3E-7	9E-10	7E-6	7E-5
52	Tellurium-129 <sup>2</sup>	W, see Te $D$ , see $^{116}$ Te	- 3E+4	2E+2 6E+4	1E-7 3E-5	3E-10 9E-8	- 4E-4	- 4E-3
		W, see <sup>116</sup> Te	-	7E+4	3E-5	1E-7	-	-
52	Tellurium-131m	D, see <sup>116</sup> Te	3E+2 Thyroid	4E+2 Thyroid	2E-7	-	-	-
		W, see <sup>116</sup> Te	(6E+2) -	(1E+3) 4E+2 Thyroid	- 2E-7	2E-9 -	8E-6 -	8E-5 -
			-	(9E+2)	-	1E-9	-	-
52	Tellurium-131 <sup>2</sup>	D, see <sup>116</sup> Te	3E+3 Thyroid	5E+3 Thyroid	2E-6	-	-	-
		W, see <sup>116</sup> Te	(6E+3) -	(1E+4) 5E+3 Thyroid	- 2E-6	2E-8 -	8E-5 -	8E-4 -
			-	(1E+4)	*	2E-8	-	-
52	Tellurium-132	D, see <sup>116</sup> Te	2E+2 Thyroid	2E+2 Thyroid	9E-8	-	-	-
		W, see <sup>116</sup> Te	(7E+2) -	(8E+2) 2E+2 Thyraid	- 9E-8	1E-9 -	9E-6 -	9E-5 -
			-	Thyroid (6E+2)	-	9E-10	-	-
52	Tellurium-133m <sup>2</sup>		D, see <sup>116</sup> Te Thyroid	3E+3 Thyroid	5E+3	2E-6	-	
		W, see <sup>116</sup> Te	(6E+3) -	(1E+4) 5E+3 Thyroid	- 2E-6	2E-8 -	9E-5 -	9E-4 -
			-	Thyroid (1E+4)	-	2E-8	-	-

			Occu	Table I pational Valu	les	Table Efflu Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomi No.	ic Radionuclide	Class	ALI (µCi)	ALIDACAirWater(μCi)(μCi/ml)(μCi/ml)(μCi/ml)		Average Concentration (µCi/ml)		
52	Tellurium-133 <sup>2</sup>	D, see <sup>116</sup> Te	1E+4 Thyroid	2E+4 Thyroid	9E-6	-	-	-
		W, see <sup>116</sup> Te	$\begin{array}{cccccccccccccccccccccccccccccccccccc$					
			-	(6E+4)	-	8E-8	-	-
52	Tellurium-134 <sup>2</sup>	D, see <sup>116</sup> Te			1E-5	-	-	-
		W, see <sup>116</sup> Te	(2E+4) -	2E+4		7E-8 -	3E-4 -	3E-3 -
			-	Thyroid (5E+4)	-	7E-8	-	-
53	Iodine-120m <sup>2</sup>	D, all compounds	1E+4 Thyroid	2E+4	9E-6	3E-8	-	-
			(1E+4)	-	-	-	2E-4	2E-3
53	Iodine-120 <sup>2</sup>	D, all compounds	4E+3 Thyroid	9E+3 Thyroid	4E-6	-	-	
			(8E+3)	(1E+4)	-	2E-8	1E-4	1E-3
53	Iodine-121	D, all compounds	1E+4 Thyroid	2E+4 Thyroid	8E-6	-	-	-
			(3E+4)	(5E+4)	-	7E-8	4E-4	4E-3
53	Iodine-123	D, all compounds	3E+3 Thyroid	6E+3 Thyroid	3E-6	-	-	-
			(1E+4)	(2E+4)	-	2E-8	1E-4	1E-3
53	Iodine-124	D, all compounds	5E+1 Thyroid	8E+1 Thyroid	3E-8	-	-	-
			(2E+2)	(3E+2)	-	4E-10	2E-6	2E-5
53	Iodine-125	D, all compounds	4E+1 Thyroid	6E+1 Thyroid	3E-8	-	-	-
			(1E+2)	(2E+2)	-	3E-10	2E-6	2E-5
53	Iodine-126	D, all compounds	2E+1 Thyroid	4E+1 Thyroid	1E-8	-	-	-
			(7E+1)	(1E+2)	-	2E-10	1E-6	1E-5
53	Iodine-128 <sup>2</sup>	D, all compounds	4E+4 St wall	1E+5	5E-5	2E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3 🤍

			Occu	Table I pational Valu	les	Table Efflu Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Aton No.	nic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inha</u> ALI (µCi)	lation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
53	Iodine-129	D, all compounds	5E+0 Thyroid	9E+0 Thyroid	4E-9	-	-	-
53	Iodine-130	D, all compounds	(2E+1) 4E+2	(3E+1) 7E+2	- 3E-7	4E-11 -	2E-7 -	2E-6 -
			Thyroid (1E+3)	Thyroid (2E+3)	-	3E-9	2E-5	2E-4
53	Iodine-131	D, all compounds	3E+1 Thyroid	5E+1 Thyroid	2E-8	-	-	-
			(9E+1)	(2E+2)	-	2E-10	1E-6	1E-5
53	Iodine-132m <sup>2</sup>	D, all compounds	4E+3 Thyroid	8E+3 Thyroid	4E-6	-	-	-
			(1E+4)	(2E+4)	-	3E-8	1E-4	1E-3
53	Iodine-132	D, all compounds	4E+3 Thyroid	8E+3 Thyroid	3E-6	-	-	-
)			(9E+3)	(1E+4)	-	2E-8	1E-4	1E-3
53	Iodine-133	D, all compounds	1E+2 Thyroid	3E+2 Thyroid	1E-7	-	-	-
			(5E+2)	(9E+2)	-	1E-9	7E-6	7E-5
53	Iodine-134 <sup>2</sup>	D, all compounds	2E+4 Thyroid	5E+4	2E-5	6E-8	-	-
			(3E+4)	-	-	-	4E-4	4E-3
53	Iodine-135	D, all compounds	8E+2 Thyroid (3E+3)	2E+3 Thyroid (4E+3)	7E-7	- 6E-9	- 3E-5	- 3E-4
54	Xenon-120 <sup>2</sup>	Submersion <sup>1</sup>	-	-	1E-5	4E-8	-	5E-4 -
54	Xenon-121 <sup>2</sup>	Submersion <sup>1</sup>	-	-	2E-6	1E-8	-	-
54	Xenon-122	Submersion <sup>1</sup>	-	-	7E-5	3E-7	-	-
54	Xenon-123	Submersion <sup>1</sup>	-	-	6E-6	3E-8	-	-
54	Xenon-125	Submersion <sup>1</sup>	-	-	2E-5	7E-8	-	-
54	Xenon-127	Submersion <sup>1</sup>	-	-	1E-5	6E-8	-	-
54	Xenon-129m	Submersion <sup>1</sup>	-	-	2E-4	9E-7	-	-

		Occu	Table I pational Val	ues	Table Efflu Concen	ent	Table III Releases to Sewers
		Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic Radionucl No.	ide Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
54 Xenon-1311	m Submersion <sup>1</sup>		-	4E-4	2E-6	-	-
54 Xenon-1331	m Submersion <sup>1</sup>	-	-	1E-4	6E-7	-	-
54 Xenon-133	Submersion <sup>1</sup>	-	-	1E-4	5E-7	-	-
54 Xenon-1351	m <sup>2</sup> Submersion <sup>1</sup>	-	-	9 <b>E-</b> 6	4E-8	-	-
54 Xenon-135	Submersion <sup>1</sup>	-	-	1E-5	7E-8	-	-
54 Xenon-138 <sup>2</sup>	Submersion <sup>1</sup>	-	-	4E-6	2E-8	-	-
55 Cesium-125	<sup>2</sup> D, all compounds	5E+4 St wall (9E+4)	1E+5	6E-5	2E-7	- 1E-3	- 1E-2
55 Cesium-127	D, all compounds	6E+4	9E+4	4E-5	1E-7	9E-4	9E-3
55 Cesium-129	-	2E+4	3E+4	1E-5	5E-8	3E-4	3E-3
55 Cesium-130	<sup>2</sup> D, all compounds	6E+4 St wall	2E+5	8E-5	3E-7	-	-
		(1E+5)	-	-	-	1E-3	1E-2
55 Cesium-131	•	2E+4	3E+4	1E-5	4E-8	3E-4	3E-3
55 Cesium-132		3E+3	4E+3	2E-6	6E-9	4E-5	4E-4
55 Cesium-134	m D, all compounds	1E+5 St wall (1E+5)	1E+5 -	6E-5	2E-7	- 2E-3	- 2E-2
55 Cesium-134	D, all compounds	7E+1	1E+2	4E-8	2E-10	9E-7	 9E-6
55 Cesium-135	m <sup>2</sup> D, all compounds	1E+5	2E+5	8E-5	3E-7	1E-3	1E-2
55 Cesium-135	D, all compounds	7E+2	1E+3	5E-7	2E-9	1E-5	1E-4
5 Cesium-136	D, all compounds	4E+2	7E+2	3E-7	9E-10	6E-6	6E-5
55 Cesium-137	D, all compounds	1E+2	2E+2	6E <b>-8</b>	2E-10	1E-6	1E-5
55 Cesium-138	<sup>2</sup> D, all compounds	2E+4 St wall	6E+4	2E-5	8E-8	-	-
		(3E+4)	-	-	-	4E-4	4E-3

			Occu	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers	
)		<b>.</b>	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average	
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (μCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)	
56	Barium-126 <sup>2</sup>	D, all compounds	6E+3	2E+4	6E-6	2E-8	8E-5	8E-4	
56	Barium-128	D, all compounds	5E+2	2E+3	7E-7	2E-9	7E-6	7E-5	
56	Barium-131m <sup>2</sup>	D, all compounds	4E+5 St wall (5E+5)	1E+6 -	6E-4	2E-6	- 7E-3	- 7E-2	
56	Barium-131	D, all compounds	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4	
56	Barium-133m	D, all compounds	2E+3 LLI wall	9E+3	4E-6	1E-8	-	-	
	D 1 100	~	(3E+3)	-	-	-	4E-5	4E-4	
56	Barium-133	D, all compounds	2E+3	7E+2	3E-7	9E-10	2E-5	2E-4	
56	Barium-135m	D, all compounds	3E+3	1E+4	5E-6	2E-8	4E-5	<b>4E-</b> 4	
56	Barium-139 <sup>2</sup>	D, all compounds	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3	
56	Barium-140	D, all compounds	5E+2 LLI wall (6E+2)	1E+3 -	6E-7 -	2E-9 -	- 8E-6	- 8E-5	
56	Barium-141 <sup>2</sup>	D, all compounds	2E+4	7E+4	3E-5	1E-7	3E-4	3E-3	
56	Barium-142 <sup>2</sup>	D, all compounds	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3	
57	Lanthanum-131 <sup>2</sup>	D, all compounds except those given for W W, oxides and hydroxides	5E+4 -	1E+5 2E+5	5E-5 7E-5	2E-7 2E-7	6E-4 -	6E-3	
57	Lanthanum-132	D, see <sup>131</sup> La W, see <sup>131</sup> La	3E+3 -	1E+4 1E+4	4E-6 5E-6	1E-8 2E-8	4E-5 -	4E4 -	
57	Lanthanum-135	D, see <sup>131</sup> La W, see <sup>131</sup> La	4E+4 -	1E+5 9E+4	4E-5 4E-5	1E-7 1E-7	5E-4 -	5E-3 -	
57	Lanthanum-137	D, see <sup>131</sup> La	1E+4	6E+1 Liver	3E-8	-	2E-4	2E-3	
		W, see <sup>131</sup> La	-	(7E+1) 3E+2 Liver	- 1E-7	1E-10 -	-	-	
/			-	(3E+2)	-	4E-10	-	-	

			Осси	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
		~	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomi No.	c Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
57	Lanthanum-138	D. see <sup>131</sup> La W. see <sup>131</sup> La	9E+2 -	4E+0 1E+1	1E-9 6E-9	5E-12 2E-11	1E-5 -	1E-4 -
57	Lanthanum-140	D, see <sup>131</sup> La W, see <sup>131</sup> La	6E+2 -	1E+3 1E+3	6E-7 5E-7	2E-9 2E-9	9E-6 -	9E-5 -
57	Lanthanum-141	D, see <sup>131</sup> La W, see <sup>131</sup> La	4E+3 -	9E+3 1E+4	4E-6 5E-6	1E-8 2E-8	5E-5	5E-4 -
57	Lanthanum-142 <sup>2</sup>	D, see <sup>131</sup> La W, see <sup>131</sup> La	8E+3 -	2E+4 3E+4	9E-6 1E-5	3E-8 5E-8	1E-4 -	1E-3 -
57	Lanthanum-143 <sup>2</sup>	D, see <sup>131</sup> La	4E+4 St wall	1E+5	4E-5	1E-7	-	-
		W, see <sup>131</sup> La	(4E+4) -	- 9E+4	- 4E-5	- 1E-7	5E-4 -	5E-3 -
58	Cerium-134	W, all compounds except those given for Y	5E+2 LLI wall	7E+2	3E-7	1E-9	-	
		Y, oxides, hydroxides, and fluorides	(6E+2) -	- 7E+2	- 3E-7	- 9E-10	8E-6 -	8E-5 -
58	Cerium-135	W, see <sup>134</sup> Ce Y, see <sup>134</sup> Ce	2E+3 -	4E+3 4E+3	2E-6 1E-6	5E-9 5E-9	2E-5 -	2E-4
58	Cerium-137m	W, see <sup>134</sup> Ce	2E+3 LLI wall	4E+3	2E-6	6E-9	-	-
		Y, see <sup>134</sup> Ce	(2E+3) -	- 4E+3	- 2E-6	- 5E-9	3E-5 -	3E-4 -
58	Cerium-137	W, see <sup>134</sup> Ce Y, see <sup>134</sup> Ce	5E+4 -	1E+5 1E+5	6E-5 5E-5	2E-7 2E-7	7E-4 -	7E-3 -
58	Cerium-139	W, see <sup>134</sup> Ce Y, see <sup>134</sup> Ce	5E+3 -	8E+2 7E+2	3E-7 3E-7	1E-9 9E-10	7E-5 -	7E-4 -
58	Cerium-141	W, see <sup>134</sup> Ce	2E+3 LLI wall	7E+2	3E-7	1E-9	-	-
		Y, see <sup>134</sup> Ce	(2E+3) -	- 6E+2	- 2E-7	- 8E-10	3E-5 -	3E-4 -
58	Cerium-143	W, see <sup>134</sup> Ce	1E+3	2E+3	8E-7	3E-9	-	•

			Occu	Table I pational Val	ues	Table Effluc Concent	ent	Table III Releases to Sewers
/		•	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	Ingestion ALI (µCi)	ALI (µCi)	lation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentratio (µCi/ml)
	· · · · · · · · · · · · · · · · · · ·							
		2	LLI wall					
		Y, see <sup>134</sup> Ce	(1E+3) -	- 2E+3	- 7E-7	- 2E-9	2E-5	2E-4
					, <u>L</u>	20-7		-
58	Cerium-144	W, see <sup>134</sup> Ce	2E+2 LLI wall	3E+1	1E-8	4E-11	-	-
		Y, see <sup>134</sup> Ce	(3E+2)	-	-	-	3E-6	3E-5
		r, see ····Ce	-	1E+1	6E-9	2E-11	-	-
59	Praseodymium-13	<sup>36<sup>2</sup></sup> W, all compounds except those given for Y	5E+4	2E+5	1E-4	3E-7	-	-
			St wall					
		Y, oxides, hydroxides,	(7E+4)	-	-	-	1E-3	1E-2
		carbides, and fluorides	-	2E+5	9E-5	3E-7	-	-
59	Praseodymium-13	7 <sup>2</sup> W, see <sup>136</sup> Pr	4E+4	2E+5	6E-5	2E-7	5E-4	5E-3
		Y, see <sup>136</sup> Pr	-	1E+5	6E-5	2E-7	-	-
59	Praseodymium-13	8m W see <sup>136</sup> Pr	1E+4	5E+4	2E-5	8E-8	1E-4	1E-3
•••		Y, see $^{136}$ Pr	-	4E+4	2E-5 2E-5	6E-8	-	-
50	D	13600						
59	Praseodymium-13	19 W, see $130$ Pr Y, see $136$ Pr	4E+4	1E+5 1E+5	5E-5 5E-5	2E-7 2E-7	6E-4	6E-3
			-	1673	JE-J	2 <b>E-</b> /	-	-
59	Praseodymium-14		8E+4	2E+5	7E-5	2E-7	1E-3	1E-2
		Y, see <sup>136</sup> Pr	-	1E+5	6E-5	2E-7	-	-
59	Praseodymium-14	2 W, see $^{136}$ Pr	1E+3	2E+3	9E-7	3E-9	1E-5	1E-4
		Y, see <sup>136</sup> Pr	-	2E+3	8E-7	3E-9	-	-
50	Data to to ta	0 MJ 136D						
39	Praseodymium-14	3 W, see <sup>130</sup> Pr	9E+2 LLI wall	8E+2	3E-7	1E-9	-	-
			(1E+3)	-	-	-	2E-5	2E-4
		Y, see <sup>136</sup> Pr	-	7E+2	3E-7	9E-10	-	
50	Praseodymium-14	$4^2$ W coo <sup>136</sup> D-	2514	1015	ETC E	0F 7		
57	1 Iascouyintum-14	++ w, see PI	3E+4 St wall	1E+5	5E-5	2E-7	-	-
		Y, see <sup>136</sup> Pr	(4E+4)	- 1E+5	- 5E-5	- 2E-7	6E-4 -	6E-3
		1,000 11	-	L   L	U-11	/-12	-	-
59	Praseodymium-14		3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
		Y, see <sup>136</sup> Pr	-	8E+3	3E-6	1E-8	-	-
50	Praseodymium-14	$7^2$ W see <sup>136</sup> Pr	5E+4	2E+5	8E-5	3E-7	_	_

			Occu	Table I pational Val	ues	Table Efflu Concen	ent	Table III Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Ĭnhc	lation			Monthly
Ator	nic Radionuclide	Class	ALI	ALI	DAC	Air	Water	Average Concentration
No.			(µCi)	(μCi)	(µCi/ml)	(µCi/ml)	(µCi/ml)	(µCi/ml)
			(8E+4)	_	_	_	1E-3	1E-2
		Y, see <sup>136</sup> Pr	-	2E+5	8E-5	3E-7	-	1E-2 -
60	Neodymium-136 <sup>2</sup>	W, all compounds except						
	-	those given for Y	1E+4	6E+4	2E-5	8E-8	2E-4	2E-3
		Y, oxides, hydroxides, carbides, and fluorides	-	5E+4	2E-5	8E-8		
		·	-	51214	26-5	02-0	-	-
60	Neodymium-138		2E+3	6E+3	3E-6	9E-9	3E-5	3E-4
		Y, see <sup>136</sup> Nd	-	5E+3	2E-6	7E-9	-	-
60	Neodymium-139n		5E+3	2E+4	7E-6	2E-8	7E-5	7E-4
		Y, see <sup>136</sup> Nd	-	1E+4	6E-6	2E-8	-	-
60	Neodymium-139 <sup>2</sup>	W, see <sup>136</sup> Nd	9E+4	3E+5	1E-4	5E-7	1E-3	1E-2
		Y, see <sup>136</sup> Nd	-	3E+5	1E-4	4E-7	-	-
60	Neodymium-141	W, see <sup>136</sup> Nd	2E+5	7E+5	3E-4	1E-6	2E-3	2E-2
		Y, see <sup>136</sup> Nd	-	6E+5	3E-4	9E-7	-	-
60	Neodymium-147	W, see <sup>136</sup> Nd	1E+3 LLI wall	9E+2	4E-7	1E-9	-	-
		Y, see <sup>136</sup> Nd	(1E+3)	- 9E ( )	-	-	2E-5	2E-4
		1,500 110	-	8E+2	4E-7	1E-9	-	-
60	Neodymium-149 <sup>2</sup>		1E+4	3E+4	1E-5	4E-8	1E-4	1E-3
		Y, see <sup>136</sup> Nd	-	2E+4	1E-5	3E-8	-	-
60	Neodymium-151 <sup>2</sup>		7E+4	2E+5	8E-5	3E-7	9E-4	9E-3
		Y, see <sup>136</sup> Nd	-	2E+5	8E-5	3E-7	-	-
61	Promethium-141 <sup>2</sup>		W, all com	pounds exce	pt			
		those given for Y	5E+4 St wall	2E+5	8E-5	3E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3
		Y, oxides, hydroxides,		2515		AF 7		
		carbides, and fluorides	-	2E+5	7E-5	2E-7	-	-
61	Promethium-143		5E+3	6E+2	2E-7	8E-10	7E-5	7E-4
		Y, see <sup>141</sup> Pm	-	7E+2	3E-7	1E-9	-	-
61	Promethium-144	W/ coo <sup>141</sup> Pm	1512	1510		<b>AR</b> 10	AT 5	
10	Fromeunum-144	W, see <sup>141</sup> Pm $Y$ , see <sup>141</sup> Pm	1E+3 -	1E+2 1E+2	5E-8 5E-8	2E-10 2E-10	2E-5	2E-4
	_	, ,			56-0	-10	-	-
51	Promethium-145	W, see <sup>141</sup> Pm	1E+4	2E+2	7E-8	-	1E-4	1E-3

			Occu	Table I pational Value	es	Table II Effluent Concentrations		Table III Releases to Sewers	
`			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly	
			Ingestion	Inhala	ation			Average	
Atom	nic Radionuclide	Class	ALI	ALI	DAC	Air	Water	Concentration	
No.			(µCi)	(µCi)	(µCi/ml)	(µCi/ml)	(µCi/ml)	(µCi/ml)	
		· · · · ·	_	Bone surf (2E+2)	_	3E-10			
		Y. see <sup>141</sup> Pm	-	(2E+2) 2E+2	- 8E-8	3E-10 3E-10	-	-	
					OL 0	5L-10	-	-	
61	Promethium-146	W, see <sup>141</sup> Pm	2E+3	5E+1	2E-8	7E-11	2E-5	2E-4	
		Y, see <sup>141</sup> Pm	-	4E+1	2E-8	6 <b>E-1</b> 1	-	-	
61	Promethium-147	W, see <sup>141</sup> Pm	4E+3	1E+2	5E-8	-	-	-	
			LLI wall	Bone surf					
			(5E+3)	(2E+2)	-	3E-10	7E-5	7E-4	
		Y, see <sup>141</sup> Pm	-	1E+2	6E <b>-8</b>	2E-10	-	-	
61	Promethium-148r	n W see <sup>141</sup> Pm	7E+2	3E+2	1E-7	4E-10	1E-5	1E-4	
•		Y, see $^{141}$ Pm	-	3E+2	1E-7 1E-7	4E-10 5E-10	-	16-4	
								_	
61	Promethium-148	W, see <sup>141</sup> Pm	4E+2	5E+2	2E-7	8E-10	-	-	
			LLI wall						
		Y, see <sup>141</sup> Pm	(5E+2)	-	- ar <i>4</i>	-	7E-6	7E-5	
/		Y, see <sup>m</sup> Pm	-	5E+2	2E-7	7E-10	-	-	
61	Promethium-149	W, see <sup>141</sup> Pm	1E+3	2E+3	8E-7	3E-9	-	-	
			LLI wall						
			(1E+3)	-	-	-	2E-5	2E-4	
		Y, see <sup>141</sup> Pm	-	2E+3	8E-7	2E-9	-	-	
61	Promethium-150	W, see <sup>141</sup> Pm	5E+3	2E+4	8E-6	3E-8	7E-5	7E-4	
		Y, see <sup>141</sup> Pm	-	2E+4	7E-6	2E-8	-	-	
		·				•			
61	Promethium-151		2E+3	4E+3	1E-6	5E-9	2E-5	2E-4	
		Y, see <sup>141</sup> Pm	-	3E+3	1E-6	4E-9	-	-	
62	Samarium-141m <sup>2</sup>	W, all compounds	3E+4	1E+5	4E-5	1E-7	4E-4	4E-3	
62	Samarium-141 <sup>2</sup>	W, all compounds	5E+4	2E+5	8E-5	2E-7	-	-	
			St wall						
			(6E+4)	-	-	-	8E-4	8E-3	
62	Samarium-142 <sup>2</sup>	W, all compounds	8E+3	3E+4	1E-5	4E-8	1E-4	1E-3	
62	Samarium-145	W, all compounds	6E+3	5E+2	2E-7	7E 10	0E 5	0E 4	
52	Samarum-145	m, an compounds	ULTJ	JLTZ	ZE-1	7E-10	8E-5	8E-4	
62	Samarium-146	W, all compounds	1E+1	4E2	1E-11	_	_	_	
/			Bone surf	Bone surf					
			(3E+1)	(6E-2)	-	9E-14	3E-7	3E-6	
			· · ·	<b>(</b> ) <b>/</b>					

-

			Oca	Table I apational Valu	es	Table Efflu Concent	ent	Table III Releases to Sewers	
		•	Col. 1 Oral Ingestion	Col. 2 Inhal	Col. 3	Col. 1	Col. 2	Monthly	
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)	
62	Samarium-147	W, all compounds	2E+1 Bone surf	4E2 Bone surf	2E-11	-	-	-	
62	Samarium-151	W, all compounds	(3E+1) 1E+4	(7E-2) 1E+2	- 4E-8	1E-13 -	4E-7 -	4E-6 -	
			LLI wall (1E+4)	Bone surf (2E+2)	-	2E-10	2E-4	2E-3	
62	Samarium-153	W, all compounds	2E+3 LLI wall	3E+3	1 <b>E-</b> 6	4E-9	-	-	
			(2E+3)	-	-	-	3E-5	3E-4	
62	Samarium-155 <sup>2</sup>	W, all compounds	6E+4 St wall	2E+5	9E-5	3E-7	-	-	
			(8E+4)	-	-	-	1E-3	1E-2	
62	Samarium-156	W, all compounds	5E+3	9E+3	4E-6	1E-8	7E-5	7E-4	
63	Europium-145	W, all compounds	2E+3	2E+3	8E-7	3E-9	2E-5	2E-4	
63	Europium-146	W, all compounds	1E+3	1E+3	5E-7	2E-9	1E-5	1E-4	
63	Europium-147	W, all compounds	3E+3	2E+3	7E-7	2E-9	4E-5	4E-4	
63	Europium-148	W, all compounds	1E+3	4E+2	1E-7	5E-10	1E-5	1E-4	
63	Europium-149	W, all compounds	1E+4	3E+3	1E-6	4E-9	2E-4	2E-3	
63	Europium-150 (12.62 h)	W, all compounds	3E+3	8E+3	4E-6	1E-8	4E-5	<b>4E-</b> 4	
63	Europium-150 (34.2 y)	W, all compounds	8E+2	<b>2E</b> +1	8E-9	3E-11	1E-5	1E-4	
63	Europium-152m	W, all compounds	3E+3	6E+3	3E-6	9E-9	4E-5	4E-4	
63	Europium-152	W, all compounds	8E+2	2E+1	1E-8	3E-11	1E-5	1E-4	
63	Europium-154	W, all compounds	5E+2	2E+1	8E-9	3E-11	7E-6	7E-5	
63	Europium-155	W, all compounds	4E+3	9E+1 Bone surf	4E-8	-	5E-5	5E-4	
			-	(1E+2)	-	2E-10	-	-	
63	Europium-156	W, all compounds	6E+2	5E+2	2E-7	6E-10	8E-6	8E-5 🤍	

			Occuj	Table I pational Valu	es	Efflue	Table II Effluent Concentrations	
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
63	Europium-157	W, all compounds	2E+3	5E+3	2E-6	7E-9	3E-5	3E-4
63	Europium-158 <sup>2</sup>	W, all compounds	2E+4	6E+4	2E-5	8E-8	3E-4	3E-3
64	Gadolinium-145 <sup>2</sup>	2	D all some	pounds except				
04	Gautimum-145	those given for W	5E+4 St wall	2E+5	6E-5	2E-7	-	-
		W, oxides, hydroxides,	(5E+4)	-	-	-	6E-4	6E-3
		and fluorides	-	2E+5	7E-5	2E-7	-	-
64	Gadolinium-146	D. see <sup>145</sup> Gd	1E+3	1E+2	5E-8	2E-10	2E-5	2E-4
		W, see <sup>145</sup> Gd	-	3E+2	1E-7	4E-10	-	-
64	Gadolinium-147	D, see <sup>145</sup> Gd	2E+3	4E+3	2E-6	6E-9	3E-5	3E-4
		W, see <sup>145</sup> Gd	-	4E+3	1E-6	5E-9	-	-
64	Gadolinium-148	D, see <sup>145</sup> Gd	1E+1 Bone surf	8E+3 Bone surf	3E-12	-	-	-
/		W, see <sup>145</sup> Gd	(2E+1) -	(2E+2) 3E-2 Bone surf	- 1E-11	2E-14 -	3E-7 -	3E-6 -
			-	(6E-2)	-	8E-14	-	-
64	Gadolinium-149		3E+3	2E+3	9E-7	3E-9	4E-5	4E-4
		W, see <sup>145</sup> Gd	-	2E+3	1E-6	3E-9	-	-
64	Gadolinium-151	D, see <sup>145</sup> Gd	6E+3	4E+2 Bone surf	2E-7	-	9E-5	9E-4
		145	-	(6E+2)	-	9E-10	-	-
		W, see <sup>145</sup> Gd	-	1E+3	5E-7	2E-9	-	-
64	Gadolinium-152	D, see <sup>145</sup> Gd	2E+1 Bone surf	1E-2 Bone surf	4E-12	-	-	-
		III 1450 t	(3E+1)	(2E-2)	-	3E-14	4E-7	4E-6
		W, see <sup>145</sup> Gd	-	4E-2 Bone surf	2E-11	-	-	-
			-	(8E-2)	-	1E-13	-	-
64	Gadolinium-153	D, see <sup>145</sup> Gd	5E+3	1E+2 Bone surf	6E-8	-	6E-5	6E-4
			-	(2E+2)	-	3E-10	-	-
		W, see <sup>145</sup> Gd	-	6E+2	2E-7	8E-10	-	-
64	Gadolinium-159	D see <sup>145</sup> Gd	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4

			Осси	Table I pational Valu	es	Table Efflue Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inhali</u> ALI (µCi)	ation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		W, see <sup>145</sup> Gd	-	6E+3	2E-6	8E-9	-	-
65	Terbium-147 <sup>2</sup>	W, all compounds	9E+3	3E+4	1E-5	5E-8	1E-4	1E-3
65	Terbium-149	W, all compounds	5E+3	7E+2	3 <b>E-</b> 7	1E-9	7E-5	7E-4
65	Terbium-150	W, all compounds	5E+3	2E+4	9E-6	3E-8	7E-5	7E-4
65	Terbium-151	W, all compounds	4E+3	9E+3	4E-6	1E-8	5E-5	5E-4
65	Terbium-153	W, all compounds	5E+3	7E+3	3E-6	1E-8	7E-5	7E-4
65	Terbium-154	W, all compounds	2E+3	4E+3	2E-6	6E-9	2E-5	2E-4
65	Terbium-155	W, all compounds	6E+3	<b>8E</b> +3	3E-6	1E-8	8E-5	8E-4
65	Terbium-156m (5.0 h)	W, all compounds	2E+4	3E+4	1E-5	4E-8	2E-4	2E-3
65	Terbium-156m (24.4 h)	W, all compounds	7E+3	8E+3	3E-6	1E-8	1E-4	1E-3
65	Terbium-156	W, all compounds	1E+3	1E+3	6E-7	2E-9	1E-5	1E-4
65	Terbium-157	W, all compounds	5E+4 LLI wall	3E+2 Bone surf	1E-7	-	-	-
			(5E+4)	(6E+2)	-	8E-10	7E-4	7E-3
65	Terbium-158	W, all compounds	1E+3	2E+1	8E-9	3E-11	2E-5	2E-4
65	Terbium-160	W, all compounds	8E+2	2E+2	9E-8	3E-10	1E-5	1E-4
65	Terbium-161	W, all compounds	2E+3 LLI wall	2E+3	7E-7	2E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
66	Dysprosium-155	W, all compounds	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
66	Dysprosium-157	W, all compounds	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
66	Dysprosium-159	W, all compounds	1E+4	2E+3	1E-6	3E-9	2E-4	2E-3
66	Dysprosium-165	W, all compounds	1E+4	5E+4	2E-5	6E-8	2E-4	2E-3

~

~

			Occu	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion		Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
66	Dysprosium-166	W, all compounds	6E+2 LLI wall	7E+2	3E-7	1E-9	-	-
			(8E+2)	-	-	-	1E-5	1 <b>E-</b> 4
67	Holmium-155 <sup>2</sup>	W, all compounds	4E+4	2E+5	6E-5	2E-7	6E-4	6E-3
67	Holmium-157 <sup>2</sup>	W, all compounds	3E+5	1E+6	6E-4	2E-6	4E-3	4E-2
67	Holmium-159 <sup>2</sup>	W, all compounds	2E+5	1E+6	4E-4	1E-6	3E-3	3E-2
67	Holmium-161	W, all compounds	1E+5	4E+5	2E-4	6 <b>E-</b> 7	1E-3	1E-2
67	Holmium-162m <sup>2</sup>	W, all compounds	5E+4	3E+5	1E-4	4E-7	7E-4	7E-3
67	Holmium-162 <sup>2</sup>	W, all compounds	5E+5 St wall	2E+6	1E-3	3E-6	-	-
			(8E+5)	-	-	-	1E-2	1E-1
67		W, all compounds	1E+5	3E+5	1E-4	4E-7	1E-3	1E-2
67	Holmium-164 <sup>2</sup>	W, all compounds	2E+5 St wall (2E+5)	6E+5 -	3E-4 -	9E-7 -	- 3E-3	- 3E-2
67	Holmium-166m	W, all compounds	6E+2	7E+0	3E-9	9E-12	9E-6	9E-5
67	Holmium-166	W, all compounds	9E+2 LLI wall	2E+3	7E-7	2E-9	-	-
			(9E+2)	-	-	-	1E-5	1E-4
67	Holmium-167	W, all compounds	2E+4	6E+4	2E-5	8E-8	2E-4	2E-3
68	Erbium-161	W, all compounds	2E+4	6E+4	3E-5	9E-8	2E-4	2E-3
68	Erbium-165	W, all compounds	6E+4	2E+5	8E-5	3E-7	9E-4	9E-3
68	Erbium-169	W, all compounds	3E+3 LLI wall	3E+3	1 <b>E-</b> 6	4E-9	-	-
<i>7</i> 0		XX7 -11	(4E+3)	-	-	-	5E-5	5E-4
68	Erbium-171	W, all compounds	4E+3	1E+4	4 <b>E-</b> 6	1E-8	5E-5	5E-4
68	Erbium-172	W, all compounds	1E+3 LLI wall	1E+3	6E-7	2E-9	-	-
			(E+3)	-	-	-	2E-5	2E-4

			Occu	Table I pational Valu	es	Table Efflu Concent	ent	Table III Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	ic Radionuclide	Class	Ingestion ALI (µCi)	Inhal ALI (μCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
69	Thulium-162 <sup>2</sup>	W, all compounds	7E+4 St wall	3E+5	1E-4	4E-7	-	-
69	Thulium 166	W oll common de	(7E+4)	-	-	-	1E-3	1E-2
	Thulium-166	W, all compounds	4E+3	1E+4	6E-6	2E-8	6E-5	6E-4
69	Thulium-167	W, all compounds	2E+3 LLI wall	2E+3	8E-7	3E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
69	Thulium-170	W, all compounds	8E+2 LLI wall	2E+2	9E-8	3E-10	-	-
	,		(1E+3)	-	-	-	1E-5	1E-4
59	Thulium-171	W, all compounds	1E+4 LLI wall	3E+2 Bone surf	1E-7	-	-	-
			(1E+4)	(6E+2)	-	8E-10	2E-4	2E-3
59	Thulium-172	W, all compounds	7E+2 LLI wall	1E+3	5E-7	2E-9	-	-
			(8E+2)	-	-	-	1E-5	1E-4
i9	Thulium-173	W, all compounds	4E+3	1E+4	5E-6	2E-8	6E-5	6E-4
59	Thulium-175 <sup>2</sup>	W, all compounds	7E+4 St wall	3E+5	1 <b>E-4</b>	4E-7	-	-
			(9E+4)	-	-	-	1E-3	1E-2
70	Ytterbium-162 <sup>2</sup>	W, all compounds except those given for Y	7E+4	3E+5	1E-4	4E-7	1E-3	1E-2
		Y, oxides, hydroxides, and fluorides	-	3E+5	1E-4	4E-7	-	-
'0	Ytterbium-166	W, see $^{162}$ Yb Y, see $^{162}$ Yb	1E+3	2E+3 2E+3	8E-7 8E-7	3E-9 3E-9	2E-5	2E-4
0	March : 1677							-
U	Ytterbium-167 <sup>2</sup>	W, see $^{162}$ Yb Y, see $^{162}$ Yb	3E+5 -	8E+5 7E+5	3E-4 3E-4	1E-6 1E-6	4E-3 -	4E-2 -
0	Ytterbium-169	W, see ${}^{162}$ Yb Y, see ${}^{162}$ Yb	2E+3 -	8E+2 7E+2	4E-7 3E-7	1E-9 1E-9	2E-5	2E-4
0	Ytterbium-175	W, see <sup>162</sup> Yb	3E+3 LLI wall	4E+3	1 <b>E-</b> 6	5E-9	-	-
		Y, see <sup>162</sup> Yb	(3E+3)	- 3E+3	- 1E-6	- 5E-9	4E-5	4E-4

			Table I Occupational Values		es	Table II Effluent Concentrations		Table III Releases to Sewers Monthly Average Concentratio (µCi/ml) 2E-3 - 2E-3 - 3E-4 - 2E-4 - 3E-4 - 3E-4 - 1E-4 - 7E-4 - 7E-4 - 7E-4 - 7E-4 - 1E-3 - 1E-3 - 1E-3 -
 		-	Col. 1 Oral Ingestion	Col. 2		Col. 1	Col. 2	Releases to Sewers Monthly Average Concentration (µCi/ml) 2E-3 - 2E-3 - 3E-4 - 3E-4 - 3E-4 - 3E-4 - 1E-4 - 7E-4 - 4E-4 - 7E-4 - 1E-3 - 1E-3 -
Aton No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
70	Ytterbium-177 <sup>2</sup>	W, see ${}^{162}$ Yb Y, see ${}^{162}$ Yb	2E+4 -	5E+4 5E+4	2E-5 2E-5	7E-8 6E-8	2E-4 -	2E-3 -
70	Ytterbium-178 <sup>2</sup>	W, see ${}^{162}$ Yb Y, see ${}^{162}$ Yb	1E+4 -	4E+4 4E+4	2E-5 2E-5	6E-8 5E-8	2E-4	2E-3 -
71	Lutetium-169	W, all compounds except those given for Y Y, oxides, hydroxides, and fluorides	3E+3 -	4E+3 4E+3	2E-6 2E-6	6E-9 6E-9	3E-5 -	3E-4
71	Lutetium-170	W, see <sup>169</sup> Lu Y, see <sup>169</sup> Lu	1E+3 -	2E+3 2E+3	9E-7 8E-7	3E-9 3E-9	2E-5 -	2E-4 -
71	Lutetium-171	W, see <sup>169</sup> Lu Y, see <sup>169</sup> Lu	2E+3 -	2E+3 2E+3	8E-7 8E-7	3E-9 3E-9	3E-5 -	3E-4 -
71	Lutetium-172	W, see <sup>169</sup> Lu Y, see <sup>169</sup> Lu	1E+3 -	1E+3 1E+3	5E-7 5E-7	2E-9 2E-9	1E-5 -	1E-4 -
71	Lutetium-173	W, see <sup>169</sup> Lu	5E+3	3E+2 Bone surf	1 <b>E-</b> 7	-	7E-5	7E-4
		Y, see <sup>169</sup> Lu	-	(5E+2) 3E+2	- 1E-7	6E-10 4E-10	-	-
71	Lutetium-174m	W, see <sup>169</sup> Lu	2E+3 LLI wall	2E+2 Bone surf	1E-7	- 5T- 10	-	-
		Y, see <sup>169</sup> Lu	(3E+3) -	(3E+2) 2E+2	- 9E-8	5E-10 3E-10	4E-5 -	4E-4 -
71	Lutetium-174	W, see <sup>169</sup> Lu	5E+3	1E+2 Bone surf	5E-8	-	7E-5	7E-4
		Y, see <sup>169</sup> Lu	- 	(2E+2) 2E+2	- 6E-8	3E-10 2E-10	-	-
71	Lutetium-176m	W, see <sup>169</sup> Lu Y, see <sup>169</sup> Lu	8E+3 -	3E+4 2E+4	1E-5 9E-6	3E-8 3E-8	1E-4 -	
71	Lutetium-176	W, see <sup>169</sup> Lu	7E+2	5E+0 Bone surf	2E-9	-	1E-5	1E-4
		Y, see <sup>169</sup> Lu	-	(1E+1) 8E+0	- 3E-9	2E-11 1E-11	-	-
71	Lutetium-177m	W, see <sup>169</sup> Lu	7E+2	1E+2 Bone surf	5E-8	-	1E-5	1E-4

•

			Occu	Table I pational Valu	es	Table Efflu Concent	ent	Table III Releases to Sewers
		- -	Col. 1 Oral Ingestion	Col. 2 Inhal	Col. 3	Col. 1	Col. 2	Monthly
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		Y, see <sup>169</sup> Lu	-	8E+1	3E-8	1E-10	-	-
71	Lutetium-177	W, see <sup>169</sup> Lu	2E+3 LLI wall	2E+3	9E-7	3E-9	-	-
		Y, see <sup>169</sup> Lu	(3E+3) -	- 2E+3	- 9E-7	- 3E-9	4E-5 -	4E-4 -
71	Lutetium-178m <sup>2</sup>	W, see <sup>169</sup> Lu	5E+4 St. wall	2E+5	8E-5	3E-7	-	-
		Y, see <sup>169</sup> Lu	(6E+4) -	- 2E+5	- 7E-5	- 2E-7	8E-4 -	8E-3 -
71	Lutetium-178 <sup>2</sup>	W, see <sup>169</sup> Lu	4E+4 St wall	1E+5	5E-5	2E-7	-	-
		Y, see <sup>169</sup> Lu	(4E+4) -	- 1E+5	- 5E-5	- 2E-7	6E-4 -	6E-3 -
71	Lutetium-179	W, see <sup>169</sup> Lu Y, see <sup>169</sup> Lu	6E+3 -	2E+4 2E+4	8E-6 6E-6	3E-8 3E-8	9E-5 -	9E-4 -
72	Hafnium-170	D, all compounds except those given for W W, oxides, hydroxides,	3E+3	6E+3	2E-6	8E-9	4E-5	4E-4
		carbides, and nitrates	-	5E+3	2E-6	6E-9	-	-
72	Hafnium-172	D, see <sup>170</sup> Hf	1E+3	9E+0 Bone surf	4E-9	-	2E-5	2E-4
		W, see <sup>170</sup> Hf	-	(2E+1) 4E+1 Bone surf	- 2E-8	3E-11 -	-	-
			-	(6E+1)	-	8E-11	-	-
72	Hafnium-173	D, see <sup>170</sup> Hf W, see <sup>170</sup> Hf	5E+3 -	1E+4 1E+4	5E-6 5E-6	2E-8 2E-8	7E-5 -	7E-4 -
72	Hafnium-175	D, see <sup>170</sup> Hf	3E+3	9E+2 Bone surf	4E-7	-	4E-5	4E-4
		W, see <sup>170</sup> Hf	-	(1E+3) 1E+3	- 5E-7	1E-9 2E-9	-	-
72	Hafnium-177m <sup>2</sup>	D, see <sup>170</sup> Hf W, see <sup>170</sup> Hf	2E+4 -	6E+4 9E+4	2E-5 4E-5	8E-8 1E-7	3E-4 -	3E-3
72	Hafnium-178m	D, see <sup>170</sup> Hf	3E+2	1E+0 Bone surf	5E-10	-	3E-6	3E-5
			-	(2E+0)	-	3E-12	-	•

			Occuj	Table I pational Value	es	Table Efflue Concent	ent	Table III Releases to Sewers
		- -	Col. 1 Oral Ingestion	Col. 2 Inhala	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ΑLΙ (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
		W, see <sup>170</sup> Hf	-	5E+0	2E-9	-	_	-
			-	Bone surf (9E+0)	-	1E-11	-	-
72	Hafnium-179m	D, see <sup>170</sup> Hf	1E+3	3E+2 Bone surf	1E-7	-	1E-5	1E-4
		W, see <sup>170</sup> Hf	-	(6E+2) 6E+2	- 3E-7	8E-10 8E-10	-	-
72	Hafnium-180m	D, see <sup>170</sup> Hf W, see <sup>170</sup> Hf	7E+3	2E+4 3E+4	9E-6 1E-5	3E-8 4E-8	1E-4	1E-3 -
72	Hafnium-181	D, see <sup>170</sup> Hf	1E+3	2E+2 Bone surf	7E-8	-	2E-5	2E-4
		W, see <sup>170</sup> Hf	-	(4E+2) 4E+2	- 2E-7	6E-10 6E-10	-	-
72	Hafnium-182m <sup>2</sup>	D, see <sup>170</sup> Hf W, see <sup>170</sup> Hf	4E+4 -	9E+4 1E+5	4E-5 6E-5	1E-7 2E-7	5E-4 -	5E-3 -
72	Hafnium-182	D, see <sup>170</sup> Hf	2E+2 Bone surf	8E-1 Bone surf	3E-10	-	-	-
		W, see <sup>170</sup> Hf	(4E+2) -	(2E+0) 3E+0 Bone surf	- 1E-9	2E-12 -	5E-6 -	5E-5 -
			-	(7E+0)	-	1E-11	-	-
72	Hafnium-183 <sup>2</sup>	D, see <sup>170</sup> Hf W, see <sup>170</sup> Hf	2E+4 -	5E+4 6E+4	2E-5 2E-5	6E-8 8E-8	3E-4 -	3E-3 -
72	Hafnium-184	D, see <sup>170</sup> Hf W, see <sup>170</sup> Hf	2E+3 -	8E+3 6E+3	3E-6 3E-6	1E-8 9E-9	3E-5 -	3E-4 -
73	Tantalum-172 <sup>2</sup>	W, all compounds except those given for Y Y, elemental Ta, oxides, hydroxides, halides, cathides, nitrates	4E+4	1E+5	5E-5	2E-7	5E-4	5E-3
		carbides, nitrates, and nitrides	-	1E+5	4E-5	1E-7	-	-
73	Tantalum-173	W, see $^{172}$ Ta Y, see $^{172}$ Ta	7E+3 -	2E+4 2E+4	8E-6 7E-6	3E-8 2E-8	9E-5 -	9E-4 -
73	Tantalum-174 <sup>2</sup>	W, see $^{172}$ Ta Y, see $^{172}$ Ta	3E+4 -	1E+5 9E+4	4E-5 4E-5	1E-7 1E-7	4E-4 -	4E-3 -

			Осси	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
73	Tantalum-175	W, see <sup>172</sup> Ta Y, see <sup>172</sup> Ta	6E+3 -	2E+4 1E+4	7E-6 6E-6	2E-8 2E-8	8E-5 -	8E-4 -
73	Tantalum-176	W, see <sup>172</sup> Ta Y, see <sup>172</sup> Ta	4E+3	1E+4 1E+4	5E-6 5E-6	2E-8 2E-8	5E-5 -	5E-4 -
73	Tantalum-177	W, see ${}^{172}$ Ta Y, see ${}^{172}$ Ta	1E+4 -	2E+4 2E+4	8E-6 7E-6	3E-8 2E-8	2E-4 -	2E-3
73	Tantalum-178	W, see <sup>172</sup> Ta Y, see <sup>172</sup> Ta	2E+4 -	9E+4 7E+4	4E-5 3E-5	1E-7 1E-7	2E-4 -	2E-3
73	Tantalum-179	W, see $^{172}$ Ta Y, see $^{172}$ Ta	2E+4 -	5E+3 9E+2	2E-6 4E-7	8E-9 1E-9	3E-4 -	3E-3 -
73	Tantalum-180m	W, see ${}^{172}$ Ta Y, see ${}^{172}$ Ta	2E+4 -	7E+4 6E+4	3E-5 2E-5	9E-8 8E-8	3E-4 -	3E-3 -
73	Tantalum-180	W, see <sup>172</sup> Ta Y, see <sup>172</sup> Ta	1E+3 -	4E+2 2E+1	2E-7 1E-8	6E-10 3E-11	2E-5 -	2E-4
73	Tantalum-182m <sup>2</sup>	W, see <sup>172</sup> Ta	2E+5 St wall	5E+5	2E-4	8E-7	-	-
		Y, see <sup>172</sup> Ta	(2E+5) -	- 4E+5	- 2E-4	- 6E-7	3E-3 -	3E-2 -
73	Tantalum-182	W, see ${}^{172}$ Ta Y, see ${}^{172}$ Ta	8E+2 -	3E+2 1E+2	1E-7 6E-8	5E-10 2E-10	1E-5 -	1E-4 -
73	Tantalum-183	W, see <sup>172</sup> Ta	9E+2 LLI wall	1E+3	5E-7	2E-9	-	-
		Y, see <sup>172</sup> Ta	(1E+3) -	- 1E+3	- 4E-7	- 1E-9	2E-5 -	2E-4 -
73	Tantalum-184	W, see <sup>172</sup> Ta Y, see <sup>172</sup> Ta	2E+3 -	5E+3 5E+3	2E-6 2E-6	8E-9 7E-9	3E-5 -	3E-4 -
73	Tantalum-185 <sup>2</sup>	W, see <sup>172</sup> Ta Y, see <sup>172</sup> Ta	3E+4 -	7E+4 6E+4	3E-5 3E-5	1E-7 9E-8	4E-4 -	4E-3
73	Tantalum-186 <sup>2</sup>	W, see <sup>172</sup> Ta	5E+4 St wall	2E+5	1E-4	3E-7	-	-
		Y, see <sup>172</sup> Ta	(7E+4) -	- 2E+5	- 9E-5	- 3E-7	1E-3 -	1E-2 -
74	Tungsten-176	D, all compounds	1E+4	5E+4	2E-5	7E-8	1E-4	1E-3

			Occuj	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
,			Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Monthly Average
Ator No.	mic Radionuclide	Class	ΑĽΙ (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
74	Tungsten-177	D, all compounds	2E+4	9E+4	4E-5	1E-7	3E-4	3E-3
74	Tungsten-178	D, all compounds	5E+3	2E+4	8E-6	3E-8	, 7E-5	7E-4
74	Tungsten-179 <sup>2</sup>	D, all compounds	5E+5	2E+6	7E-4	2E-6	7E-3	7E-2
74	Tungsten-181	D, all compounds	2E+4	3E+4	1E-5	5E-8	2E-4	2E-3
74	Tungsten-185	D, all compounds	2E+3 LLI wall	7E+3	3E-6	9E-9	-	-
			(3E+3)	-	-	-	4E-5	4E-4
74	Tungsten-187	D, all compounds	2E+3	9E+3	4E-6	1E-8	3E-5	3E-4
74	Tungsten-188	D, all compounds	4E+2 LLI wall	1E+3	5E-7	2E-9	-	-
			(5E+2)	-	-	-	7E-6	7E-5
75	Rhenium-177 <sup>2</sup>	D, all compounds except those given for W	9E+4 St wall	3E+5	1E-4	4E-7	-	-
		W, oxides, hydroxides,	(1E+5)	-	-	-	2E-3	2E-2
		and nitrates	-	4E+5	1E-4	5E-7	-	-
75	Rhenium-178 <sup>2</sup>	D, see <sup>177</sup> Re	7E+4 St wall	3E+5	1E-4	4E-7	-	-
		W, see <sup>177</sup> Re	(1E+5) -	- 3E+5	- 1E-4	- 4E-7	1E-3 -	1E-2 -
75	Rhenium-181	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	5E+3 -	9E+3 9E+3	4E-6 4E-6	1E-8 1E-8	7E-5 -	7E-4 -
75	Rhenium-182 (12.7 h)	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	7E+3 -	1E+4 2E+4	5E-6 6E-6	2E-8 2E-8	9E-5 -	9E-4 -
75	Rhenium-182 (64.0 h)	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	1E+3 -	2E+3 2E+3	1E-6 9E-7	3E-9 3E-9	2E-5 -	2E-4 -
75	Rhenium-184m	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	2E+3 -	3E+3 4E+2	1E-6 2E-7	4E-9 6E-10	3E-5 -	3E-4 -
75	Rhenium-184	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	2E+3 -	4E+3 1E+3	1E-6 6E-7	5E-9 2E-9	3E-5	3E-4 -
75	Rhenium-186m	D, see <sup>177</sup> Re	1E+3	2E+3	7E-7	-	-	_

			Occu	Table I pational Val	ues	Table Efflu Concen	ent	Table III Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomi No.	ic Radionuclide	Class	Ingestion ALI (µCi)	<u>Inha</u> ALI (µCi)	lation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		-	St wall (2E+3)	St wall (2E+3)	_	3E-9	2E-5	2E-4
		W, see <sup>177</sup> Re	-	2E+2	6E-8	2E-10	-	- -
75	Rhenium-186	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	2E+3 -	3E+3 2E+3	1E-6 7E-7	4E-9 2E-9	3E-5 -	3E-4 -
75	Rhenium-187	D, see <sup>177</sup> Re	6E+5 St wall	8E+5	4E-4	-	8E-3	8E-2
		W, see <sup>177</sup> Re	-	(9E+5) 1E+5	- 4E-5	1E-6 1E-7	- -	-
75	Rhenium-188m <sup>2</sup>	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	8E+4 -	1E+5 1E+5	6E-5 6E-5	2E-7 2E-7	1E-3 -	1E-2 -
75	Rhenium-188	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	2E+3 -	3E+3 3E+3	1E-6 1E-6	4E-9 4E-9	2E-5 -	2E-4 -
75	Rhenium-189	D, see <sup>177</sup> Re W, see <sup>177</sup> Re	3E+3 -	5E+3 4E+3	2E-6 2E-6	7E-9 6E-9	4E-5	4E-4
76	Osmium-180 <sup>2</sup>	D, all compounds except	15 - 5					
		those given for W and Y W, halides and nitrates Y, oxides and hydroxides	1E+5 -	4E+5 5E+5 5E+5	2E-4 2E-4 2E-4	5E-7 7E-7 6E-7	1E-3 - -	1E-2 - -
76	Osmium-181 <sup>2</sup>	D, see <sup>180</sup> Os W, see <sup>180</sup> Os	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		Y, see $^{180}$ Os	-	5E+4 4E+4	2E-5 2E-5	6E-8 6E-8	-	-
76	Osmium-182	D, see <sup>180</sup> Os W, see <sup>180</sup> Os	2E+3	6E+3 4E+3	2E-6 2E-6	8E-9 6E-9	3E-5	3E-4
		Y, see <sup>180</sup> Os	-	4E+3	2E-6	6E-9	-	-
76	Osmium-185	D, see <sup>180</sup> Os W, see <sup>180</sup> Os	2E+3	5E+2 8E+2	2E <b>-</b> 7 3E-7	7E-10 1E-9	3E-5	3E-4
		Y, see <sup>180</sup> Os	-	8E+2	3E-7 3E-7	1E-9 1E-9	-	-
76	Osmium-189m	D, see <sup>180</sup> Os W, see <sup>180</sup> Os	8E+4 -	2E+5 2E+5	1E-4 9E-5	3E-7 3E-7	1E-3	1E-2
		Y, see $^{180}$ Os	-	2E+5 2E+5	7E-5	2E-7	-	-
76	Osmium-191m	D, see <sup>180</sup> Os W, see <sup>180</sup> Os	1E+4 -	3E+4 2E+4	1E-5 8E-6	4E-8 3E-8	2E-4	2E-3
		Y, see $^{180}$ Os	-	2E+4 2E+4	3E-6 7E-6	2E-8	-	- ``

			Occu	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
76	Osmium-191	D, see <sup>180</sup> Os	2E+3 LLI wall	2E+3	9E-7	3E-9	-	-
		W, see <sup>180</sup> Os Y, see <sup>180</sup> Os	(3E+3) - -	- 2E+3 1E+3	- 7E-7 6E-7	- 2E-9 2E-9	3E-5 - -	3E-4 - -
76	Osmium-193	D, see <sup>180</sup> Os	2E+3 LLI wall	5E+3	2E-6	6E-9	-	-
		W, see <sup>180</sup> Os Y, see <sup>180</sup> Os	(2E+3) - -	- 3E+3 3E+3	- 1E-6 1E-6	- 4E-9 4E-9	2E-5 - -	2E-4 - -
76	Osmium-194	D, see <sup>180</sup> Os	4E+2 LLI wall	4E+1	2E-8	6E-11	-	-
		W, see <sup>180</sup> Os Y, see <sup>180</sup> Os	(6E+2) - -	- 6E+1 8E+0	- 2E-8 3E-9	- 8E-11 1E-11	8E-6 - -	8E-5 - -
77	Iridium-182 <sup>2</sup>	D, all compounds except those given for W and Y	4E+4 St wall	1E+5	6E-5	2E-7	-	-
		W, halides, nitrates, and metallic iridium Y, oxides and hydroxides	(4E+4) - -	- 2E+5 1E+5	- 6E-5 5E-5	- 2E-7 2E-7	6E-4 - -	6E-3 - -
77	Iridium-184	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	8E+3 - -	2E+4 3E+4 3E+4	1E-5 1E-5 1E-5	3E-8 5E-8 4E-8	1E-4 - -	1E-3 - -
77	Iridium-185	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	5E+3 - -	1E+4 1E+4 1E+4	5E-6 5E-6 4E-6	2E-8 2E-8 1E-8	7E-5 - -	7E-4 - -
77	Iridium-186	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	2E+3 - -	8E+3 6E+3 6E+3	3E-6 3E-6 2E-6	1E-8 9E-9 8E-9	3E-5 - -	3E-4 -
77	Iridium-187	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	1E+4 - -	3E+4 3E+4 3E+4	1E-5 1E-5 1E-5	5E-8 4E-8 4E-8	1E-4 -	1E-3 - -
_ 77	Iridium-188	D, see $^{182}$ Ir W, see $^{182}$ Ir	2E+3 -	5E+3 4E+3	2E-6 1E-6	6E-9 5E-9	3E-5 -	3E-4 -

-

			Осси	Table I pational Val	lues	Table Efflu Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atom No.	nic Radionuclide	Class	Ingestion ALI (µCi)	ALI (µCi)	alation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		Y, see <sup>182</sup> Ir	-	3 <b>E</b> +3	1E-6	5E-9	_	-
77	Iridium-189	D, see <sup>182</sup> Ir	5E+3 LLI wall (5E+3)	5E+3	2E-6	7E-9	-	-
		W, see ${}^{182}$ Ir Y, see ${}^{182}$ Ir	-	4E+3 4E+3	- 2E-6 1E-6	- 5E-9 5E-9	7E-5 - -	7E-4 - -
77	Iridium-190m <sup>2</sup>	D, see <sup>182</sup> Ir W, see <sup>182</sup> Ir	2E+5	2E+5 2E+5	8E-5 9E-5	3E-7 3E-7	2E-3	2E-2
		Y, see $^{182}$ Ir	-	2E+5 2E+5	8E-5	3E-7	-	-
77	Iridium-190	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	1E+3 - -	9E+2 1E+3 9E+2	4E-7 4E-7 4E-7	1E-9 1E-9 1E-9	1E-5 - -	1E-4 - -
77	Iridium-192m	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	3E+3 - -	9E+1 2E+2 2E+1	4E-8 9E-8 6E-9	1E-10 3E-10 2E-11	4E-5 -	4E-4 -
77	Iridium-192	D, see $^{182}$ Ir W, see $^{182}$ Ir	9E+2 -	3E+2 4E+2	1E-7 2E-7	4E-10 6E-10	1E-5 -	1E-4 -
77	Iridium-194m	Y, see $^{182}$ Ir D, see $^{182}$ Ir W, see $^{182}$ Ir	- 6E+2	2E+2 9E+1	9E-8 4E-8	3E-10 1E-10	- 9E-6	- 9E-5
		Y, see $^{182}$ Ir	-	2E+2 1E+2	7E-8 4E-8	2E-10 1E-10	-	-
77	Iridium-194	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	1E+3 - -	3E+3 2E+3 2E+3	1E-6 9E-7 8E-7	4E-9 3E-9 3E-9	1E-5 - -	1E-4 - -
77	Iridium-195m	D, see $^{182}$ Ir W, see $^{182}$ Ir Y, see $^{182}$ Ir	8E+3 - -	2E+4 3E+4 2E+4	1E-5 1E-5 9E-6	3E-8 4E-8 3E-8	1E-4 -	1E-3 - -
77	Iridium-195	D, see $^{182}$ Ir W, see $^{182}$ Ir	1E+4 -	4E+4 5E+4	2E-5 2E-5	6E-8 7E-8	2E-4	2E-3 -
78	Platinum-186	Y, see <sup>182</sup> Ir D, all compounds	- 1E+4	4E+4 4E+4	2E-5	6E-8	-	-
78	Platinum-188	D, all compounds	2E+3	4£+4 2E+3	2E-5 7E-7	5E-8 2E-9	2E-4 2E-5	2E-3 2E-4
78	Platinum-189	D, all compounds	1E+4	3E+4	1E-5	4E-8	1E-4	1E-3

			Occuj	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers	
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly	
Atom No.	ic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)	
78	Platinum-191	D, all compounds	4E+3	8E+3	4 <b>E-</b> 6	1E-8	5E-5	5E-4	
78	Platinum-193m	D, all compounds	3E+3 LLI wall	6E+3	3 <b>E-</b> 6	8E-9	-	-	
			(3E+4)	-	-	-	4E-5	4E-4	
78	Platinum-193	D, all compounds	4E+4 LLI wall	2E+4	1E-5	3E-8	-	-	
			(5E+4)	-	-	-	6E-4	6E-3	
78	Platinum-195m	D, all compounds	2E+3 LLI wall	4E+3	2E-6	6E-9	-	-	
			(2E+3)	-	-	-	3E-5	3E-4	
78	Platinum-197m <sup>2</sup>	D, all compounds	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3	
78	Platinum-197	D, all compounds	3E+3	1E+4	4E-6	1E-8	4E-5	4E-4	
78	Platinum-199 <sup>2</sup>	D, all compounds	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3	
78	Platinum-200	D, all compounds	1E+3	3E+3	1E-6	5E-9	2E-5	2E-4	
79	Gold-193	D, all compounds except those given for W and Y W, halides and nitrates Y, oxides and hydroxides	9E+3 - -	3E+4 2E+4 2E+4	1E-5 9E-6 8E-6	4E-8 3E-8 3E-8	1E-4 - -	1E-3 - -	
79	Gold-194	D, see <sup>193</sup> Au W, see <sup>193</sup> Au Y, see <sup>193</sup> Au	3E+3 -	8E+3 5E+3 5E+3	3E-6 2E-6 2E-6	1E-8 8E-9 7E-9	4E-5 - -	4E-4 -	
79	Gold-195	D, see <sup>193</sup> Au W, see <sup>193</sup> Au Y, see <sup>193</sup> Au	5E+3 - -	1E+4 1E+3 4E+2	5E-6 6E-7 2E-7	2E-8 2E-9 6E-10	7E-5 - -	7E-4 - -	
79	Gold-198m	D, see <sup>193</sup> Au W, see <sup>193</sup> Au Y, see <sup>193</sup> Au	1E+3 - -	3E+3 1E+3 1E+3	1E-6 5E-7 5E-7	4E-9 2E-9 2E-9	1E-5 - -	1E-4 - -	
79	Gold-198	D, see <sup>193</sup> Au W, see <sup>193</sup> Au Y, see <sup>193</sup> Au	1E+3 - -	4E+3 2E+3 2E+3	2E-6 8E-7 7E-7	5E-9 3E-9 2E-9	2E-5 - -	2E-4 - -	
79	Gold-199	D, see <sup>193</sup> Au	3E+3	9E+3	4E-6	1E-8	-	-	
			LLI wall (3E+3)	-	-	-	4E-5	4E-4	

			Occu	Table I pational Val	ues	Table Efflu Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	Ingestion ALI (µCi)	ALI (µCi)	llation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
		W, see <sup>193</sup> Au		4E+3	2E 6			
		Y, see $^{193}$ Au	-	4E+3 4E+3	2E-6 2E-6	6E-9 5E-9	-	-
79 (	Gold-200m	D, see <sup>193</sup> Au	1E+3	4E+3	1E-6	5E-9	2E-5	2E-4
		W, see <sup>193</sup> Au	-	3E+3	1E-6	4E-9	-	-
		Y, see <sup>193</sup> Au	-	2E+4	1E-6	3E-9	-	-
79 (	Gold-200 <sup>2</sup>	D, see <sup>193</sup> Au	3E+4	6E+4	3E-5	9E-8	4E-4	4E-3
		W, see <sup>193</sup> Au	-	8E+4	3E-5	1E-7	-	-
		Y, see <sup>193</sup> Au	-	7E+4	3E-5	1E-7	-	-
79 (	Gold-201 <sup>2</sup>	D, see <sup>193</sup> Au	7E+4 St wall	2E+5	9E-5	3E-7	-	-
		102 .	(9E+4)	-	-	-	1E-3	1E-2
		W, see $^{193}$ Au	-	2E+5	1E-4	3E-7	-	-
		Y, see <sup>193</sup> Au	-	2E+5	9E-5	3E-7	-	-
80 N	Mercury-193m	Vapor Organia D	-	8E+3	4E-6	1E-8	-	-
		Organic D D, sulfates W, oxides, hydroxides,	4E+3 3E+3	1E+4 9E+3	5E-6 4E-6	2E-8 1E-8	6E-5 4E-5	6E-4 4E-4
		halides, nitrates, and sulfides	-	8E+3	3E-6	1E-8	-	-
30 N	Aercury-193	Vapor	-	3E+4	1E-5	4E-8	_	_
	-	Organic D	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		D, see <sup>193m</sup> Hg	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, see <sup>193m</sup> Hg	-	4E+4	2E-5	6E-8	-	-
80 N	Aercury-194	Vapor	-	3E+1	1E <b>-8</b>	4E-11	-	-
		Organic D	2E+1	3E+1	1E-8	4E-11	2E-7	2E-6
		D, see <sup>193m</sup> Hg W, see <sup>193m</sup> Hg	8E+2	4E+1 1E+2	2E-8 5E-8	6E-11 2E-10	1E-5	1E-4
		Ū.	_		512-0	2E-10	-	-
80 N	Mercury-195m	Vapor	-	4E+3	2E-6	6E-9	-	-
		Organic D D, see <sup>193m</sup> Hg	3E+3	6E+3	3E-6	8E-9	4E-5	4E-4
		D, see <sup>193m</sup> Hg	2E+3 -	5E+3 4E+3	2E-6 2E-6	7E-9 5E-9	3E-5 -	3E-4 -
30 N	Aercury-195	Vapor	-	3E+4	1E-5	4E-8	_	
		Organic D	- 2E+4	5E+4	2E-5	4E-8 6E-8	- 2E-4	- 2E-3
		D, see <sup>193m</sup> Hg	1E+4	4E+4	1E-5	5E-8	2E-4	2E-3 2E-3
		W, see <sup>193m</sup> Hg	-	3E+4	1E-5	5E-8	-	-
30 N	Mercury-197m	Vapor	-	5E+3	<b>2E-</b> 6	7E-9		
	-	Organic D	4E+3	9E+3	4E-6	1E-8	5E-5	5E-4

-----

.

	<u>, , , , , , , , , , , , , , , , , , , </u>		Осси	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Ator No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
		D, see <sup>193m</sup> Hg W, see <sup>193m</sup> Hg	3E+3 -	7E+3 5E+3	3E-6 2E-6	1 <b>E-8</b> 7E-9	4E-5 -	4E-4 -
80	Mercury-197	Vapor Organic D D, see <sup>193m</sup> Hg W, see <sup>193m</sup> Hg	- 7E+3 6E+3 -	8E+3 1E+4 1E+4 9E+3	4E-6 6E-6 5E-6 4E-6	1E-8 2E-8 2E-8 1E-8	- 9E-5 8E-5 -	- 9E-4 8E-4 -
80	Mercury-199m <sup>2</sup>	Vapor Organic D	- 6E+4 St wall	8E+4 2E+5	3E-5 7E-5	1E-7 2E-7	-	-
		D, see <sup>193m</sup> Hg W, see <sup>193m</sup> Hg	(1E+5) 6E+4 -	- 1E+5 2E+5	- 6E-5 7E-5	- 2E-7 2E-7	1E-3 8E-4 -	1E-2 8E-3 -
80	Mercury-203	Vapor Organic D D, see <sup>193m</sup> Hg W, see <sup>193m</sup> Hg	- 5E+2 2E+3 -	8E+2 8E+2 1E+3 1E+3	4E-7 3E-7 5E-7 5E-7	1E-9 1E-9 2E-9 2E-9	- 7E-6 3E-5 -	- 7E-5 3E-4 -
81	Thallium-194m <sup>2</sup>	D, all compounds	5E+4 St wall (7E+4)	2E+5 -	6E-5 -	2E-7 -	- 1E-3	- 1E-2
81	Thallium-194 <sup>2</sup>	D, all compounds	3E+5 St wall	6E+5	2E-4	8E-7	-	-
81	Thallium-195 <sup>2</sup>	D, all compounds	(3E+5) 6E+4	- 1E+5	- 5E-5	- 2E-7	4E-3 9E-4	4E-2 9E-3
81	Thallium-197	D, all compounds	7E+4	1E+5	5E-5	2E-7	1E-3	1E-2
81	Thallium-198m <sup>2</sup>	D, all compounds	3E+4	5E+4	2E-5	8E-8	4E-4	4E-3
81	Thallium-198	D, all compounds	2E+4	3E+4	1E-5	5E-8	3E-4	3E-3
81	Thallium-199	D, all compounds	6E+4	8E+4	4E-5	1E-7	9E-4	9E-3
81	Thallium-200	D, all compounds	8E+3	1E+4	5E-6	2E-8	1E-4	1E-3
81	Thallium-201	D, all compounds	2E+4	2E+4	9E-6	3E-8	2E-4	2E-3
81 81	Thallium-202 Thallium-204	D, all compounds D, all compounds	4E+3 2E+3	5E+3 2E+3	2E-6 9E-7	7E-9 3E-9	5E-5 2E-5	5E-4 2E-4

			Осси	Table I pational Valu	ies	Table Efflu Concen	ent	Table III Releases to Sewers
		-	Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
<b>A</b> 4 .	·	<b>C1</b>	Oral Ingestion	Inhal				Monthly Average
Aton No.	nic Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
82	Lead-195m <sup>2</sup>	D, all compounds	6E+4	2E+5	8E-5	3E-7	8E-4	8E-3
82	Lead-198	D, all compounds	3E+4	6E+4	3E-5	9E-8	4E-4	4E-3
82	Lead-199 <sup>2</sup>	D, all compounds	2E+4	7E+4	3E-5	1 <b>E-7</b>	3E-4	3E-3
82	Lead-200	D, all compounds	3E+3	6E+3	3E-6	9E-9	4E-5	4E-4
82	Lead-201	D, all compounds	7E+3	2E+4	8E-6	3E-8	1E-4	1E-3
82	Lead-202m	D, all compounds	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
82	Lead-202	D, all compounds	1E+2	5E+1	2E-8	7E-11	2E-6	2E-5
82	Lead-203	D, all compounds	5E+3	9E+3	4E-6	1E-8	7E-5	7E-4
82	Lead-205	D, all compounds	4E+3	1E+3	6E-7	2E-9	5E-5	5E-4
82	Lead-209	D, all compounds	2E+4	6E+4	2E-5	8E-8	3E-4	3E-3
82	Lead-210	D, all compounds	6E1 Bone surf (1E+0)	2E1 Bone surf (4E-1)	1E-10 -	- 6E-13	- 1E-8	- 1E-7
82	Lead-211 <sup>2</sup>	D, all compounds	1E+4	6E+2	3E <b>-</b> 7	9E-10	2E-4	2E-3
82	Lead-212	D, all compounds	8E+1	3E+1	1E-8	5E-11	-	-
			Bone surf (1E+2)	-	-	-	2E-6	2E-5
32	Lead-214 <sup>2</sup>	D, all compounds	9E+3	8E+2	3E-7	1E-9	1E-4	1E-3
83	Bismuth-200 <sup>2</sup>	D, nitrates W, all other compounds	3E+4 -	8E+4 1E+5	4E-5 4E-5	1E-7 1E-7	4E-4 -	4E-3
83	Bismuth-201 <sup>2</sup>	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	1E+4 -	3E+4 4E+4	1E-5 2E-5	4E-8 5E-8	2E-4	2E-3 -
33	Bismuth-202 <sup>2</sup>	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	1E+4 -	4E+4 8E+4	2E-5 3E-5	6 <b>E-8</b> 1 <b>E-</b> 7	2E-4 -	2E-3 -
3	Bismuth-203	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	2E+3 -	7E+3 6E+3	3E-6 3E-6	9E-9 9E-9	3E-5 -	3E-4 -
13	Bismuth-205	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	1E+3 -	3E+3 1E+3	1E-6 5E-7	3E-9 2E-9	2E-5	2E-4

			Occu	Table I pational Valu	ies	Table Efflue Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Inhal	Col. 3	Col. 1	Col. 2	Monthly
Atomi No.	ic Radionuclide	Class	ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
83	Bismuth-206	D. see <sup>200</sup> Bi W. see <sup>200</sup> Bi	6E+2 -	1E+3 9E+2	6E-7 4E-7	2E-9 1E-9	9E-6 -	9E-5 -
83	Bismuth-207	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	1E+3 -	2E+3 4E+2	7E-7 1E-7	2E-9 5E-10	1E-5 -	1E-4 -
83	Bismuth-210m	D, see <sup>200</sup> Bi	4E+1 Kidneys	5E+0 Kidneys	2E-9	-	-	-
		W, see <sup>200</sup> Bi	(6E+1) -	(6E+0) 7E-1	- 3E-10	9E-12 9E-13	8E-7 -	8E-6 -
83	Bismuth-210	D, see <sup>200</sup> Bi	8E+2 -	2E+2 Kidneys	1E-7	-	1E-5	1E-4
		W, see <sup>200</sup> Bi	-	(4E+2) 3E+1	- 1E-8	5E-10 4E-11	-	-
83	Bismuth-212 <sup>2</sup>	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	5E+3 -	2E+2 3E+2	1E-7 1E-7	3E-10 4E-10	7E-5 -	7E-4 -
83	Bismuth-213 <sup>2</sup>	D, see <sup>200</sup> Bi W, see <sup>200</sup> Bi	7E+3 -	3E+2 4E+2	1E-7 1E-7	4E-10 5E-10	1E-4 -	1E-3 -
83	Bismuth-214 <sup>2</sup>	D, see <sup>200</sup> Bi	2E+4 St wall	8E+2	3E-7	1E-9	-	-
		W, see <sup>200</sup> Bi	(2E+4) -	- 9E-2	- 4E-7	- 1E-9	3E-4 -	3E-3 -
84	Polonium-203 <sup>2</sup>	D, all compounds except those given for W W, oxides, hydroxides,	3E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		and nitrates	-	9E+4	4E-5	1E-7	-	-
84	Polonium-205 <sup>2</sup>	D, see <sup>203</sup> Po W, see <sup>203</sup> Po	2E+4 -	4E+4 7E+4	2E-5 3E-5	5E-8 1E-7	3E-4 -	3E-3 -
84	Polonium-207	D, see <sup>203</sup> Po W, see <sup>203</sup> Po	8E+3 -	3E+4 3E+4	1E-5 1E-5	3E-8 4E-8	1E-4 -	1E-3 -
84	Polonium-210	D, see <sup>203</sup> Po W, see <sup>203</sup> Po	3E+0 -	6E-1 6E-1	3E-10 3E-10	9E-13 9E-13	4E-8 -	4E-7 -
85	Astatine-207 <sup>2</sup>	D, halides W	6E+3 -	3E+3 2E+3	1E-6 9E-7	4E-9 3E-9	8E-5 -	8E-4 -
_85	Astatine-211	D, halides W	1E+2	8E+1 5E+1	3E-8 2E-8	1E-10 8E-11	2E-6	2E-5

·

			Осси	Table I pational Valu	ies	Table Efflu Concent	ent	Table III Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomi No.	c Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
86	Radon-220	With daughters removed With daughters present	-	2E+4 2E+1 (or 12 wor level mont		2E-8 3E-11 (or 1.0 working level)	-	-
86	Radon-222	With daughters removed With daughters present	-	1E+4 1E+2 (or 4 worki level monti	Ų	1E-8 1E-10 (or 0.33 working level)	-	-
87	Francium-222 <sup>2</sup>	D, all compounds	2E+3	5E+2	2E-7	6E-10	3E-5	3E-4
87	Francium-223 <sup>2</sup>	D, all compounds	6E+2	8E+2	3E-7	1E-9	8E-6	8E-5
88	Radium-223	W, all compounds	5E+0 Bone surf	7E-1	3E-10	9E-13	-	-
			(9E+0)	-	-	-	1E-7	1E-6
88	Radium-224	W, all compounds	8E+0 Bone surf (2E+1)	2E+0 -	7E-10 -	2E-12	- 2E-7	- 2E-6
88	Radium-225	W, all compounds	8E+0 Bone surf	7E-1	3E-10	9E-13	-	-
<b></b>			(2E+1)	-	<b>-</b> .	-	2E-7	2E-6
88	Radium-226	W, all compounds	2E+0 Bone surf (5E+0)	6E-1 -	3E-10	9E-13	- 6E-8	- 6E-7
88	Radium-227 <sup>2</sup>	W, all compounds	2E+4 Bone surf	1E+4	6E-6	-	-	-
			(2E+4)	Bone surf (2E+4)	-	3E-8	3E-4	3E-3
88	Radium-228	W, all compounds	2E+0 Bone surf	1E+0	5E-10	2E-12	-	-
			(4E+0)	-	-	-	6E-8	6E-7
89	Actinium-224	D, all compounds except those given for W and Y	2E+3 LLI wall	3E+1 Bone surf	1E-8	-	-	-
		W, halides and nitrates Y, oxides and hydroxides	(2E+3) - -	(4E+1) 5E+1 5E+1	- 2E-8 2E-8	5E-11 7E-11 6E-11	3E-5 - -	3E-4 -

			Occu	Table I pational Value	25	Table Effluc Concent	ent	Table III Releases to Sewers
		-	Col. 1 Oral Ingestion	Col. 2 Inhala	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
89	Actinium-225	D, see <sup>224</sup> Ac	5E+1	3E-1	1E-10	_	-	-
		· · ·	LLI wall (5E+1)	Bone surf (5E-1)		7E-13	7E-7	7E-6
		W, see <sup>224</sup> Ac	-	6E-1	3E-10	9E-13	-	720
		Y, see $^{224}$ Ac	-	6E-1	3E-10	9E-13	-	-
89	Actinium-226	D, see <sup>224</sup> Ac	1E+2	3E+0	1E-9	_	-	-
			LLI wall	Bone surf				
			(1E+2)	(4E+0)	-	5E-12	2E-6	2E-5
		W, see $^{224}Ac$	-	5E+0	2E-9	7E-12	-	-
		Y, see <sup>224</sup> Ac	-	5E+0	2E-9	6E-12	-	-
89	Actinium-227	D, see <sup>224</sup> Ac	2E-1 Bone surf	4E-4 Bone surf	2E-13	-	-	-
			(4E-1)	(8E-4)	-	1E-15	5E-9	5E-8
		W, see <sup>224</sup> Ac	-	2E-3 Bone surf	7E-13	-	-	-
			-	(3E-3)	-	4E-15	-	-
		Y, see $^{224}Ac$	-	4E-3	2E-12	6E-15	-	-
89	Actinium-228	D, see <sup>224</sup> Ac	2E+3	9E+0 Bone surf	4E-9	-	3E-5	3E-4
			-	(2E+1)	-	2E-11	-	-
		W, see <sup>224</sup> Ac	-	4E+1 Bone surf	2E-8	-	-	-
		Y, see <sup>224</sup> Ac	-	(6E+1) 4E+1	- 2E-8	8E-11 6E-11	-	-
90	Thorium-226 <sup>2</sup>	W, all compounds except those given for Y	5E+3	2E+2	6E-8	2E-10	_	-
			St wall		0 <u>L</u> -0	21-10	_	
		Y, oxides and hydroxides	(5E+3) -	- 1E+2	- 6E-8	- 2E-10	7E-5 -	7E-4 -
90	Thorium 227	NV and <sup>226</sup> Th					<b>AF</b> (	
90	Thorium-227	W, see <sup>226</sup> Th Y, see <sup>226</sup> Th	1E+2 -	3E-1 3E-1	1E-10 1E-10	5E-13 5E-13	2E-6 -	2E-5 -
90	Thorium-228	W, see <sup>226</sup> Th	6E+0 Bone surf	1E-2 Bone surf	4E-12	-	-	-
		Y, see <sup>226</sup> Th	(1E+1) -	(2E-2) 2E-2	- 7E-12	3E-14 2E-14	2E-7 -	2E-6 -
90	Thorium-229	W, see <sup>226</sup> Th	6E-1 Bone surf	9E-4 Bone surf	4E-13	-	-	-
			(1E+0)	(2E-3)	-	3E-15	2E-8	2E-7
		Y, see <sup>226</sup> Th	-	2E-3	1E-12	-	-	-

			Occuj	Table I pational Value	es	Table Efflue Concent	ent	Table III Releases to Sewers
	·	-	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Aton No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
		<u>.</u>	-	Bone surf (3E-3)	-	4E-15	-	-
90	Thorium-230	W, see <sup>226</sup> Th	4E+0 Bone surf	6E-3 Bone surf	3E-12	-	-	-
		Y, see <sup>226</sup> Th	(9E+0) -	(2E-2) 2E-2	- 6E-12	2E-14 -	1E-7 -	1E-6 -
			-	Bone surf (2E-2)	-	3E-14	-	-
90	Thorium-231	W, see $^{226}$ Th Y, see $^{226}$ Th	4E+3 -	6E+3 6E+3	3E-6 3E-6	9E-9 9E-9	5E-5 -	5E-4 -
90	Thorium-232	W, see <sup>226</sup> Th	7E-1 Bone surf	1E-3 Bone surf	5E-13	-	-	-
		Y, see <sup>226</sup> Th	(2E+0) -	(3E-3) 3E-3 Bone surf	- 1E-12	4E-15 -	3E-8 -	3E-7 -
			-	(4E-3)	-	6E-15	-	
90	Thorium-234	W, see <sup>226</sup> Th	3E+2 LLI wall (4E+2)	2E+2	8E-8	3E-10	- 5E-6	- 5E-5
		Y, see <sup>226</sup> Th	-	- 2E+2	- 6E-8	- 2E-10	JE-0 -	3
91	Protactinium-227 <sup>2</sup>	W, all compounds except those given for Y Y, oxides and hydroxides	4E+3 -	1E+2 1E+2	5E-8 4E-8	2E-10 1E-10	5E-5 -	5E-4 -
91	Protactinium-228	W, see <sup>227</sup> Pa	1E+3	1E+1 Bone surf	5E-9	-	2E-5	2E-4
		Y, see <sup>227</sup> Pa	-	(2E+1) 1E+1	- 5E-9	3E-11 2E-11	-	-
91	Protactinium-230	W, see <sup>227</sup> Pa	6E+2 Bone surf	5E+0	2E-9	7E-12	-	-
		Y, see <sup>227</sup> Pa	(9E+2) -	- 4E+0	- 1E-9	- 5E-12	1E-5 -	1E-4 -
91	Protactinium-231	W, see <sup>227</sup> Pa	2E-1 Bone surf	2E-3 Bone surf	6E-13	-	-	-
		Y, see <sup>227</sup> Pa	(5E-1) -	(4E-3) 4E-3 Bone surf	- 2E-12	6E-15 -	6E-9 -	6E-8 -
			-	(6E-3)	-	8E-15	-	- 🔍

			Occuj	Table I pational Value	es	Table Efflue Concent	ent	Table III Releases to Sewers
· /			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Ator No.	nic Radionuclide	Class	ΑLΙ (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
91	Protactinium-232	W, see <sup>227</sup> Pa	1E+3	2E+1 Bone surf	9E-9	-	2E-5	2E-4
			-	(6E+1)	-	8E-11	-	-
		Y, see <sup>227</sup> Pa	-	6E+1	2E-8	-	-	-
			-	Bone surf (7E+1)	-	1E-10	-	-
91	Protactinium-233	W, see <sup>227</sup> Pa	1E+3 LLI wall	7E+2	3E-7	1E-9	-	-
		Y, see <sup>227</sup> Pa	(2E+3)	- 6E+2	- 2E-7	- 8E-10	2E-5 -	2E-4
		1,000 14				00-10	-	-
91	Protactinium-234		2E+3	8E+3	3E-6	1 <b>E-8</b>	3E-5	3E-4
		Y, see <sup>227</sup> Pa	-	7E+3	3E-6	9E-9	-	-
92	Uranium-230	D, UF, UOF, UO(NO)	4E+0 Bone surf	4E-1 Bone surf	2E-10	-	-	-
			(6E+0)	(6E-1)	-	8E-13	8E-8	8E-7
		W, UO, UF, UCI	-	4E-1	1E-10	5E-13	-	-
		Y, UO, UO	-	3E-1	1E-10	4E-13	-	-
92	Uranium-231	D, see <sup>230</sup> U	5E+3 LLI wall	8E+3	3E-6	1E-8	-	-
		W, see <sup>230</sup> U	(4E+3)	-	-	-	6E-5	6E-4
		Y, see $^{230}$ U	-	6E+3 5E+3	2E-6 2E-6	8E-9 6E-9	-	-
				5115	20-0	01-7	-	-
92	Uranium-232	D, see <sup>230</sup> U	2E+0 Bone surf	2E-1 Bone surf	9E-11	-	-	-
			(4E+0)	(4E-1)	-	6E-13	6E-8	6E-7
		W, see ${}^{230}$ U Y, see ${}^{230}$ U	-	4E-1	2E-10	5E-13	-	-
		Y, seeU	-	<b>8E-</b> 3	3E-12	1E-14	-	-
92	Uranium-233	D, see <sup>230</sup> U	1E+1 Bone surf	1E+0 Bone surf	5E-10	-	-	-
			(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see ${}^{230}$ U	-	7E-1	3E-10	1E-12	-	-
		Y, see <sup>230</sup> U	-	4E-2	2E-11	5E-14	-	-
92	Uranium-234 <sup>3</sup>	D, see <sup>230</sup> U	1E+1 Bone surf	1E+0 Bone surf	5E-10	-	-	-
			(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see <sup>230</sup> U	-	7E-1	3E-10	1E-12	-	-
		Y, see <sup>230</sup> U	-	4E-2	2E-11	5E-14	-	-

		Осси	Table I pational Valu	es	Table Efflu Concen	ent	Table III Releases to Sewers	
		Col. 1	Col. 2	Col. 3	Col. 1	Col. 2		
	-	Oral	T., 1, 1		*-		Monthly 🧹	
Atomic Radionuclide	Class		Ingestion <u>Inhalation</u> ALI ALI DAC				Average	
No.	Class		ALI	DAC	Air	Water	Concentration	
		(µCi)	(µCi)	(µCi/ml)	(µCi/ml)	(µCi/ml)	(µCi/ml)	
		Bone surf	Bone surf					
	N	(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6	
	W, see ${}^{230}$ U Y, see ${}^{230}$ U	-	8E-1	3E-10	1E-12	-	-	
	Y, see $230$	-	4E-2	2E-11	6E-14	-	-	
92 Uranium-236	D, see <sup>230</sup> U	1E+1	1E+0	5E-10	_			
	·	Bone surf	Bone surf				-	
		(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6	
	W, see <sup>230</sup> U	-	8E-1	3E-10	1E-12	512-7	512-0	
	Y, see <sup>230</sup> U	-	4E-2	2E-11	6E-14	_	-	
				22	01-14		-	
92 Uranium-237	D, see $^{230}$ U	2E+3	3E+3	1E-6	4E-9	-	-	
		LLI wall						
		(2E+3)	-	-	-	3E-5	3E-4	
	W, see <sup>230</sup> U	-	2E+3	7E-7	2E-9	-	-	
	Y, see <sup>230</sup> U	-	2E+3	6E-7	2E-9	-	-	
92 Uranium-238 <sup>3</sup>	D, see <sup>230</sup> U	1E+1	1E+0	6E-10	_	_	-	
		Bone surf	Bone surf	-				
		(2E+1)	(2E+0)	_	3E-12	3E-7	3E-6	
	W, see <sup>230</sup> U	-	8E-1	3E-10	1E-12	512-7	512-0	
	Y, see <sup>230</sup> U	-	4E-2	2E-11	6E-14	-	-	
92 Uranium-239 <sup>2</sup>	D, see <sup>230</sup> U	75:14	25 1 5		<u></u>			
72 Oranium-237	W, see $^{230}$ U	7E+4	2E+5	8E-5	3E-7	9E-4	9E-3	
	Y, see $^{230}$ U	-	2E+5	7E-5	2E-7	-	-	
	1, see U	-	2E+5	6E-5	2E-7	-	-	
92 Uranium-240	D, see <sup>230</sup> U	1E+3	4E+3	2E-6	5E-9	2E-5	2E-4	
	W, see <sup>230</sup> U	-	3E+3	1 <b>E-6</b>	4E-9	-	-	
	Y, see <sup>230</sup> U	-	2E+3	1E-6	3E-9	-	-	
92 Uranium-natura	1 <sup>3</sup> D see 230TT	1 <b>E</b> +1	1E+0	<b>5T</b> 10				
	D, Sec U	Bone surf		5E-10	-	-	-	
			Bone surf					
	W, see <sup>230</sup> U	(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6	
	W, see $^{230}$ U Y, see $^{230}$ U	-	8E-1	3E-10	9E-13	-	-	
	r, see	-	5E-2	2E-11	9E-14	-	-	
93 Neptunium-232 <sup>2</sup>	<sup>2</sup> W, all compounds	1E+5	2E+3	7E-7	-	2E-3	2E-2	
			Bone surf					
		-	(5E+2)	-	6E-9	-	-	
93 Neptunium-233 <sup>2</sup>	W, all compounds	8E+5	3E+6	1E-3	4E-6	15.2	15 1	
	··· , ···· vompounus	, Y	0120	11-3	412-0	1E-2	1E-1	
93 Neptunium-234	W, all compounds	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4	
93 Neptunium-235	W, all compounds	2E+4	8E+2	3E-7	_		$\smile$	
pramum 200	n, un oompoundo	μL, Τ	OL TZ	JE-/	-	-	-	

			Occuj	Table I pational Value	es	Table Efflue Concent	ent	Table III Releases to Sewers
		~	Col. 1 Oral Ingestion	Col. 2		Col. 1	Col. 2	Monthly Average
Atom No.	ic Radionuclide	Class	ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
			LLI wall (2E+4)	Bone surf (1E+3)	-	2E-9	3E-4	3E-3
93	Neptunium-236 (1.15E+5 y)	W, all compounds	3E+0 Bone surf	2E-2 Bone surf	9E-12	-	-	-
			(6E+0)	(5E-2)	-	8E-14	9E-8	9E-7
93	Neptunium-236 (22.5 h)	W, all compounds	3E+3 Bone surf	3E+1 Bone surf	1E-8	-	-	-
			(4E+3)	(7E+1)	-	1E-10	5E-5	5E-4
93	Neptunium-237	W, all compounds	5E-1 Bone surf	4E-3 Bone surf	2E-12	-	-	-
			(1E+0)	(1E-2)	-	1E-14	2E-8	2E-7
93	Neptunium-238	W, all compounds	1E+3	6E+1 Bone surf	3E-8	-	2E-5	2E-4
			-	(2E+2)	-	2E-10	-	-
93	Neptunium-239	W, all compounds	2E+3 LLI wall	2E+3	9E-7	3E-9	-	-
			(2E+3)	-	-	-	2E-5	2E-4
93	Neptunium-240 <sup>2</sup>	W, all compounds	2E+4	8E+4	3E-5	1E-7	3E-4	3E-3
94	Plutonium-234	W, all compounds			0 <b>.</b>			
		except PuO Y, PuO	8E+3 -	2E+2 2E+2	9E-8 8E-8	3E-10 3E-10	1E-4 -	1E-3 -
94	Plutonium-235 <sup>2</sup>	•	9E+5	3E+6	1E-3	4E-6	1E-2	1E-1
		Y, see <sup>234</sup> Pu	-	3E+6	1E-3	3E-6	-	-
94	Plutonium-236	W, see <sup>234</sup> Pu	2E+0 Bone surf	2E-2 Bone surf	8E-12	-	-	-
		Y, see <sup>234</sup> Pu	(4E+0) -	(4E-2) 4E-2	- 2E-11	5E-14 6E-14	6E-8 -	6E-7 -
94	Plutonium-237	W, see <sup>234</sup> Pu Y, see <sup>234</sup> Pu	1E+4 -	3E+3 3E+3	1E-6 1E-6	5E-9 4E-9	2E-4 -	2E-3
94	Plutonium-238	W, see <sup>234</sup> Pu	9E-1 Bone surf	7E-3 Bone surf	3E-12	-	-	-
		Y, see <sup>234</sup> Pu	(2E+0) -	(1E-2) 2E-2	- 8E-12	2E-14 2E-14	2E-8 -	2E-7 -
94	Plutonium-239	W, see <sup>234</sup> Pu	8E-1	6E-3	3E-12			

-

			Occu	Table I pational Valu	les	Table Efflu Concen	ent	Table III Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral					Monthly
Atom	ic Radionuclide	Class	Ingestion	Inhal				Average
No.	ic Radionactiue	Class	ALI	ALI	DAC	Air	Water	Concentration
110.			(µCi)	(µCi)	(µCi/ml)	(µCi/ml)	(µCi/ml)	(µCi/ml)
			Bone surf	Bone surf				
			(1E+0)	(1E <b>-</b> 2)	-	2E-14	2E-8	2E-7
		Y, see <sup>234</sup> Pu	-	2E-2	7E-12	-	-	-
				Bone surf				
			-	(2E-2)	-	2E-14	-	-
94	Plutonium-240	W, see <sup>234</sup> Pu	8E-1	6E-3	3E-12	-		
			Bone surf	Bone surf	-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	an <i>a</i>
		Y, see <sup>234</sup> Pu	-	2E-2	- 7E-12	26-14		2E-7
		,		Bone surf	12-12	-	-	-
			-	(2E-2)	_	2E-14	-	
				(20-2)	-	21-14	-	-
94	Plutonium-241	W, see <sup>234</sup> Pu	4E+1	3E-1	1E-10	-	-	-
			Bone surf	Bone surf				
			(7E+1)	(6E-1)	-	8E-13	1E-6	1E-5
		Y, see <sup>234</sup> Pu	-	8E-1	3E-10	-	-	-
				Bone surf				
			-	(1E+0)	-	1E-12	-	-
94	Plutonium-242	W, see <sup>234</sup> Pu	8E-1	7E-3	3E-12			•
	· · · · · · · · · · · · · · · · · · ·		Bone surf	Bone surf	JE-12	-	-	-
			(1E+0)	(1E-2)		2E-14	25.0	AF
		Y, see <sup>234</sup> Pu	(12:0)	(HE-2) 2E-2	- 7E-12	2E-14 -	2E-8	2E-7
		-,		Bone surf	/E-12	-	-	-
			-	(2E-2)	-	25.14		
				(213-2)	-	2E-14	-	-
94	Plutonium-243	W, see <sup>234</sup> Pu	2E+4	4E+4	2E-5	5E-8	2E-4	2E-3
		Y, see <sup>234</sup> Pu	-	4E+4	2E-5	5E-8	-	-
					20 5	51-8	-	-
94	Plutonium-244	W, see <sup>234</sup> Pu	8E-1	7E-3	3E-12	-	_	-
			Bone surf	Bone surf				
			(2E+0)	(1E-2)	-	2E-14	2E-8	2E-7
		Y, see <sup>234</sup> Pu	-	2E-2	7E-12	-	-	-
				Bone surf				
			-	(2E-2)	-	2E-14	-	-
4	Plutonium-245	W, see <sup>234</sup> Pu		6 <b>5</b> - 2				
Ŧ	- sutomull1=2+3	Y, see $^{234}$ Pu	2E+3	5E+3	2E-6	6E-9	3E-5	3E-4
		1, 500 FU	-	4E+3	2E-6	6E-9	-	-
94	Plutonium-246	W, see <sup>234</sup> Pu	15-1	2010	15.5	AT 10		
	utomum-240	w, 300 Fu	4E+2	3E+2	1E-7	4E-10	-	-
			LLI wall					
		Y, see <sup>234</sup> Pu	(4E+2)	-	-	-	6E-6	6E-5
		r, see - Pu	-	3E+2	1E-7	4E-10	-	-
5	Americium-2372	W, all compounds	OE I A	2015		(F) -		
-	menerum-23/	w, an compounds	8E+4	3E+5	1E-4	4E-7	1E-3	1E-2

			Occu	Table I pational Value	es	Table II Effluent Concentrations		Table III Releases to Sewers	
		-	Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average	
Ator No.	nic Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)	
95	Americium-238 <sup>2</sup>	W, all compounds	4E+4	3E+3 Bone surf	1E-6	-	5E-4	5E-3	
			-	(6E+3)	-	9E-9	-	-	
95	Americium-239	W, all compounds	5E+3	1E+4	5E-6	2E-8	7E-5	7E-4	
95	Americium-240	W, all compounds	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4	
95	Americium-241	W, all compounds	8E-1 Bone surf	6E-3 Bone surf	3E-12	-	-	-	
			(1E+0)	(1E-2)	-	2E-14	2E <b>-</b> 8	2E-7	
95	Americium-242m	W, all compounds	8E-1 Bone surf	6E-3 Bone surf	3E-12	-	-	-	
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7	
95	Americium-242	W, all compounds	4E+3	8E+1 Bone surf	4E-8	-	5E-5	5E-4	
			-	(9E+1)	-	1E-10	-	-	
95	Americium-243	W, all compounds	8E-1 Bone surf	6E-3 Bone surf	3E-12	-	-	-	
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7	
95	Americium-244m	<sup>2</sup> W, all compounds	6E+4 St wall	4E+3 Bone surf	2E-6	-	-	-	
			(8E+4)	(7E+3)	-	1E-8	1E-3	1E-2	
95	Americium-244	W, all compounds	3E+3	2E+2 Bone surf	8E-8	-	4E-5	4E-4	
			-	(3E+2)	-	4E-10	-	-	
95	Americium-245	W, all compounds	3E+4	8E+4	3E-5	1E-7	4E-4	4E-3	
95	Americium-246m	<sup>2</sup> W, all compounds	5E+4 St wall	2E+5	8E-5	3E-7	-	-	
			(6E+4)	-	-		8E-4	8E-3	
95	Americium-246 <sup>2</sup>	W, all compounds	3E+4	1E+5	4E-5	1E-7	4E-4	4E-3	
96	Curium-238	W, all compounds	2E+4	1E+3	5E-7	2E-9	2E-4	2E-3	
96	Curium-240	W, all compounds	6E+1 Bone surf	6E-1 Bone surf	2E-10	-	-	-	
			(8E+1)	(6E-1)	-	9E-13	1E-6	1E-5	

			Осси	Table I pational Value	es	Table II Effluent Concentrations		Table III Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Aton No.	nic Radionuclide	Class	Ingestion ALI (µCi)	n <u>Inhala</u> ALI (µCi)	DAC (µCi/ml)	— Air nl) (μCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
96	Curium-241	W, all compounds	1E+3	3E+1 Bone surf	1E-8	-	2E-5	2E-4
			-	(4E+1)	-	5E-11	-	-
96	Curium-242	W, all compounds	3E+1 Bone surf	3E-1 Bone surf	1E-10	-	-	-
			(5E+1)	(3E-1)	-	4E-13	7E-7	7E-6
96	Curium-243	W, all compounds	1E+0 Bone surf	9E-3 Bone surf	4E-12	-	-	-
			(2E+0)	(2E-2)	-	2E-14	3E-8	3E-7
96	Curium-244	W, all compounds	1E+0 Bone surf	1E-2 Bone surf	5E-12	-	-	-
			(3E+0)	(2E-2)	-	3E-14	3E-8	3E-7
96	Curium-245	W, all compounds	7E-1 Bone surf (1E+0)	6E-3 Bone surf	3E-12	-	-	-
			(12+0)	(1E-2)	-	2E-14	2E-8	2E-7
96	Curium-246	W, all compounds	7E-1 Bone surf	6E-3 Bone surf	3E-12	-	-	-
			(1E+0)	(1E-2)	<b>_</b> ·	2E-14	2E-8	2E-7
96	Curium-247	W, all compounds	8E-1 Bone surf	6E-3 Bone surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
96	Curium-248	W, all compounds	2E-1 Bone surf	2E-3 Bone surf	7E-13	-	-	-
			(4E-1)	(3E-3)	-	4E-15	5E-9	5E-8
96	Curium-249 <sup>2</sup>	W, all compounds	5E+4	2E+4 Bone surf	7E-6	-	7E-4	7E-3
			-	(3E+4)	-	4E-8	-	-
96	Curium-250	W, all compounds	4E-2 Bone surf	3E-4 Bone surf	1E-13	-	-	-
			(6E-2)	(5E-4)	-	8E-16	9E-10	9E-9
97	Berkelium-245	W, all compounds	2E+3	1E+3	5E-7	2E-9	3E-5	3E-4
97	Berkelium-246	W, all compounds	3E+3	3E+3	1 <b>E-</b> 6	4E-9	4E-5	4E-4
97	Berkelium-247	W, all compounds	5E-1	4E-3	2E-12	-	-	-

------

-

			Table I Occupational Values			Table II Effluent Concentrations		Table III Releases to Sewers	
Aton	nic Radionuclide	Class	Col. 1 Oral Ingestion ALI	Col. 2 Inhalat ALI	Col. 3 tion DAC	Col. 1 Air	Col. 2 Water	Monthly Average Concentration	
No.			(μCi)	(μCi)	(µCi/ml)	μCi/ml)	(µCi/ml)	(µCi/ml)	
			Bone surf (1E+0)	Bone surf (9E-3)	-	1E-14	2E-8	2E-7	
97	Berkelium-249	W. all compounds	2E+2 Bone surf	2E+0 Bone surf	7E-10	-	-	-	
			(5E+2)	(4E+0)	-	5E-12	6E-6	6E-5	
97	Berkelium-250	W, all compounds	9E+3	3E+2 Bone surf	1E-7	-	1E-4	1E-3	
			-	(7E+2)	-	1E-9	-	-	
98	Californium-244	2 those given for Y	W, all con 3E+4 St wall	ipounds except 6E+2	2E-7	8E-10	-	-	
		Y, oxides and hydroxides	(3E+4) -	- 6E+2	- 2E-7	- 8E-10	4E-4 -	4E-3 -	
98	Californium-246	W, see <sup>244</sup> Cf Y, see <sup>244</sup> Cf	4E+2 -	9E+0 9E+0	4E-9 4E-9	1E-11 1E-11	5E-6 -	5E-5 -	
98	Californium-248	W, see <sup>244</sup> Cf	8E+0 Bone surf	6E-2 Bone surf	3E-11	-	-	-	
		Y, see <sup>244</sup> Cf	(2E+1) -	(1E-1) 1E-1	- 4E-11	2E-13 1E-13	2E-7 -	2E-6 -	
98	Californium-249	W, see <sup>244</sup> Cf	5E-1 Bone surf	4E-3 Bone surf	2E-12	-	-	-	
		Y, see <sup>244</sup> Cf	(1E+0) -	(9E-3) 1E-2	- 4E-12	1E-14 -	2E-8 -	2E-7 -	
			-	Bone surf (1E-2)	-	2E-14	-	-	
98	Californium-250	W, see <sup>244</sup> Cf	1E+0 Bone surf	9E-3 Bone surf	4E-12	-	-	-	
		Y, see <sup>244</sup> Cf	(2E+0) -	(2E-2) 3E-2	- 1E-11	3E-14 4E-14	3E-8 -	3E-7 -	
98	Californium-251	W, see <sup>244</sup> Cf	5E-1 Bone surf	4E-3 Bone surf	2E-12	-	-	-	
		Y, see <sup>244</sup> Cf	(1E+0) -	(9E-3) 1E-2	- 4E-12	1E-14 -	2E-8 -	2E-7 -	
				Bone surf					

----

				Table I pational Value	es	Table II Effluent Concentrations		Table III Releases to Sewers	
		-	Col. 1 Oral Ingestion	Col. 2 Inhala	Col. 3	Col. 1	Col. 2	Monthly	
Atomi No.	c Radionuclide	Class	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)	
98	Californium-252	W, see <sup>244</sup> Cf	2E+0 Bone surf	2E-2 Bone surf	8E-12	-	-	-	
		Y, see <sup>244</sup> Cf	(5E+0) -	(4E-2) 3E-2	- 1E-11	5E-14 5E-14	7E-8 -	7E-7 -	
98	Californium-253	W, see <sup>244</sup> Cf	2E+2 Bone surf	2E+0	8E-10	3E-12	-	-	
		Y, see <sup>244</sup> Cf	(4E+2) -	- 2E+0	- 7E-10	- 2E-12	5E-6 -	5E-5 -	
98	Californium-254	W, see <sup>244</sup> Cf Y, see <sup>244</sup> Cf	2E+0 -	2E-2 2E-2	9E-12 7E-12	3E-14 2E-14	3E-8 -	3E-7	
99	Einsteinium-250	W, all compounds	4E+4	5E+2 Bone surf	2E-7	-	6E-4	6E-3	
			-	(1E+3)	-	2E-9	-	-	
99	Einsteinium-251	W, all compounds	7E+3	9E+2 Bone surf	4E-7	-	1E-4	1E-3	
			-	(1E+3)	-	2E-9	-	-	
		W, all compounds	2E+2	1E+0	6E-10	2E-12	2E-6	2E-5	
9 I	Einsteinium-254m	W, all compounds	3E+2 LLI wall (3E+2)	1E+1	4E-9	1E-11	-	• '	
9 E	Finctoinium 254	W, all compounds		-	-	-	4E-6	4E-5	
<i>,</i>	Sinstemuni-234	w, an compounds	8E+0 Bone surf	7E-2 Bone surf	3E-11	-	-	-	
			(2E+1)	(1E-1)	-	2E-13	2E-7	2E-6	
00	Fermium-252	W, all compounds	5E+2	1E+1	5E-9	2E-11	6E-6	6E-5	
00	Fermium-253	W, all compounds	1E+3	1E+1	4E-9	1E-11	1E-5	1E-4	
00	Fermium-254	W, all compounds	3E+3	9E+1	4E-8	1E-10	4E-5	4E-4	
00	Fermium-255	W, all compounds	5E+2	2E+1	9E-9	3E-11	7E-6	7E-5	
00 ]	Fermium-257	W, all compounds	2E+1 Bone surf (4E+1)	2E-1 Bone surf (2E-1)	7E-11	- 3E-13	- 5E-7	- 5E-6	
01 N	landelarium 257	W all across to			-	JL"IJ			
OI N	nenuelevium-23/	W, all compounds	7E+3	8E+1 Bone surf	4E-8	-	1E-4	1E-3	

.

•

	Occuj	Table I pational Value	es	Effluent Rel		Table III Releases to Sewers
· / · · ·	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
	Ingestion	Inhala	tion			Average
Atomic Radionuclide Class No.	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
101 Mendelevium-258 W, all compounds	3E+1 Bone surf	2E-1 Bone surf	1E-10	-	-	-
•	(5E+1)	(3E-1)	-	5E-13	6E-7	6E-6
- Any single radionuclide not listed above with decay mode other than alpha emission or spontaneous fis- sion and with radioactive half- life less than 2 hours Submersion <sup>1</sup>		-	2E+2	1E-7	1 <b>E-</b> 9	
- Any single radionuclide not listed above with decay mode other than alpha emission or spontaneous fis- sion and with radioactive half- life greater than 2 hours	-	2E-1	1E-10	1E-12	1E-8	1E-7
<ul> <li>Any single radionuclide not listed above that decays by alpha emission or spontaneous fission, or any mix- ture for which either the identity or the concentration of any radio- nuclide in the mixture is not</li> </ul>						
known	-	4E-4	2E-13	1E-15	2E-9	2E-8

•

		Оссц	Table I pational Val	ues	Table II Effluent Concentrations		Table III Releases to Sewers
	-	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic Radionuclide No.	Class	Ingestion ALI (µCi)	<u>Inha</u> ALI (µCi)	llation DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)

#### FOOTNOTES:

"Submersion" means that values given are for submersion in a hemispherical semi-infinite cloud of airborne material.

<sup>2</sup>These radionuclides have radiological half-lives of less than 2 hours. The total effective dose equivalent received during operations with these radionuclides might include a significant contribution from external exposure. The DAC values for all radionuclides, other than those designated Class "Submersion," are based upon the committed effective dose equivalent due to the intake of the radionuclide into the body and do <u>NOT</u> include potentially significant contributions to dose equivalent from external exposures. The licensee may substitute 1E-7  $\mu$ Ci/ml for the listed DAC to account for the submersion dose prospectively, but should use individual monitoring devices or other radiation measuring instruments that measure external exposure to demonstrate compliance with the limits. (See § 20.1203.)

<sup>3</sup>For soluble mixtures of U-238, U-234, and U-235 in air, chemical toxicity may be the limiting factor (see § 20.1201(e)). If the percent by weight (enrichment) of U-235 is not greater than 5, the concentration value for a 40-hour workweek is 0.2 milligrams uranium per cubic meter of air average. For any enrichment, the product of the average concentration and time of exposure during a 40-hour workweek shall not exceed 8E-3 (SA)  $\mu$ Ci-hr/ml, where SA is the specific activity of the uranium inhaled. The specific activity for natural uranium is 6.77E-7 curies per gram U. The specific activity for other mixtures of U-238, U-235, and U-234, if not known, shall be:

SA = 3.6E-7 curies/gram U U-depleted

SA =  $[0.4 + 0.38 \text{ (enrichment)} + 0.0034 \text{ (enrichment)}^2]$  E-6, enrichment  $\ge 0.72$ 

where enrichment is the percentage by weight of U-235, expressed as percent.

#### NOTE:

- 1. If the identity of each radionuclide in a mixture is known but the concentration of one or more of the radionuclides in the mixture is not known, the DAC for the mixture shall be the most restrictive DAC of any radionuclide in the mixture.
- 2. If the identity of each radionuclide in the mixture is not known, but it is known that certain radionuclides specified in this appendix are not present in the mixture, the inhalation ALI, DAC, and effluent and sewage concentrations for the mixture are the lowest values specified in this appendix for any radionuclide that is not known to be absent from the mixture; or

	Оссиј	Table I pational Val	ues	Table Efflue Concent	ent	Table III Releases to Sewers
	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic Radionuclide Class No.	Ingestion ALI (µCi)	ALI (µCi)	llation DAC (μCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
If it is known that Ac-227-D and Cm-250-W are not present	_	7E-4	3E-13	_	_	-
If, in addition, it is known that Ac-227-W,Y, Th-229-W,Y, Th-230-W, Th-232-W,Y, Pa-231-W,Y Np-237-W, Pu-239-W, Pu-240-W, Pu-242-W, Am-2 Am-242m-W, Am-243-W, Cm-245-W, Cm-246-W, Cm-248-W, Bk-247-W, Cf-249-W, and Cf-251-W are not present	241-W,	7E-3	3E-12			
If, in addition, it is known that Sm-146-W, Sm-147-W, Gd-148-D,W, Gd-152-D,W, Th-228-W, Th-230-Y, U-232-Y, U-233-Y, U-234-Y, U-235-Y, U-236-Y, U-238-Y, Np-236-W, Pu-236-W,Y, Pu-238-W,Y, Pu-239-Y, Pu-240-Y, Pu-242-Y, Pu-244-W,Y, Cm-243-W, Cm-244-W, Cf-248-W, Cf-249-Y, Cf-250-W,Y, Cf-251-Y, Cf-252-W,Y,	,Y,			-	-	-
and Cf-254-W,Y are not present If, in addition, it is known that Pb-210-D, Bi-210m-W, Po-210-D,W, Ra-223-W, Ra-225-W, Ra-226-W, Ac-225-D,W,Y, Th-227-W,Y, U-230-D, U-232-D,W, Pu-241-W, Cm-240-W, Cm-242-W, Cf-248-Y, Es-254-W, Fm-257-W, and Md-258-W	W,Y,	7E-2	3E-11	-	-	-
are not present If, in addition, it is known that Si-32-Y, Ti-44-Y, Fe-60-D, Sr-90-Y, Zr-93-D, Cd-113m-D, Cd-113-D, In-115-D, W, La-138-D, Lu-176-W, Hf-178m-D,W, Hf-182-D,W, Bi-210m-E Ra-224-W, Ra-228-W, Ac-226-D,W,Y, Pa-230-W,Y U-233-D,W, U-234-D,W, U-235-D,W, U-236-D,W, U-238-D,W, Pu-241-Y, Bk-249-W, Cf-253-W,Y,	Ź,	7E-1	3E-10	-	-	-
and Es-253-W are not present If it is known that Ac-227-D,W,Y, Th-229-W,Y, Th-232-W,Y, Pa-231-W,Y, Cm-248-W, and Cm-250-W are not present	-	7E+0 -	3E-9 -	<b>-</b> .	- 1E-14	-
- If, in addition, it is known that Sm-146-W, Gd-148-D,W, Gd-152-D, Th-228-W,Y, Th-230-W,Y U-232-Y, U-233-Y, U-234-Y, U-235-Y, U-236-Y, U-238-Y, U-Nat-Y, Np-236-W, Np-237-W, Pu-236- Pu-238-W,Y, Pu-239-W,Y, Pu-240-W,Y, Pu-242-W Pu-244-W,Y, Am-241-W, Am-242m-W, Am-243-W	-W,Y, 7,Y,					

.

	Table I Occupational Values			Table II Effluent Concentrations		Table III Releases to Sewers	
· .	Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly	
Atomic Radionuclide Class	Ingestion		lation			Average Concentration (µCi/ml)	
No.	ALI (µCi)	ALI (µCi)	DAC (µCi/ml)	Air (µCi/ml)	Water (µCi/ml)		
Cm-243-W, Cm-244-W, Cm-245-W, Cm-246-W, Cm-247-W, Bk-247-W, Cf-249-W,Y, Cf-250-W,Y, Cf-251-W,Y, Cf-252-W,Y, and Cf-254-W,Y are not present		-	-	1E-13	-		
If, in addition, it is known that Sm-147-W, Gd-152-W, Pb-210-D, Bi-210m-W, Po-210-D,W, Ra-223-W, Ra-225-W, Ra-226-W, Ac-225-D,W,Y, Th-227-W,Y, U-230-D,W,Y, U-232-D,W, U-Nat-W, Pu-241-W, Cm-240-W, Cm-242-W, Cf-248-W,Y, Es-254-W, Fm-257-W, and Md-258-W are not present	,			15 10			
If, in addition it is known that Fe-60, Sr-90, Cd-113m, Cd-113, In-115, I-129, Cs-134, Sm-145, Sm-147, Gd-148, Gd-152, Hg-194 (organic), Bi-210m, Ra-223, Ra-224, Ra-225, Ac-225, Th-228, Th-230, U-233, U-234, U-235, U-236, U-238, U-Nat, Cm-242, Cf-248,		-	-	1E-12	-		
Es-254, Fm-257, and Md-258 are not present	-	-	-	-	1E-6	IE-5	

- 3. If a mixture of radionuclides consists of uranium and its daughters in ore dust (10 μm AMAD particle distribution assumed) prior to chemical separation of the uranium from the ore, the following values may be used for the DAC of the mixture: 6E-11 μCi of gross alpha activity from uranium-238, uranium-234, thorium-230, and radium-226 per milliliter of air; 3E-11 μCi of natural uranium per milliliter of air; or 45 micrograms of natural uranium per cubic meter of air.
- 4. If the identity and concentration of each radionuclide in a mixture are known, the limiting values should be derived as follows: determine, for each radionuclide in the mixture, the ratio between the concentration present in the mixture and the concentration otherwise established in Appendix B to 420-3-26-.03 for the specific radionuclide when not in a mixture. The sum of such ratios for all of the radionuclides in the mixture may not exceed "1" (i.e., "unity").

Example: If radionuclides "A," "B," and "C" are present in concentrations  $C_A$ ,  $C_B$ , and  $C_c$ , and if the applicable DACs are DAC<sub>A</sub>, DAC<sub>B</sub>, and DAC<sub>C</sub>, respectively, then the concentrations shall be limited so that the following relationship exists:

$$\begin{array}{cccc} C_{A} & C_{B} & C_{C} \\ \hline \\ \overline{DAC}_{A} & \overline{DAC}_{B} & \overline{DAC}_{C} \end{array} \stackrel{\leq}{=} 1$$

### APPENDIX C

-

Radionuclide	Quantity (µCi)*	Radionuclide	Quantity (µCi)*
 Hydrogen-3	1,000	Chromium-48	1,000
Beryllium-7	1,000	Chromium-49	1,000
Beryllium-10	1	Chromium-51	1,000
Carbon-11	1,000	Manganese-51	1,000
Carbon-14	1,000	Manganese-52m	1,000
Fluorine-18	1,000	Manganese-52	100
Sodium-22	10	Manganese-53	1,000
Sodium-24	100	Manganese-54	100
Magnesium-28	100	Manganese-56	1,000
Aluminum-26	10	Iron-52	100
Silicon-31	1,000	Iron-55	100
Silicon-32	1	Iron-59	10
Phosphorus-32	10	Iron-60	10
Phosphorus-33	100	Cobalt-55	100
Sulfur-35	100	Cobalt-56	10
Chlorine-36	10	Cobalt-57	100
Chlorine-38	1,000	Cobalt-58m	1,000
Chlorine-39	1,000	Cobalt-58	100
Argon-39	1,000	Cobalt-60m	1,000
Argon-41	1,000	Cobalt-60	1
Potassium-40	100	Cobalt-61	1,000
Potassium-42	1,000	Cobalt-62m	1,000
Potassium-43	1,000	Nickel-56	100
otassium-44	1,000	Nickel-57	100
otassium-45	1,000	Nickel-59	100
Calcium-41	100	Nickel-63	100
Calcium-45	100	Nickel-65	1,000
Calcium-47	100	Nickel-66	10
Scandium-43	1,000	Copper-60	1,000
Scandium-44m	100	Copper-61	1,000
Scandium-44	100	Copper-64	1,000
Scandium-46	10	Copper-67	1,000
Scandium-47	100	Zinc-62	100
candium-48	100	Zinc-63	1,000
candium-49	1,000	Zinc-65	10
Titanium-44	1	Zinc-69m	100
Titanium-45	1,000	Zinc-69	1,000
/anadium-47	1,000	Zinc-71m	1,000
/anadium-48	100	Zinc-72	100
/anadium-49	1,000	Gallium-65	1,000

## **QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING**

\* To convert  $\mu$ Ci to kBq, multiply the  $\mu$ Ci value by 37.

Radionuclide	Quantity	Radionuclide	Quanti	ty	
<u> </u>	<u>(µCi)*</u>			(μCi)*	
Gallium-66	100	Krypton-81		1,000	
Gallium-67	1,000	Krypton-83m		1,000	
Gallium-68	1,000	Krypton-85m		1,000	
Gallium-70 Gallium-72	1,000	Krypton-85		1,000	
Gallium-72	100	Krypton-87		1,000	
	1,000	Krypton-88		1,000	
Germanium-66 Germanium-67	1,000	Rubidium-79		1,000	
Germanium-68	1,000	Rubidium-81m		1,000	
Germanium-69	10	Rubidium-81		1,000	
Germanium-71	1,000	Rubidium-82m		1,000	
Germanium-75	1,000	Rubidium-83		100	
Germanium-77	1,000	Rubidium-84		100	
Germanium-78	1,000	Rubidium-86		100	
Arsenic-69	1,000	Rubidium-87		100	
Arsenic-70	1,000	Rubidium-88		1,000	
Arsenic-70	1,000 100	Rubidium-89		1,000	
Arsenic-72	100	Strontium-80		100	
Arsenic-72 Arsenic-73	100	Strontium-81		1,000	
Arsenic-74	100	Strontium-83		100	
Arsenic-76	100	Strontium-85m		1,000	
Arsenic-77	100	Strontium-85		100	$\sim$
Arsenic-78	1,000	Strontium-87m		1,000	
Selenium-70	1,000	Strontium-89		10	
Selenium-73m	1,000	Strontium-90 Strontium-91		0.1	
Selenium-73	1,000	Strontium-91 Strontium-92		100	
Selenium-75	100	Yttrium-86m	1 000	100	
Selenium-79	100	Yttrium-86	1,000	100	
Selenium-81m	1,000	Yttrium-87		100	
Selenium-81	1,000	Yttrium-88		100 10	
Selenium-83	1,000	Yttrium-90m	1,000	10	
Bromine-74m	1,000	Yttrium-90	1,000	10	
Bromine-74	1,000	Yttrium-91m	1,000	10	
Bromine-75	1,000	Yttrium-91	1,000	10	
Bromine-76	100	Yttrium-92		100	
Bromine-77	1,000	Yttrium-92		100	
Bromine-80m	1,000	Yttrium-94		1,000	
Bromine-80	1,000	Yttrium-95		1,000	
Bromine-82	100	Zirconium-86		100	
Bromine-83	1,000	Zirconium-88		10	
Bromine-84	1,000	Zirconium-89			
	1,000	Zirconium-93	1	100	
	1,000	Zirconium-95	1		
• •	1,000	Zirconium-95 Zirconium-97	10		
	1,000 1,000	ZIICOIIIQIII-97	100		

### 420-3-26-.03 <u>APPENDIX C</u> <u>QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING</u>

#### APPENDIX C QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING

Radionuclide	Quantity (µCi)*	Radionuclide -	Quantity (µCi)*
Niobium-88	1,000	Palladium-101	1,000
Niobium-89m		Palladium-103	100
(66 min)	1,000	Palladium-107	10
Niobium-89		Palladium-109	100
(122 min)	1,000	Silver-102	1,000
Niobium-90	100	Silver-103	1,000
Niobium-93m	10	Silver-104m	1,000
Niobium-94	1	Silver-104	1,000
Niobium-95m	100	Silver-105	100
Niobium-95	100	Silver-106m	100
Niobium-96	100	Silver-106	1,000
Niobium-97	1,000	Silver-108m	1
Niobium-98	1,000	Silver-11Om	10
Molybdenum-90	100	Silver-111	100
Molybdenum-93m	100	Silver-112	100
Molybdenum-93	10	Silver-115	1,000
Molybdenum-99	100	Cadmium-104	1,000
Molybdenum-101	1,000	Cadmium-107	1,000
Fechnetium-93m	1,000	Cadmium-109	-,
Fechnetium-93	1,000	Cadmium-113m	0.1
Fechnetium-94m	1,000	Cadmium-113	100
Technetium-94	1,000	Cadmium-115m	10
Fechnetium-96m	1,000	Cadmium-115	100
Fechnetium-96	100	Cadmium-117m	1,000
Fechnetium-97m	100	Cadmium-117	1,000
Fechnetium-97	1,000	Indium-109	1,000
Fechnetium-98	10	Indium-110	-,
Fechnetium-99m	1,000	(69.1m)	1,000
Fechnetium-99	100	Indium-11O	-,
Cechnetium-101	1,000	(4.9h)	1,000
Fechnetium-104	1,000	Indium-111	100
Ruthenium-94	1,000	Indium-112	1,000
Ruthenium-97	1,000	Indium-113m	1,000
Ruthenium-103	100	Indium-114m	10
Ruthenium-105	1,000	Indium-115m	1,000
Ruthenium-106	1	Indium-115	100
Rhodium-99m	1,000	Indium-116m	1,000
Rhodium-99	100	Indium-117m	1,000
Rhodium-100	100	Indium-117	1,000
Rhodium-101m	1,000	Indium-119m	1,000
Chodium-101	10	Tin-110	100
Chodium-102m	10	Tin-111	1,000
Chodium-102	10	Tin-113	100
Chodium-103m	1,000	Tin-115 Tin-117m	100
Chodium-105	100	Tin-119m	100
Chodium-105 Chodium-106m	1,000	Tin-121m	100
	•		
Rhodium-107	1,000	Tin-121	1,000

\* To convert  $\mu$ Ci to kBq, multiply the  $\mu$ Ci value by 37.

1

 $\sim$ 

## APPENDIX C

-		-		$\sim$
Radionuclide	Quantity (µCi)*	Radionuclide	Quantity	 ,
Tin-123m	1,000	Tellurium-133	(μCi)* 1,000	
Tin-123	10	Tellurium-134	1,000	
Tin-125	10	Iodine-120m	1,000	
Tin-126	10	Iodine-120	1,000	
Tin-127	1,000	Iodine-121	1,000	
Tin-128	1,000	Iodine-123	100	
Antimony-115	1,000	Iodine-124	10	
Antimony-116m	1,000	Iodine-125	1	
Antimony-116	1,000	Iodine-126	ĩ	
Antimony-117	1,000	Iodine-128	1,000	
Antimony-118m	1,000	Iodine-129	1	
Antimony-119	1,000	Iodine-130	10	
Antimony-120		Iodine-131	1	
(16m)	1,000	Iodine-132m	100	
Antimony-120		Iodine-132	100	
(5.76d)	100	Iodine-133	10	
Antimony-122	100	Iodine-134	1,000	
Antimony-124m	1,000	Iodine-135	100	
Antimony-124	10	Xenon-120	1,000	
Antimony-125	100	Xenon-121	1,000	
Antimony-126m	1,000	Xenon-122	1,000	~
Antimony-126	100	Xenon-123	1,000	<u> </u>
Antimony-127	100	Xenon-125	1,000	
Antimony-128		Xenon-127	1,000	
(10.4m)	1,000	Xenon-129m	1,000	
Antimony-128		Xenon-131m	1,000	
(9.01h)	100	Xenon-133m	1,000	
Antimony-129	100	Xenon-133	1,000	
Antimony-130	1,000	Xenon-135m	1,000	
Antimony-131	1,000	Xenon-135	1,000	
Tellurium-116	1,000	Xenon-138	1,000	
Tellurium-121m	10	Cesium-125	1,000	
Tellurium-121	100	Cesium-127	1,000	
Tellurium-123m	10	Cesium-129	1,000	
Tellurium-123	100	Cesium-130	1,000	
Tellurium-125m	10	Cesium-131	1,000	
Tellurium-127m	10	Cesium-132	100	
Tellurium-127	1,000	Cesium-134m	1,000	
Tellurium-129m	10	Cesium-134	10	
Tellurium-129	1,000	Cesium-135m	1,000	
Tellurium-131m	10	Cesium-135	100	
Tellurium-131	100	Cesium-136	100	
Fellurium-132	10	Cesium-137	10	
Fellurium-133m	100	Cesium-138	1,000	
	multiply the uCi value by		1,000	$\sim$

# **QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING**

\* To convert  $\mu$ Ci to kBq, multiply the  $\mu$ Ci value by 37.

## <u>APPENDIX C</u> QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING

Radionuclide	Quantity (µCi)*	Radionuclide	Quantity (µCi)*
Barium-126	1,000	Promethium-141	1,000
Barium-128	100	Promethium-143	100
Barium-131m	1,000	Promethium-144	10
Barium-131	100	Promethium-145	10
Barium-133m	100	Promethium-146	1
Barium-133	100	Promethium-147	10
Barium-135m	100	Promethium-148m	10
Barium-139	1,000	Promethium-148	10
Barium-140	100	Promethium-149	100
Barium-141	1,000	Promethium-150	1,000
Barium-142	1,000	Promethium-151	100
Lanthanum-131	1,000	Samarium-141m	1,000
Lanthanum-132	100	Samarium-141	1,000
Lanthanum-135	1,000	Samarium-142	1,000
Lanthanum-137	10	Samarium-145	100
Lanthanum-138	100	Samarium-146	1
Lanthanum-140	100	Samarium-147	100
Lanthanum-141	100	Samarium-151	10
Lanthanum-142	1,000	Samarium-153	100
Lanthanum-143	1,000	Samarium-155	1,000
Cerium-134	100	Samarium-156	1,000
Cerium-135	100	Europium-145	100
Cerium-137m	100	Europium-146	100
Cerium-137	1,000	Europium-147	100
Cerium-139	100	Europium-148	10
Cerium-141	100	Europium-149	100
Cerium-143	100	Europium-150	
Cerium-144	1	(12.62h)	100
Praseodymium-136	1,000	Europium-150	
Praseodymium-137	1,000	(34.2y)	1
Praseodymium-138m	1,000	Europium-152m	100
Praseodymium-139	1,000	Europium-152	1
Praseodymium-142m	1,000	Europium-154	1
Praseodymium-142	100	Europium-155	10
Praseodymium-143	100	Europium-156	100
Praseodymium-144	1,000	Europium-157	100
Praseodymium-145	100	Europium-158	1,000
Praseodymium-147	1,000	Gadolinium-145	1,000
Neodymium-136	1,000	Gadolinium-146	10
Neodymium-138	100	Gadolinium-147	100
Neodymium-139m	1,000	Gadolinium-148	0.001
Neodymium-139	1,000	Gadolinium-149	100
Neodymium-141	1,000	Gadolinium-151	10
Neodymium-147	100	Gadolinium-152	100
Neodymium-149	1,000	Gadolinium-153	10
Neodymium-151	1,000	Gadolinium-159	100

-

### APPENDIX C

## **QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING**

Radionuclide	Quantity	Radionuclide	Quantity	
	(µCi)*		(µCi)*	
Terbium-147	1,000	Ytterbium-162	1,000	
Terbium-149	100	Ytterbium-166	100	
Terbium-150	1,000	Ytterbium-167	1,000	
Terbium-151	100	Ytterbium-169	100	
Terbium-153	1,000	Ytterbium-175	100	
Terbium-154	100	Ytterbium-177	1,000	
Terbium-155	1,000	Ytterbium-178	1,000	
Terbium-156m	1 0 0 0	Lutetium-169	100	
(5.Oh)	1,000	Lutetium-170	100	
Terbium-156m		Lutetium-171	100	
(24.4h)	1,000	Lutetium-172	100	
Terbium-156	100	Lutetium-173	10	
Terbium-157	10	Lutetium-174m	10	
Terbium-158	1	Lutetium-174	10	
Terbium-160	10	Lutetium-176m	1,000	
Terbium-161	100	Lutetium-176	100	
Dysprosium-155	1,000	Lutetium-177m	10	
Dysprosium-157	1,000	Lutetium-177	100	
Dysprosium-159	100	Lutetium-178m	1,000	
Dysprosium-165	1,000	Lutetium-178	1,000	
Dysprosium-166	100	Lutetium-179	1,000	$\sim$
Holmium-155	1,000	Hafnium-170	100	
Holmium-157	1,000	Hafnium-172	1	
Holmium-159	1,000	Hafnium-173	1,000	
Holmium-161	1,000	Hafnium-175	100	
Holmium-162m	1,000	Hafnium-177m	1,000	
Holmium-162	1,000	Hafnium-178m	0.1	
Holmium-164m	1,000	Hafnium-179m	10	
Holmium-164	1,000	Hafnium-180m	1,000	
Holmium-166m	1	Hafnium-181	10	
Holmium-166	100	Hafnium-182m	1,000	
Holmium-167	1,000	Hafnium-182	0.1	
Erbium-161	1,000	Hafnium-183	1,000	
Erbium-165	1,000	Hafnium-184	100	
Erbium-169	100	Tantalum-172	1,000	
Erbium-171	100	Tantalum-173	1,000	
Erbium-172	100	Tantalum-174	1,000	
Thulium-162	1,000	Tantalum-175	1,000	
Thulium-166	100	Tantalum-176	100	
Thulium-167	100	Tantalum-177	1,000	
Thulium-170	10	Tantalum-178	1,000	
Thulium-171	10	Tantalum-179	100	
Thulium-172	100	Tantalum-180m	1,000	
Thulium-173	100	Tantalum-180	100	,

## APPENDIX C

## **<u>OUANTITIES1 OF LICENSED MATERIAL REQUIRING LABELING</u>**

Radionuclide	Quantity (µCi)*	Radionuclide	Quantity (µCi)*
Tantalum-182	10	Iridium-188	100
Tantalum-183	100	Iridium-189	100
Tantalum-184	100	Iridium-190m	1,000
Tantalum-185	1,000	Iridium-190	100
Tantalum-186	1,000	Iridium-192m	
Tungsten-176	1,000	(1.4m)	10
Tungsten-177	1,000	Iridium-192	
Tungsten-178	1,000	(73.8d)	1
Tungsten-179	1,000	Iridium-194m	10
Tungsten-181	1,000	Iridium-194	100
Tungsten-185	100	Iridium-195m	1,000
Tungsten-187	100	Iridium-195	1,000
Tungsten-188	10	Platinum-186	1,000
Rhenium-177	1,000	Platinum-188	100
Rhenium-178	1,000	Platinum-189	1,000
Rhenium-181	1,000	Platinum-191	100
Rhenium-182		Platinum-193m	100
(12.7h)	1,000	Platinum-193	1,000
Rhenium-182	·	Platinum-195m	100
(64. <b>O</b> h)	100	Platinum-197m	1,000
Rhenium-184m	10	Platinum-197	100
Rhenium-184	100	Platinum-199	1,000
Rhenium-186m	10	Platinum-200	100
Rhenium-186	100	Gold-193	1,000
Rhenium-187	1,000	Gold-194	100
Rhenium-188m	1,000	Gold-195	10
Rhenium-188	100	Gold-198m	100
Rhenium-189	100	Gold-198	100
Osmium-180	1,000	Gold-199	100
Osmium-181	1,000	Gold-200m	100
Osmium-182	100	Gold-200	1,000
Osmium-185	100	Gold-201	1,000
Osmium-189m	1,000	Mercury-193m	100
Osmium-191m	1,000	Mercury-193	1,000
Osmium-191	100	Mercury-194	1
Osmium-193	100	Mercury-195m	100
Osmium-194	1	Mercury-195	1,000
Iridium-182	1,000	Mercury-197m	100
Iridium-184	1,000	Mercury-197	1,000
Iridium-185	1,000	Mercury-199m	1,000
Iridium-186	100	Mercury-203	100
Iridium-187	1,000	····· <b>····</b> ···························	

Radionuclide	Quantity	Radionuclide	Quantity	
	(µCi)*		(µCi)*	
Thallium-194m	1,000	Francium-223	100	
Thallium-194	1,000	Radium-223	0.1	
Thallium-195	1,000	Radium-224	0.1	
Thallium-197	1,000	Radium-225	0.1	
Thallium-198m	1,000	Radium-226	0.1	
Thallium-198	1,000	Radium-227	1,000	
Thallium-199	1,000	Radium-228	0.1	
Thallium-201	1,000	Actinium-224	1	
Thallium-200	1,000	Actinium-225	0.01	
Thallium-202	100	Actinium-226	0.1	
Thallium-204	100	Actinium-227	0.001	
Lead-195m	1,000	Actinium-228	1	
Lead-198	1,000	Thorium-226	10	
Lead-199	1,000	Thorium-227	0.01	
Lead-200	100	Thorium-228	0.001	
Lead-201	1,000	Thorium-229	0.001	
Lead-202m	1,000	Thorium-230	0.001	
Lead-202	10	Thorium-231	100	
Lead-203	1,000	Thorium-232	100	
Lead-205	100	Thorium-234	10	
Lead-209	1,000	Thorium-natural	100	
Lead-210	0.01	Protactinium-227	10	
Lead-211	100	Protactinium-228	1	$\sim$
Lead-212	1	Protactinium-230	0.1	
Lead-214	100	Protactinium-231	0.001	
Bismuth-200	1,000	Protactinium-232	1	
Bismuth-201	1,000	Protactinium-232	100	
Bismuth-202	1,000	Protactinium-234	100	
Bismuth-203	100	Uranium-230	0.01	
Bismuth-205	100	Uranium-231	100	
Bismuth-206	100	Uranium-232		
Bismuth-200	10		0.001	
Bismuth-210m	0.1	Uranium-233	0.001	
Bismuth-210		Uranium-234	0.001	
Bismuth-212	1	Uranium-235	0.001	
	10	Uranium-236	0.001	
Bismuth-213	10	Uranium-237	100	
Bismuth-214	100	Uranium-238	100	
Polonium-203	1,000	Uranium-239	1,000	
Polonium-205	1,000	Uranium-240	100	
Polonium-207	1,000	Uranium-natural	100	
Polonium-210	0.1	Neptunium-232	100	
Astatine-207	100	Neptunium-233	1,000	
Astatine-211	10	Neptunium-234	100	
Radon-220	1	Neptunium-235	100	
Radon-222	1	Neptunium-236		
Francium-222	100	(1.15E+5)	0.001	/

### APPENDIX C QUANTITIES<sup>1</sup> OF LICENSED MATERIAL REQUIRING LABELING

-----

#### APPENDIX C

Radionuclide	Quantity	Radionuclide	Quantity
	(µCi)*		(μCi)*
Neptunium-236		Curium-242	0.01
(22.5h)	- 1	Curium-243	0.001
Neptunium-237	0.001	Curium-244	0.001
Neptunium-238	10	Curium-245	0.001
Neptunium-239	100	Curium-246	0.001
Neptunium-240	1,000	Curium-247	0.001
Plutonium-234	10	Curium-248	0.001
Plutonium-235	1,000	Curium-249	1,000
Plutonium-236	0.001	Berkelium-245	100
Plutonium-237	100	Berkelium-246	100
Plutonium-238	0.001	Berkelium-247	0.001
Plutonium-239	0.001	Berkelium-249	0.1
Plutonium-240	0.001	Berkelium-250	10
Plutonium-241	0.01	Californium-244	100
Plutonium-242	0.001	Californium-246	1
Plutonium-243	1,000	Californium-248	0.01
Plutonium-244	0.001	Californium-249	0.001
Plutonium-245	100	Californium-250	0.001
Americium-237	1,000	Californium-251	0.001
Americium-238	100	Californium-252	0.001
Americium-239	1,000	Californium-253	0.1
Americium-240	100	Californium-254	0.001
Americium-241	0.001	Einsteinium-250	100
Americium-242m	0.001	Einsteinium-251	100
Americium-242	10	Einsteinium-253	0.1
mericium-243	0.001	Einsteinium-254m	1
mericium-244m	100	Einsteinium-254	0.01
mericium-244	10	Fermium-252	1
mericium-245	1,000	Fermium-253	1
mericium-246m	1,000	Fermium-254	10
mericium-246	1,000	Fermium-255	10
Curium-238	100	Fermium-257	0.01
Curium-240	0.1	Mendelevium-257	10
Curium-241	1	Mendelevium-258	
	L	wienderevium-256	0.01
ny alpha-emitting		Any radionuclide	
adionuclide not		other than alpha-	
sted above or		emitting radionuclides	
ixtures of alpha		not listed above, or	
mitters of unknown		mixtures of beta	
omposition	0.001	emitters of unknown	
-		composition	0.01

# **OUANTITIES' OF LICENSED MATERIAL REQUIRING LABELING**

#### <u>APPENDIX C</u>

# **QUANTITIES' OF LICENSED MATERIAL REQUIRING LABELING**

Radionuclide	Quantity	Radionuclide	Quantity
<u> </u>	(µCi)*		(µCi)*

NOTE: For purposes of 420-3-26-.03(28)(e), 420-3-26-.03(31)(a), and 420-3-26-.03(51)(a) where there is involved a combination of radionuclides in known amounts, the limit for the combination shall be derived as follows: determine, for each radionuclide in the combination, the ratio between the quantity present in the combination and the limit otherwise established for the specific radionuclide when not in combination. The sum of such ratios for all radionuclides in the combination may not exceed "1" -- that is, unity.

The quantities listed above were derived by taking 1/10th of the most restrictive ALI listed in Table I, Columns 1 and 2, of Appendix B to this Rule, rounding to the nearest factor of 10, and constraining the values listed between 37 Bq and 37 MBq (0.001 and 1,000  $\mu$ Ci). Values of 3.7 MBq (100  $\mu$ Ci) have been assigned for radionuclides having a radioactive half-life in excess of E+9 years, except rhenium, 37 MBq (1,000  $\mu$ Ci), to take into account their low specific activity.

\* To convert  $\mu$ Ci to kBq, multiply the  $\mu$ Ci value by 37.

1

(Appendix D Deleted May 25, 2000)

#### **APPENDIX E**

### CLASSIFICATION AND CHARACTERISTICS OF LOW-LEVEL RADIOACTIVE WASTE

## I. Classification of Radioactive Waste for Land Disposal

- a) Considerations. Determination of the classification of radioactive waste involves two considerations. First, consideration must be given to the concentration of long-lived radionuclides (and their shorter-lived precursors) whose potential hazard will persist long after such precautions as institutional controls, improved waste form, and deeper disposal have ceased to be effective. These precautions delay the time when long-lived radionuclides could cause exposures. In addition, the magnitude of the potential dose is limited by the concentration and availability of the radionuclide at the time of exposure. Second, consideration must be given to the concentration of shorter-lived radionuclides for which requirements on institutional controls, waste form, and disposal methods are effective.
- b) <u>Classes of waste</u>.
  - Class A waste is waste that is usually segregated from other waste classes at the disposal site. The physical form and characteristics of Class A waste must meet the minimum requirements set forth in Section II. (a). If Class A waste also meets the stability requirements set forth in Section II. (b), it is not necessary to segregate the waste for disposal.
  - 2) Class B waste is waste that must meet more rigorous requirements on waste form to ensure stability after disposal. The physical form and characteristics of Class B waste must meet both the minimum and stability requirements set forth in Section II.
  - 3) Class C waste is waste that not only must meet more rigorous requirements on waste form to ensure stability but also requires additional measures at the disposal facility to protect against inadvertent intrusion. The physical form and characteristics of Class C waste must meet both the minimum and stability requirements set forth in Section II.
- c) <u>Classification determined by long-lived radionuclides</u>. If the radioactive waste contains only radionuclides listed in Table I, classification shall be determined as follows:
  - 1) If the concentration does not exceed 0.1 times the value in Table I, the waste is Class A.

- 2) If the concentration exceeds 0.1 times the value in Table I, but does not exceed the value in Table I, the waste is Class C.
- 3) If the concentration exceeds the value in Table I, the waste is not generally acceptable for land disposal.
- 4) For wastes containing mixtures of radionuclides listed in Table I, the total concentration shall be determined by the sum of fractions rule described in Section I.(g).

-	Concentration		
Radionuclide	curie/cubic meter <sup>a</sup>	nanocurie/gram	
C-14	8		
C-14 in activated metal	80		
Ni-59 in activated metal	220		
Nb-94 in activated metal	0.2		
Tc-99		3	
I-129		0.08	
Alpha emitting transuranic radionuclides with half- life greater than five		0.00	
years		100	
Pu-241		3,500	
Cm-242		20,000	
Ra-226		100	

TABLE I

<sup>a</sup>To convert the Ci/m<sup>3</sup> values to gigabecquerel (GBq) per cubic meter, multiply the Ci/m<sup>3</sup> value by 37.

<sup>b</sup>To convert the nCi/g values to becquerel (Bq) per gram, multiply the nCi/g value by 37.

- d) <u>Classification determined by short-lived radionuclides</u>. If the waste does not contain any of the radionuclides listed in Table I, classification shall be determined based on the concentrations shown in Table II. However, as specified in Section I.(f), if radioactive waste does not contain any nuclides listed in either Table I or II, it is Class A.
  - 1) If the concentration does not exceed the value in Column 1, the waste is Class A.

- 2) If the concentration exceeds the value in Column 1 but does not exceed the value in Column 2, the waste is Class B.
- 3) If the concentration exceeds the value in Column 2 but does not exceed the value in Column 3, the waste is Class C.
- 4) If the concentration exceeds the value in Column 3, the waste is not generally acceptable for near-surface disposal.
- 5) For wastes containing mixtures of the radionuclides listed in Table II, the total concentration shall be determined by the sum of fractions rule described in Section I.(g).

Radio	nuclide	Concentration, Column 1		oic meter* Column 3
nucli	of all radio- des with less 5-year half-			
life	2	700	*	*
H-3		40	*	*
Co-60		700	*	*
Ni-63 Ni-63	in activated	3.5	70	700
metal	l	35	700	7000
Sr-90		0.04	150	7000
Cs-137	7	1	44	4600

#### TABLE II

\*AGENCY NOTE: To convert the Ci/m<sup>3</sup> value to gigabecquerel (GBq) per cubic meter, multiply the Ci/m<sup>3</sup> value by 37. There are no limits established for these radionuclides in Class B or C wastes. Practical considerations such as the effects of external radiation and internal heat generation on transportation, handling, and disposal will limit the concentrations for these wastes. These wastes shall be Class B unless the concentrations of other radionuclides in Table II determine the waste to be Class C independent of these radionuclides.

e) <u>Classification determined by both long- and short-lived radionuclides</u>. If the radioactive waste contains a mixture of radionuclides, some of which are listed in Table I and some of which are listed in Table II, classification shall be determined as follows:

- 1) If the concentration of a radionuclide listed in Table I is less than 0.1 times the value listed in Table I, the class shall be that determined by the concentration of radionuclides listed in Table II.
- 2) If the concentration of a radionuclide listed in Table I exceeds 0.1 times the value listed in Table I, but does not exceed the value in Table I, the waste shall be Class C, provided the concentration of radionuclides listed in Table II does not exceed the value shown in Column 3 of Table II.
- f) <u>Classification of wastes with radionuclides other than those listed in Tables I</u> and II. If the waste does not contain any radionuclides listed in either Table I or II, it is Class A.
- g) The sum of the fractions rule for mixtures of radionuclides. For determining classification for waste that contains a mixture of radionuclides, it is necessary to determine the sum of fractions by dividing each radionuclide's concentration by the appropriate limit and adding the resulting values. The appropriate limits must all be taken from the same column of the same table. The sum of the fractions for the column must be less than 1.0 if the waste class is to be determined by that column. Example: A waste contains Sr-90 in a concentration of 1.85 TBq/m<sup>3</sup> (50 Ci/m<sup>3</sup>) and Cs-137 in a concentration of 814 GBq/m<sup>3</sup> (22 Ci/m<sup>3</sup>). Since the concentrations both exceed the values in Column 1, Table II, they must be compared to Column 2 values. For Sr-90 fraction, 50/150 = 0.33., for Cs-137 fraction, 22/44 = 0.5; the sum of the fractions = 0.83. Since the sum is less than 1.0, the waste is Class B.
- h) <u>Determination of concentrations in wastes</u>. The concentration of a radionuclide may be determined by indirect methods such as use of scaling factors which relate the inferred concentration of one radionuclide to another that is measured, or radionuclide material accountability, if there is reasonable assurance that the indirect methods can be correlated with actual measurements. The concentration of a radionuclide may be averaged over the volume of the waste, or weight of the waste if the units are expressed as becquerel (nanocurie) per gram.

## II. Radioactive Waste Characteristics

- a) The following are minimum requirements for all classes of waste and are intended to facilitate handling and provide protection of health and safety of personnel at the disposal site.
  - Wastes shall be packaged in conformance with the conditions of the license issued to the site operator to which the waste will be shipped. Where the conditions of the site license are more restrictive than the provisions of this Rule, the site license conditions shall govern.

- 2) Wastes shall not be packaged for disposal in cardboard or fiberboard boxes.
- 3) Liquid waste shall be packaged in sufficient absorbent material to absorb twice the volume of the liquid.
- 4) Solid waste containing liquid shall contain as little free-standing and non-corrosive liquid as is reasonably achievable, but in no case shall the liquid exceed 1% of the volume.
- 5) Waste shall not be readily capable of detonation or of explosive decomposition or reaction at normal pressures and temperatures, or of explosive reaction with water.
- 6) Waste shall not contain, or be capable of generating, quantities of toxic gases, vapors, or fumes harmful to persons transporting, handling, or disposing of the waste. This does not apply to radioactive gaseous waste packaged in accordance with Section II.(a)(8).
- Waste must not be pyrophoric. Pyrophoric materials contained in wastes shall be treated, prepared, and packaged to be nonflammable.<sup>1</sup>
- 8) Wastes in a gaseous form shall be packaged at an absolute pressure that does not exceed 1.5 atmospheres at 20°C. Total activity shall not exceed 3.7 TBq (100 Ci) per container.
- 9) Wastes containing hazardous, biological, pathogenic, or infectious material shall be treated to reduce to the maximum extent practicable the potential hazard from the non-radiological materials.
- b) The following requirements are intended to provide stability of the waste. Stability is intended to ensure that the waste does not degrade and affect overall stability of the site through slumping, collapse, or other failure of the disposal unit and thereby lead to water infiltration. Stability is also a factor in limiting exposure to an inadvertent intruder, since it provides a recognizable and nondispersible waste.
  - Waste shall have structural stability. A structurally stable waste form will generally maintain its physical dimensions and its form, under the expected disposal conditions such as weight of overburden and compaction equipment, the presence of moisture, and microbial activity, and internal factors such as radiation effects and chemical changes. Structural stability can be provided by the waste form itself, processing the waste to a stable form, or placing the waste in a disposal container or structure that provides stability after disposal.

<sup>&</sup>lt;sup>1</sup>See. 420-3-26-.01(2)(a)76. of these rules for definition of pyrophoric.

- 2) Notwithstanding the provisions in Section II.(a)(3) and (4), liquid wastes, or wastes containing liquid, shall be converted into a form that contains as little free-standing and non-corrosive liquid as is reasonably achievable, but in no case shall the liquid exceed 1% of the volume of the waste when the waste is in a disposal container designed to ensure stability, or 0.5% of the volume of the waste for waste processed to a stable form.
- 3) Void spaces within the waste and between the waste and its package shall be reduced to the extent practicable.

#### III. Labeling

Each package of waste shall be clearly labeled to identify whether it is Class A, Class B, or Class C waste, in accordance with Section I.

## APPENDIX F

# **QUANTITIES FOR USE WITH DECOMMISSIONING**

Material	Microcurie*
Americium-241	0.01
Antimony-122	100
Antimony-124	10
Antimony-125	10
Arsenic-73	100
Arsenic-74	10
Arsenic-76	10
Arsenic-77	100
Barium-131	10
Barium-133	10
Barium-140	10
Bismuth-210	1
Bromine-82	10
Cadmium-109	10
Cadmium-115m	10
Cadmium-115	100
Calcium-45	10
Calcium-47	10
Carbon-14	100
Cerium-141	100
Cerium-143	100
Cerium-144	1
Cesium-131	1,000
Cesium-134m	100
Cesium-134	1
Cesium-135	10
Cesium-136	10
Cesium-137	10
Chlorine-36	10
Chlorine-38	10
Chromium-51	1,000
	,

## APPENDIX F

# **QUANTITIES FOR USE WITH DECOMMISSIONING**

Material	Microcurie*
Cobalt-58m	10
Cobalt-58	10
Cobalt-60	1
Copper-64	100
Dysprosium-165	10
Dysprosium-166	100
Erbium-169	100
Erbium-171	100
Europium-152 (9.2 h)	100
Europium-152 (13 yr)	1
Europium-154	1
Europium-155	10
Florine-18	1,000
Gadolinium-153	10
Gadolinium-159	100
Gallium-72	10
Germanium-71	100
Gold-198	100
Gold-199	100
Hafnium-181	10
Holmium-166	100
Hydrogen-3	1,000
Indium-113m	100
Indium-114m	10
Indium-115m	100
Indium-115	10
Iodine-125	1
Iodine-126	1
Iodine-129	0.1
Iodine-131	1
Iodine-132	10

# APPENDIX F

# **OUANTITIES FOR USE WITH DECOMMISSIONING**

Material	Microcurie*
Iodine-133	1
Iodine-134	10
Iodine-135	10
Iridium-192	10
Iridium-194	100
Iron-55	100
Iron-59	10
Krypton-85	100
Krypton-87	10
Lanthanum-140	10
Lutetium-177	100
Manganese-52	10
Manganese-54	10
Manganese-56	10
Mercury-197m	100
Mercury-197	100
Mercury-203	10
Molybdenum-99	100
Neodymium-147	100
Neodymium-149	100
Nickel-59	100
Nickel-63	10
Nickel-65	100
Niobium-93m	10
Niobium-95	10
Niobium-97	10
Osmium-185	10
Osmium-191m	100
Osmium-191	100
Osmium-193	100
Palladium-103	100
Palladium-109	- 100
Phosphorus-32	10

## APPENDIX F

# **QUANTITIES FOR USE WITH DECOMMISSIONING**

Material	Microcurie*
Platinum-191	
Platinum-193m	100
Platinum-193	100
Platinum-197m	100
Platinum-197	100
Plutonium-239	100
Polonium-210	0.01
Potassium-42	0.1
Praseodymium-142	10
•	100
Praseodymium-143 Promethium-147	100
Promethium-149	10
	10
Radium-226	0.01
Rhenium-186	100
Rhenium-188	100
Rhodium-103m	100
Rhodium-105	100
Rubidium-86	10
Rubidium-87	10
Ruthenium-97	100
Ruthenium-103	10
Ruthenium-105	10
Ruthenium-106	1
Samarium-151	10
Samarium-153	100
	100

## APPENDIX F

# **QUANTITIES FOR USE WITH DECOMMISSIONING**

Material	Microcurie*
Scandium-46	10
Scandium-47	100
Scandium-48	10
Selenium-75	10
Silicon-31	100
Silver-105	10
Silver-110m	1
Silver-111	100
Sodium-22	1
Sodium-24	10
Strontium-85	10
Strontium-89	1
Strontium-90	0.1
Strontium-91	10
Strontium-92	10
Sulfur -35	100
Tantalum-182	10
Technetium-96	10
Technetium-97m	100
Technetium-97	100
Technetium-99m	100
Technetium-99	10
Tellurium-125m	10
Tellurium-127m	10
Tellurium-127	100
Tellurium-129m	10
Tellurium-129	100
Tellurium-131m	10
Tellurium-132	10
Terbium-160	10
Thallium-200	100

#### <u>420-3-26-.03</u>

#### APPENDIX F

# **QUANTITIES FOR USE WITH DECOMMISSIONING**

Thallium-201       100         Thallium-202       100         Thallium-204       10         Thorium (natural)**       100         Thulium-170       10         Thulium-171       10         Tin-113       10         Tin-125       10         Tungsten-181       10         Tungsten-185       10         Tungsten-187       100         Uranium (natural)***       100         Uranium-233       0.01         Uranium-234       0.01         Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-133       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10         Zinc-69m       100	Material	Microcurie*
Thallium-202100Thallium-20410Thorium (natural)**100Thulium-17010Thulium-17110Tin-11310Tin-12510Tungsten-18110Tungsten-18510Tungsten-187100Uranium (natural)***100Uranium-2330.01Uranium-2350.01Vanadium-4810Xenon-131m1,000Xenon-135100Yttrium-9010Yttrium-9110Yttrium-92100Zine-6510	Thallium-201	100
Thallium-20410Thorium (natural)**100Thulium-17010Thulium-17110Tin-11310Tin-12510Tungsten-18110Tungsten-18510Tungsten-187100Uranium (natural)***100Uranium-2330.01Uranium-2340.01Uranium-350.01Vanadium-4810Xenon-131m1,000Xenon-135100Yttrium-9010Yttrium-9110Yttrium-9110Yttrium-93100Zine-6510	Thallium-202	
Thorium (natural)**100Thulium-17010Thulium-17110Tin-11310Tin-12510Tungsten-18110Tungsten-18510Tungsten-187100Uranium (natural)***100Uranium-2330.01Uranium-2340.01Uranium-2350.01Vanadium-4810Xenon-131m1,000Xenon-135100Yttrium-9010Yttrium-9110Yttrium-9110Yttrium-93100Zinc-6510	Thallium-204	
Thulium-170       10         Thulium-171       10         Tin-113       10         Tin-125       10         Tungsten-181       10         Tungsten-185       10         Tungsten-187       100         Uranium (natural)***       100         Uranium-233       0.01         Uranium-234       0.01         Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-93       100         Zinc-65       10	Thorium (natural)**	
Thulium-171       10         Tin-113       10         Tin-125       10         Tungsten-181       10         Tungsten-185       10         Tungsten-187       100         Uranium (natural)***       100         Uranium-233       0.01         Uranium-234       0.01         Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Thulium-170	
Tin-11310Tin-12510Tungsten-18110Tungsten-18510Tungsten-187100Uranium (natural)***100Uranium-2330.01Uranium-2340.01Uranium-2350.01Vanadium-4810Xenon-131m1,000Xenon-133100Ytterbium-175100Yttrium-9010Yttrium-9110Yttrium-92100Yttrium-93100Zinc-6510	Thulium-171	
Tin-12510Tungsten-18110Tungsten-18510Tungsten-187100Uranium (natural)***100Uranium-2330.01Uranium-2340.01Uranium-2350.01Vanadium-4810Xenon-131m1,000Xenon-135100Ytterbium-175100Yttrium-9010Yttrium-9110Yttrium-92100Yttrium-93100Zinc-6510	Tin-113	
Tungsten-18110Tungsten-18510Tungsten-187100Uranium (natural)***100Uranium-2330.01Uranium-2340.01Uranium-2350.01Vanadium-4810Xenon-131m1,000Xenon-133100Ytterbium-175100Yttrium-9010Yttrium-9110Yttrium-92100Yttrium-93100Zinc-6510	Tin-125	
Tungsten-185       10         Tungsten-187       100         Uranium (natural)***       100         Uranium-233       0.01         Uranium-234       0.01         Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-133       100         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-93       100         Zinc-65       10	Tungsten-181	
Tungsten-187100Uranium (natural)***100Uranium-233 $0.01$ Uranium-234 $0.01$ Uranium-235 $0.01$ Vanadium-48 $10$ Xenon-131m $1,000$ Xenon-133 $100$ Xenon-135 $100$ Yttrium-90 $10$ Yttrium-91 $10$ Yttrium-91 $100$ Yttrium-92 $100$ Yttrium-93 $100$ Zinc-65 $10$	-	
Uranium (natural)***       100         Uranium-233       0.01         Uranium-234       0.01         Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-133       100         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Tungsten-187	
Uranium-2330.01Uranium-2340.01Uranium-2350.01Vanadium-4810Xenon-131m1,000Xenon-133100Xenon-135100Ytterbium-175100Yttrium-9010Yttrium-9110Yttrium-92100Yttrium-93100Zinc-6510	Uranium (natural)***	
Uranium-234       0.01         Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-133       100         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Uranium-233	
Uranium-235       0.01         Vanadium-48       10         Xenon-131m       1,000         Xenon-133       100         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Uranium-234	
Vanadium-48       10         Xenon-131m       1,000         Xenon-133       100         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Uranium-235	
Xenon-131m       1,000         Xenon-133       100         Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Vanadium-48	
Xenon-133100Xenon-135100Ytterbium-175100Yttrium-9010Yttrium-9110Yttrium-92100Yttrium-93100Zinc-6510	Xenon-131m	
Xenon-135       100         Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Xenon-133	-
Ytterbium-175       100         Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Xenon-135	
Yttrium-90       10         Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Ytterbium-175	-
Yttrium-91       10         Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Yttrium-90	
Yttrium-92       100         Yttrium-93       100         Zinc-65       10	Yttrium-91	
Yttrium-93     100       Zinc-65     10	Yttrium-92	
Zinc-65 10	Yttrium-93	
7:00	Zinc-65	
	Zinc-69m	100

\* To convert  $\mu$ Ci to kBq, multiply the  $\mu$ Ci value by 37.

\*\* Based on alpha disintegration rate of Th-232, Th-230 and their daughter products

\*\*\* Based on alpha disintegration rate of U-238, U-234, and U-235:

## <u>420-3-26-.03</u>

## APPENDIX F

## **QUANTITIES FOR USE WITH DECOMMISSIONING**

Material	Microcurie*
Zinc-69	1,000
Zirconium-93	10
Zirconium-95	10
Zirconium-97	10
Any alpha emitting	
radionuclide not listed	
above or mixtures of	
alpha emitters of	
unknown composition	0.01
Any radionuclide other	
than alpha emitting	
radionuclides, not	
listed above or	
mixtures of beta	
emitters of unknown	
composition	0.1
<b>r</b>	0.1

#### **APPENDIX F**

# **QUANTITIES FOR USE WITH DECOMMISSIONING**

NOTE:

Where there is involved a combination of isotopes in known amounts, the limit for the combination should be derived as follows: Determine, for each isotope in the combination, the ratio between the quantity present in the combination and the limit otherwise established for the specific isotope when not in combination. The sum of such ratios for all the isotopes in the combination may not exceed "1" -- that is, unity.]

#### **APPENDIX G**

### REQUIREMENTS FOR TRANSFERS OF LOW-LEVEL RADIOACTIVE WASTE INTENDED FOR DISPOSAL AT LICENSED LAND DISPOSAL FACILITIES AND MANIFESTS

#### I. Manifest

A waste generator, collector, or processor who transports, or offers for transportation, low-level radioactive waste intended for ultimate disposal at a licensed lowlevel radioactive waste land disposal facility must prepare a Manifest (OMB Control Numbers 3150-0164, -0165, and -0166) reflecting information requested on applicable NRC Form 540 (Uniform Low-Level Radioactive Waste Manifest (Shipping Paper)) and 541 (Uniform Low-Level Radioactive Waste Manifest (Container and Waste Description)) and, if necessary, of an applicable NRC Form 542 (Uniform Low-Level Radioactive Waste Manifest Index and Regional Compact Tabulation)). NRC Forms 540 and 540A must be completed and must physically accompany the pertinent low-level waste shipment. Upon agreement between shipper and consignee, NRC Forms 541 and 541A and 542 and 542A may be completed, transmitted, and stored in electronic media with the capability for producing legible, accurate, and complete records on the respective forms. Licensees are not required by NRC to comply with the manifesting requirements of this part when they ship:

- (a) LLW for processing and expect its return (i.e., for storage under their license) prior to disposal at a licensed land disposal facility.
- (b) LLW that is being returned to the licensee who is the "waste generator" or "generator," as defined in this part; or
- (c) Radioactively contaminated material to a "waste processor" that becomes the processor's "residual waste."

For guidance in completing these forms, refer to the instructions that accompany the forms. Copies of manifests required by this appendix may be legible carbon copies, photocopies, or computer printouts that reproduce the data in the format of the uniform manifest.

NRC Forms 540, 540A, 541, 541A, 542 and 542A, and the accompanying instructions, in hard copy, may be obtained from the information and Records Management Branch, Office of Information Resources Management, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555., telephone (301) 415-7232.

This appendix includes information requirements of the Department of Transportation, as codified in 49 CFR Part 172. Information on hazardous, medical, or other waste, required to meet Environmental Protection Agency regulations, as codified in 40 CFR Parts 259, 261 or elsewhere, is not addressed in this section, and must be provided on the required EPA forms. However, the required EPA forms must accompany the Uniform Low-Level Radioactive Waste Manifest required by this chapter.

As used in this appendix, the following definitions apply:

Chelating agent has the same meaning as that given in 10 CFR Part 61.2.

*Chemical description* means a description of the principal chemical characteristics of a low-level radioactive waste.

*Computer-readable medium* means that the regulatory agency's computer can transfer the information from the medium into its memory.

Consignee means the designated receiver of the shipment of low-level radioactive waste.

Decontamination facility means a facility operating under a Commission, Agency, or Agreement State license whose principal purpose is decontamination of equipment or materials to accomplish recycle, reuse, or other waste management objectives, and, for purposes of this part, is not considered to be a consignee for LLW shipments.

*Disposal container* means a container principally used to confine low-level radioactive waste during disposal operations at a land disposal facility (also see "high integrity container"). Note that for some shipments, the disposal container may be the transport package.

*EPA identification number* means the number received by a transporter following application to the Administrator of EPA as required by 40 CFR Part 263.

*Generator* means a licensee operating under a Commission, Agency, or Agreement State license who (1) is a waste generator as defined in his part, or (2) is the licensee to whom waste can be attributed within the context of the Low-Level Radioactive Waste Policy Amendments Act of 1985 (e.g., waste generated as a result of decontamination or recycle activities).

*High integrity container (HIC)* means a container commonly designed to meet the structural stability requirements of 10 CFR Part 61.56, and to meet Department of Transportation requirements for a Type A package.

Land disposal facility has the same meaning as that given in 10 CFR Part 61.2.

NRC Forms 540, 540A, 541, 541A, 542, and 542A are official NRC Forms referenced in this appendix. Licensees need not use originals of these NRC Forms as long as any substitute forms are equivalent to the original documentation in

respect to content, clarity, size, and location of information. Upon agreement between the shipper and consignee, NRC Forms 541 (and 541A) and NRC Forms 542 (and 542A) may be completed, transmitted, and stored in electronic media. The electronic media must have the capability for producing legible, accurate, and complete records in the format of the uniform manifest.

*Package* means the assembly of components necessary to ensure compliance with the package requirements of DOT regulations, together with its radioactive contents, as presented for transport.

*Physical description* means the items called for on NRC Form 541 to describe a low-level radioactive waste.

*Residual waste* means low-level radioactive waste resulting from processing or decontamination activities that cannot be easily separated into distinct batches attributable to specific waste generators. This waste is attributable to the processor or decontamination facility, as applicable.

*Shipper* means the licensed entity (i.e., the waste generator, waste collector, or waste processor) who offers low-level radioactive waste for transportation, typically consigning this type of waste to a licensed waste collector, waste processor, or land disposal facility operator.

Shipping paper means NRC Form 540 and, if required, NRC Form 540A which includes the information required by DOT in 49 CFR part 172.

Source material has the same meaning as that given in 10 CFR Part 40.4.

Special nuclear material has the same meaning as that given in 10 CFR Part 70.4.

Uniform Low-Level Radioactive Waste Manifest or uniform manifest means the combination of NRC Forms 540, 541, and, if necessary, 542, and their respective continuation sheets as needed, or equivalent.

*Waste collector* means an entity, operating under a Commission, Agency, or Agreement State license, whose principal purpose is to collect and consolidate waste generated by others, and to transfer this waste, without processing or repackaging the collected waste, to another licensed waste collector, licensed waste processor, or licensed land disposal facility.

*Waste description* means the physical, chemical and radiological description of a low-level radioactive waste as called for on NRC Form 541.

Waste generator means an entity, operating under a Commission, Agency, or Agreement State license, who (1) possesses any material or component that contains radioactivity or is radioactively contaminated for which the licensee foresees no further use, and (2) transfers this material or component to a licensed land disposal facility or to a licensed waste collector or processor for handling or treatment prior to disposal. A licensee performing processing or decontamination services may be a "waste generator" if the transfer of low-level radioactive waste from its facility is defined as "residual waste."

*Waste processor* means an entity, operating under a Commission, Agency, or Agreement State license, whose principal purpose is to process, repackage, or otherwise treat low-level radioactive material or waste generated by others prior to eventual transfer of waste to a licensed low-level radioactive waste land disposal facility.

*Waste type* means a waste within a disposal container having a unique physical description (i.e., a specific waste descriptor code or description; or a waste sorbed on or solidified in a specifically defined media).

Information Requirements

A. General Information

The shipper of the radioactive waste, shall provide the following information on the uniform manifest:

- 1. The name, facility address, and telephone number of the licensee shipping the waste;
- 2. An explicit declaration indicating whether the shipper is acting as a waste generator, collector, processor, or a combination of these identifiers for purposes of the manifested shipment; and
- 3. The name, address, and telephone number, or the name and EPA identification number for the carrier transporting the waste.
- B. Shipment Information

The shipper of the radioactive waste shall provide the following information regarding the waste shipment on the uniform manifest:

- 1. The date of the waste shipment;
- 2. The total number of packages/disposal containers;
- 3. The total disposal volume and disposal weight in the shipment;
- 4. The total radionuclide activity in the shipment;
- 5. The activity of each of the radionuclides H-3, C-14, Tc-99, and I-129 contained in the shipment; and

- 6. The total masses of U-233, U-235, and plutonium in special nuclear material, and the total mass of uranium and thorium in source material.
- C. Disposal Container and Waste Information

The shipper of the radioactive waste shall provide the following information on the uniform manifest regarding the waste and each disposal container of waste in the shipment:

- 1. An alphabetic or numeric identification that uniquely identifies each disposal container in the shipment;
- 2. A physical description of the disposal container, including the manufacturer and model of any high integrity container;
- 3. The volume displaced by the disposal container;
- 4. The gross weight of the disposal container, including the waste;
- 5. For waste consigned to a disposal facility, the maximum radiation level at the surface of each disposal container;
- 6. A physical and chemical description of the waste;
- 7. The total weight percentage of chelating agent for any waste containing more than 0.1% chelating agent by weight, plus the identity of the principal chelating agent;
- 8. The approximate volume of waste within a container;
- 9. The sorbing or solidification media, if any, and the identity of the solidification media vendor and brand name;
- 10. The identities and activities of individual radionuclides contained in each container, the masses of U-233, U-235, and plutonium in special nuclear material, and the masses of uranium and thorium in source material. For discrete waste types (i.e., activated materials, contaminated equipment, mechanical filters, sealed source/devices, and wastes in solidification/stabilization media), the identities and activities of individual radionuclides associated with or contained on these waste types within a disposal container shall be reported;
- 11. The total radioactivity within each container; and
- 12. For wastes consigned to a disposal facility, the classification of the waste pursuant to 10 CFR Part 61.55. Waste not meeting the structural stability requirements of 10 CFR Part 61.56(b) must be identified.

D. Uncontainerized Waste Information

The shipper of the radioactive waste shall provide the following information on the uniform manifest regarding a waste shipment delivered without a disposal container:

- 1. The approximate volume and weight of the waste;
- 2. A physical and chemical description of the waste;
- 3. The total weight percentage of chelating agent if the chelating agent exceeds 0.1% by weight, plus the identity of the principal chelating agent;
- 4. For waste consigned to a disposal facility, the classification of the waste pursuant to 10 CFR Part 61.55. Waste not meeting the structural stability requirements of 10 CFR Part 61.56(b) must be identified;
- 5. The identities and activities of individual radionuclides contained in the waste, the masses of U-233, U-235, and plutonium in special nuclear material, and the masses of uranium and thorium in source material; and
- 6. For wastes consigned to a disposal facility, the maximum radiation levels at the surface of the waste.
- E. Multi-Generator Disposal Container Information

This section applies to disposal containers enclosing mixtures of waste originating from different generators. (Note: The origin of the LLW resulting from a processor's activities may be attributable to one or more "generators" (including "waste generators") as defined in this part). It also applies to mixtures of wastes shipped in an uncontainerized form, for which portions of the mixture within the shipment originate from different generators.

- 1. For homogeneous mixtures of waste, such as incinerator ash, provide the waste description applicable to the mixture and the volume of the waste attributed to each generator.
- 2. For heterogeneous mixtures of waste, such as the combined products from a large compactor, identify each generator contributing waste to the disposal container, and, for discrete waste types (i.e., activated materials, contaminated equipment, mechanical filters, sealed source/devices, and wastes in solidification/stabilization media), the identities and activities of individual radionuclides contained on these waste types within the disposal container. For each generator, provide the following:
  - (a) The volume of waste within the disposal container;

- (b) A physical and chemical description of the waste, including the solidification agent, if any;
- (c) The total weight percentage of chelating agents for any disposal container containing more than 0.1% chelating agent by weight, plus the identity of the principal chelating agent;
- (d) The sorbing or solidification media, if nay, and the identity of the solidification media vendor and brand name if the media is claimed to meet stability requirements in 10 CFR 61.56(b); and
- (e) Radionuclide identities and activities contained in the waste, the masses of U-233, U-235, and plutonium in special nuclear material, and the masses of uranium and thorium in source material if contained in the waste.

#### II. Certification

An authorized representative of the waste generator, processor, or collector shall certify by signing and dating the shipment manifest that the transported materials are properly classified, described, packaged, marked, and labeled and are in proper condition for transportation according to the applicable regulations of the Department of Transportation, the Commission, and the Agency. A collector in signing the certification is certifying that nothing has been done to the collected waste which would invalidate the waste generator's certification.

#### III. Control and Tracking

- A. Any licensee who transfers radioactive waste to a land disposal facility or a licensed waste collector shall comply with the requirements in paragraphs A.1 through 9 of this section. Any licensee who transfers waste to a licensed waste processor for waste treatment or repackaging shall comply with the requirements of paragraphs A.4 through 9 of this section. A licensee shall:
  - 1. Prepare all wastes so that the waste is classified according to 10 CFR Part 61.55 and meets the waste characteristics requirements in 10 CFR Part 61.56;
  - 2. Label each disposal container (or transport package if potential radiation hazards preclude labeling of the individual disposal container) of waste to identify whether it is Class A waste, Class B waste, Class C waste, or greater than Class C waste. In accordance with 10 CFR Part 61.55;

- 3. Conduct a quality assurance program to assure compliance with 10 CFR Parts 61.55 and 61.56 (the program must include management evaluation of audits);
- 4. Prepare the NRC Uniform Low-Level Radioactive Waste Manifest as required by this appendix;
- 5. Forward a copy or electronically transfer the Uniform Low-Level radioactive Waste Manifest to the intended consignee so that either (i)receipt of the manifest precedes the LLW shipment or (ii) the manifest is delivered to the consignee with the waste at the time the waste is transferred to the consignee. Using both (i) and (ii) is also acceptable;
- 6. Include NRC Form 540 (and NRC Form 540A, if required) with the shipment regardless of the option chosen in paragraph A.5 of this section;
- 7. Receive acknowledgment of the receipt of this shipment in the form of a signed copy of NRC Form 540;
- 8. Retain a copy of or electronically store the Uniform Low-Level Radioactive Waste Manifest and documentation of acknowledgment of receipt as the record of transfer of licensed material as required by 10 CFR Parts 30, 40, and 70; and
- 9. For any shipments or any part of a shipment for which acknowledgment of receipt has not been received within the times set forth in this appendix, conduct an investigation in accordance with paragraph E of this appendix.
- B. Any waste collector licensee who handles only prepackaged waste shall:
  - 1. Acknowledge receipt of the waste from the shipper within one week of receipt by returning a signed copy of NRC Form 540;
  - 2. Prepare a new manifest to reflect consolidated shipments that meet the requirements of this appendix. The waste collector shall ensure that, for each container of waste in the shipment, the manifest identifies the generator of that container of waste;
  - 3. Forward a copy or electronically transfer the Uniform Low-Level Radioactive Waste Manifest to the intended consignee so that either: (i) Receipt of the manifest precedes the LLW shipment or (ii) the manifest is delivered to the consignee with the waste at the time the waste is transferred to the consignee. Using both (i) and (ii) is also acceptable;

Include NRC Form 540 (and NRC Form 540A, if required) with the shipment regardless of the option chosen in paragraph B.3 of this section;

4.

- 5. Receive acknowledgment of the receipt of the shipment in the form of a signed copy of NRC Form 540;
- 6. Retain a copy of or electronically store the Uniform Low-Level Radioactive Waste Manifest and documentation of acknowledgment of receipt as the record of transfer or licensed material as required by 10 CFR Parts 30, 40, and 70;
- 7. For any shipments or any part of a shipment for which acknowledgment of receipt has not been received within the times set forth in this appendix, conduct an investigation in accordance with paragraph E of this appendix; and
- 8. Notify the shipper and the Administrator of the nearest Commission Regional Office when any shipment, or part of a shipment, has not arrived within 60 days after receipt of an advance manifest, unless notified by the shipper that the shipment has been canceled.
- C. Any licensed waste processor who treats or repackages waste shall:
  - 1. Acknowledge receipt of the waste form the shipper within one week of receipt by returning a signed copy of NRC Form 540;
  - 2. Prepare a new manifest that meets the requirements of this appendix. Preparation of the new manifest reflects that the processor is responsible for meeting these requirements. For each container of waste in the shipment, the manifest shall identify the waste generators, the preprocessed waste volume, and the other information as required in paragraph 1.E. of this appendix;
  - 3. Prepare all wastes so that the waste is classified according to 10 CFR Part 61.55;
  - 4. Label each package of waste to identify whether it is Class A waste, Class B waste, or Class C waste, in accordance with 10 CFR Parts 61.55 and 61.57;
  - 5. Conduct a quality assurance program to assure compliance with 10 CFR Parts 61.55 and 61.56 (the program shall include management; evaluation of audits);
  - 6. Forward a copy or electronically transfer the Uniform Low-Level Radioactive Waste Manifest to the intended consignee so that either; (i) Receipt of the manifest precedes the LLW shipment or

(ii) the manifest is delivered to the consignee with the waste at the time the waste is transferred to the consignee. Using both (i) and (ii) is also acceptable;

- 7. Include NRC Form 540 (and NRC Form 540A, if required) with the shipment regardless of the option chosen in paragraph C.6 of this section;
- 8. Receive acknowledgment of the receipt of the shipment in the form of a signed copy of NRC Form 540;
- 9. Retain a copy of or electronically store the Uniform Low-Level Radioactive Waste Manifest and documentation of acknowledgment of receipt as the record of transfer of licensed material as required by 10 CFR Parts 30, 40, and 70;
- 10. For any shipment or any part of a shipment for which acknowledgment of receipt has not been received within the times set forth in this appendix, conduct an investigation in accordance with paragraph E of this appendix; and
- 11. Notify the shipper and the Administrator of the nearest Commission Regional Office when any shipment, or part of a shipment, has not arrived within 60 days after receipt of an advance manifest, unless notified by the shipper that the shipment has been canceled.
- D. The land disposal facility operator shall:
  - 1. Acknowledge receipt of the waste within one week of receipt by returning, as a minimum, a signed copy of NRC Form 540 to the shipper. The shipper to be notified is the licensee who last possessed the waste and transferred the waste to the operator. If any discrepancy exists between materials listed on the Uniform Low-Level Radioactive Waste Manifest and materials received, copies or electronic transfer of the affected forms must be returned indicating the discrepancy;
  - 2. Maintain copies of all completed manifests and electronically store the information required by 10 CFR 61.80(1) until the commission terminates the license; and
  - 3. Notify the shipper and the Administrator of the nearest commission Regional Office when any shipment, or part of a shipment, has not arrived within 60 days after receipt of an advance manifest, unless notified by the shipper that the shipment has been canceled.
- E. Any shipment or part of a shipment for which acknowledgment is not received within the times set forth in this section must:

- Be investigated by the shipper if shipper has not received notification receipt within 20 days after transfer;
- Be traced and reported. The investigation shall include tracing the shipment and filing a report with the nearest Commission Regional Office. Each licensee who conducts a trace investigation shall file a written report with the appropriate NRC Regional Office within 2 weeks of completion of the investigation.

296D

2.

1.

Chapter 420-3-26

#### 420-3-26-.04

#### **RADIATION SAFETY REQUIREMENTS FOR INDUSTRIAL RADIOGRAPHIC OPERATIONS**

- (1) **Purpose**. This Rule prescribes requirements for the issuance of licenses or registrations for the industrial use of sources of radiation and radiation safety requirements for persons using these sources of radiation in industrial radiography.
- (2) Scope. The provisions and requirements of this Rule are in addition to, and not in substitution for, other requirements of the Rules of State Board of Health, Chapter 420-3-26 Radiation Control, Alabama Administrative Code. In particular, the general requirements and provisions of Rules 420-3-26-.01, 420-3-26-.02, 420-3-26-.03, 420-3-26-.04, 420-3-26-.05, and 420-3-26-.02 apply to applicants, licensees and registrants subject to this Rule. Rule 420-3-26-.02 applies to licensing and transportation of radioactive material and 420-3-26-.05 applies to the registration of radiation machines. Except for sections which are applicable only to sealed radioactive sources, radiation machines and sealed radioactive sources are both covered by this Rule. This rule does not apply to medical uses of sources of radiation.
- (3) **Definitions.** As used in this Rule, the following definitions apply:
  - (a) "Annual refresher safety training" means a review conducted or provided by the licensee or registrant for its employees on radiation safety aspects of industrial radiography. The review shall include, as a minimum, any results of internal inspections, new procedures or equipment, new or revised rules, and accidents or errors that have been observed. The review shall also provide opportunities for employees to ask safety questions.
  - (b) "ANSI" means the American National Standards Institute.
  - (c) "Associated equipment" means equipment that is used in conjunction with a radiographic exposure device to make radiographic exposures that drives, guides, or comes in contact with the source. \*/

<sup>\*/</sup> e.g., guide tube, control tube, control (drive) cable, removable source stop, "J" tube and collimator when used as an exposure head.

- (d) "Cabinet radiography" means industrial radiography conducted in an enclosure or cabinet so shielded that every location on the exterior meets the dose limits for individual members of the public as specified in 420-3-26-.03(14).
- (e) "Cabinet x-ray system" means an x-ray system with the x-ray tube installed in an enclosure, hereinafter termed a cabinet, that is independent of existing architectural structures except the floor. The cabinet x-ray system is intended to contain at least that portion of a material being irradiated, provide radiation attenuation, and exclude personnel from its interior during generation of radiation. This definition includes x-ray systems designed primarily for the inspection of carry-on baggage at airline, railroad, and bus terminals, and in similar facilities. An x-ray tube used within a shielded part of a building, or x-ray equipment that may temporarily or occasionally incorporate portable shielding, is not considered a cabinet x-ray system.
- (f) "Camera" see "Radiographic exposure device".
- (g) "Certifiable cabinet x-ray system" means an existing uncertified x-ray system that has been modified to meet the certification requirements specified in 21 CFR 1020.40.
- (h) "Certified cabinet x-ray system" means an x-ray system that has been certified in accordance with 21 CFR 1010.2 as being manufactured and assembled pursuant to the provisions of 21 CFR 1020.40.
- (i) "Certifying entity" means an independent certifying organization meeting the requirements in Appendix A of this Rule or a state regulatory program meeting the requirements in Appendix A, Parts II and III of this Rule.
- (j) "Collimator" means a radiation shield that is placed on the end of the guide tube or directly onto a radiographic exposure device to restrict the size of the radiation beam when the sealed source is cranked into position to make a radiographic exposure.
- (k) "Control cable" means the cable that is connected to the source assembly and used to drive the source to and from the exposure location.
- (1) "Control drive mechanism" means a device that enables the source assembly to be moved into and out of the exposure device.

- (m) "Control tube" means a protective sheath for guiding the control cable. The control tube connects the control drive mechanism to the radiographic exposure device.
- (n) "Drive cable" see "Control cable".
- (o) "Exposure head" means a device that locates the gamma radiography sealed source in the selected working position.
- (p) "Field station" means a facility at which sources of radiation may be stored or used and from which equipment is dispatched.
- (q) "Guide tube" means a flexible or rigid tube, or "J" tube, for guiding the source assembly and the attached control cable from the exposure device to the exposure head. The guide tube may also include the connections necessary for attachment to the exposure device and to the exposure head.
- (r) "Hands-on experience" means experience in all of those areas considered to be directly involved in the radiography process, and includes taking radiographs, calibration of survey instruments, operational and performance testing of survey instruments and devices, film development, posting of radiation areas, transportation of radiography equipment, posting of records and radiation area surveillance, etc., as applicable. Excessive time spent in only one or two of these areas, such as film development or radiation area surveillance, shall not be counted toward the 2000 hours of hands-on experience required for a radiation safety officer in 420-3-26-.04(15) or the hands-on experience for a radiographer as required by 420-3-26-.04(16)(a).
- (s) "Independent certifying organization" means an independent organization that meets all of the criteria of Appendix A of this Rule.
- (t) "Industrial radiography" means an examination of the structure of materials by the nondestructive method of utilizing ionizing radiation to make radiographic images.
- (u) "Lay-barge radiography" means industrial radiography performed on any water vessel used for laying pipe.
- (v) "Offshore platform radiography" means industrial radiography conducted from a platform over a body of water.

- (w) "Permanent radiographic installation" means an enclosed shielded room, cell, or vault, not located at a temporary jobsite, in which radiography is performed.
- (x) "Pigtail" see "Source assembly".
- (y) "Pill" see "Sealed source".
- (z) "Practical examination" means a demonstration through application of the safety rules and principles in industrial radiography including use of all procedures and equipment to be used by radiographic personnel.
- (aa) "Projection sheath" see "Guide tube".
- (bb) "Projector" see "Radiographic exposure device".
- (cc) "Radiation machine" means any device capable of producing radiation except, those devices with radioactive material as the only source of radiation.
- (dd) "Radiation monitor badge" means an individual personnel dosimeter used to measure the radiation dose to the individual's whole body and is processed and evaluated by a dosimetry processor meeting the requirements of 420-3-26-.03(17)(c)1 and 2.
- (ee) "Radiation safety officer for industrial radiography" means an individual with the responsibility for the overall radiation safety program on behalf of the licensee or registrant and who meets the requirements of 420-3-26-.04(15).
- (ff) "Radiographer" means any individual who performs or who, in attendance at the site where the sources of radiation are being used, personally supervises industrial radiographic operations and who is responsible to the licensee or registrant for assuring compliance with requirements of Agency rules and the conditions of the license or registration.
- (gg) "Radiographer certification" means written approval received from a certifying entity stating that an individual has satisfactorily met the radiation safety, testing, and experience criteria in 420-3-26-.04(16).
- (hh) "Radiographer's assistant" means any individual who under the direct supervision of a radiographer, uses radiographic exposure devices,

Chapter 420-3-26

sources of radiation, related handling tools, or radiation survey instruments in industrial radiography.

- (ii) "Radiographic exposure device" means any instrument containing a sealed source fastened or contained therein, in which the sealed source or shielding thereof may be moved, or otherwise changed, from a shielded to unshielded position for purposes of making a radiographic exposure.
- (jj) "Radiographic operations" means all activities performed with a radiographic exposure device, or with a radiation machine. Activities include using, transporting except by common or contract carriers, or storing at a temporary job site, performing surveys to confirm the adequacy of boundaries, setting up equipment, and any activity inside restricted area boundaries. Transporting a radiation machine is not considered a radiographic operation.
- (kk) "Radiography" see "Industrial radiography."
- (ll) "S-tube" means a tube through which the radioactive source travels when inside a radiographic exposure device.
- (mm) "Sealed source" means any radioactive material that is encased in a capsule designed to prevent leakage or escape of the radioactive material.
- (nn) "Shielded position" means the location within the radiographic exposure device, source changer, or storage container that, by manufacturer's design, is the proper location for storage of the sealed source.
- (00) "Source assembly" means an assembly that consists of the sealed source and a connector that attaches the source to the control cable. The source assembly may include a ballstop to secure the source in the shielded position.
- (pp) "Source changer" means a device designed and used for replacement of sealed sources in radiographic exposure devices. They may also be used for transporting and storing sealed sources.
- (qq) "Source stop" see "Exposure head."
- (rr) "Storage area" means any location, facility, or vehicle that is used to store and secure a radiographic exposure device, a radiation machine, or a storage container when it is not being used for radiographic operations.

Storage areas must be capable of being locked or have a physical barrier to prevent accidental exposure, tampering, or unauthorized removal of the device, machine, or container.

- (ss) "Storage container" means a device in which sealed sources or radiation machines are secured and stored.
- (tt) "Temporary jobsite" means a location where radiographic operations are performed and where sources of radiation may be stored other than the location(s) of use authorized on the license or registration.
- (uu) "Underwater radiography" means radiographic operations performed when the radiographic exposure device or radiation machine and/or related equipment are beneath the surface of the water.
- (4) **Exemptions for Cabinet X-Ray Systems.** Uses of certified and certifiable cabinet x-ray systems are exempt from the requirements of this Rule except for the following:
  - (a) For certified and certifiable cabinet x-ray systems, including those designed to allow admittance of individuals:
    - 1. No registrant shall permit any individual to operate a cabinet x-ray system until the individual has received a copy of and instruction in the operating procedures for the unit. Records that demonstrate compliance with this subparagraph shall be maintained for Agency inspection until disposal is authorized by the Agency.
    - 2. Tests for proper operation of interlocks must be conducted and recorded at intervals not to exceed six months. Records of these tests shall be maintained for Agency inspection until disposal is authorized by the Agency.
    - 3. The registrant shall perform an evaluation of the radiation dose limits to determine compliance with 420-3-26-.03(14) (a), (b), and (c) of these rules, and 21 CFR 1020.40, Cabinet X-Ray Systems, at intervals not to exceed one year. Records of these evaluations shall be maintained for Agency inspection for two years after the evaluation.
  - (b) Certified cabinet x-ray systems shall be maintained in compliance with 21

Chapter 420-3-26

CFR 1020.40, Cabinet X-Ray Systems and no modification shall be made to the system unless prior Agency approval has been granted.

- (5) **Performance Requirements for Industrial Radiography Equipment**. Equipment used in industrial radiographic operations must meet the following minimum criteria:
  - Each radiographic exposure device, source assembly or sealed source, and all associated equipment must meet the requirements specified in ANSI N432-1980 "Radiological Safety for the Design and Construction of Apparatus for Gamma Radiography," (published as NBS Handbook 136, issued January 1981);
  - (b) In addition to the requirements specified in 420-3-26-.04(5)(a), the following requirements apply to radiographic exposure devices, source changers, source assemblies and sealed sources;
    - 1. The licensee shall ensure that each radiographic exposure device has attached to it a durable, legible, clearly visible label bearing the:
      - (i) Chemical symbol and mass number of the radionuclide in the device;
      - (ii) Activity and the date on which this activity was last measured;
      - (iii) Model or product code and serial number of the sealed source;
      - (iv) Name of the manufacturer of the sealed source; and
      - (v) Licensee's name, address, and telephone number.
    - 2. Radiographic exposure devices intended for use as Type B packages must meet the applicable transportation requirements of 420-3-26-.02 (21), 420-3-26-.02(23), and 420-3-26-.04(24).
    - 3. Modification of radiographic exposure devices, source changers, and source assemblies and associated equipment is prohibited, unless approved by the Agency or other approval body.

- (c) In addition to the requirements specified in 420-3-26-.04(5)(a) and (b), the following requirements apply to radiographic exposure devices, source assemblies, and associated equipment that allow the source to be moved out of the device for radiographic operations or to source changers;
  - 1. The coupling between the source assembly and the control cable must be designed in such a manner that the source assembly will not become disconnected if cranked outside the guide tube. The coupling must be such that it cannot be unintentionally disconnected under normal and reasonably foreseeable abnormal conditions.
  - 2. The device must automatically secure the source assembly when it is cranked back into the fully shielded position within the device. This securing system may only be released by means of a deliberate operation on the exposure device.
  - 3. The outlet fittings, lock box, and drive cable fittings on each radiographic exposure device must be equipped with safety plugs or covers which must be installed during storage and transportation to protect the source assembly from water, mud, sand or other foreign matter.
  - 4. Each sealed source or source assembly must have attached to it or engraved on it, a durable, legible, visible label with the words:

"DANGER -- RADIOACTIVE."

The label may not interfere with the safe operation of the exposure device or associated equipment.

- 5. The guide tube must be able to withstand a crushing test that closely approximates the crushing forces that are likely to be encountered during use, and be able to withstand a kinking resistance test that closely approximates the kinking forces that are likely to be encountered during use.
- 6. Guide tubes must be used when moving the source out of the device.
- 7. An exposure head or similar device designed to prevent the source assembly from passing out of the end of the guide tube

Chapter 420-3-26

must be attached to the outermost end of the guide tube during industrial radiography operations.

- The guide tube exposure head connection must be able to withstand the tensile test for control units specified in ANSI N432-1980.
- 9. Source changers must provide a system for ensuring that the source will not be accidentally withdrawn from the changer when connecting or disconnecting the drive cable to or from a source assembly.
- (d) All radiographic exposure devices and associated equipment in use after January 10, 1996, must comply with the requirements of this section; and
- (e) As an exception to rule 420-3-26-.04(5)(a), equipment used in industrial radiographic operations need not comply with § 8.9.2(c) of the Endurance Test in ANSI N432-1980, if the prototype equipment has been tested using a torque value representative of the torque that an individual using the radiography equipment can reasonably exert on the lever or crankshaft of the drive mechanism.
- (6) Limits on External Radiation Levels From Storage Containers and Source Changers. The maximum exposure rate limits for storage containers and source changers are 2 millisieverts (200 mrem) per hour at any exterior surface, and 0.1 millisieverts (10 mrem) per hour at 1 meter from any exterior surface with the sealed source in the shielded position.

# (7) Locking of Sources of Radiation, Storage Containers and Source Changers.

- (a) Each radiographic exposure device must have a lock or outer locked container designed to prevent unauthorized or accidental removal of the sealed source from its shielded position. The exposure device and/or its container must be kept locked, with the key removed if it is a keyed lock, at all times when not under the direct surveillance of a radiographer or a radiographer's assistant except at permanent radiographic installations as stated in 420-3-26-.04(21). In addition, during radiographic operations the sealed source assembly must be secured in the shielded position each time the source is returned to that position.
- (b) Each sealed source storage container and source changer must have a lock

Chapter 420-3-26

## Radiation Control

or outer locked container designed to prevent unauthorized or accidental removal of the sealed source from its shielded position. Storage containers and source changers must be kept locked, with the key removed if it is a keyed lock, at all times when containing sealed sources except when under the direct surveillance of a radiographer or a radiographer's assistant.

(c) The control panel of each radiation machine shall be equipped with a lock that will prevent the unauthorized use of an x-ray system or the accidental production of radiation. The radiation machine shall be kept locked and the key removed at all times except when under the direct visual surveillance of a radiographer or a radiographer's assistant.

## (8) Radiation Survey Instruments.

- (a) The licensee or registrant shall keep a sufficient number of calibrated and operable radiation survey instruments at each location where sources of radiation are present to make the radiation surveys required by this Rule and by Rule 420-3-26-.03 of these rules. Instrumentation required by this section must be capable of measuring a range from 0.02 millisieverts (2 mrem) per hour through 0.01 sievert (1 rem) per hour.
- (b) The licensee or registrant shall have each radiation survey instrument required under 420-3-26-.04(8)(a) calibrated:
  - 1. At energies appropriate for use and at intervals not to exceed 6 months or after instrument servicing, except for battery changes;
  - 2. For linear scale instruments, at two points located approximately one-third and two-thirds of full-scale on each scale; for logarithmic scale instruments, at mid-range of each decade, and at two points of at least one decade; and for digital instruments, at 3 points between 0.02 and 10 millisieverts (2 and 1000 mrem) per hour; and
  - 3. So that an accuracy within plus or minus 20 percent of the true radiation dose rate can be demonstrated at each point checked.
- (c) The licensee or registrant shall maintain records of the results of the instrument calibrations in accordance with 420-3-26-.04(25).

# (9) Leak Testing and Replacement of Sealed Sources.

- (a) The replacement of any sealed source fastened to or contained in a radiographic exposure device and leak testing of any sealed source must be performed by persons authorized to do so by the Agency, the Nuclear Regulatory Commission, or another Agreement State.
- (b) The opening, repair, or modification of any sealed source must be performed by persons specifically authorized to do so by the Agency, the Nuclear Regulatory Commission, or another Agreement State.
- (c) Testing and recordkeeping requirements.
  - 1. Each licensee who uses a sealed source shall have the source tested for leakage at intervals not to exceed 6 months. The leak testing of the source must be performed using a method approved by the Agency, the Nuclear Regulatory Commission, or by another Agreement State. The wipe sample should be taken from the nearest accessible point to the sealed source where contamination might accumulate. The wipe sample must be analyzed for radioactive contamination. The analysis must be capable of detecting the presence of 185 becquerel (0.005 microcuries) of radioactive material on the test sample and must be performed by a person specifically authorized by the Agency, the Nuclear Regulatory Commission, or another Agreement State to perform the analysis.
  - 2. The licensee shall maintain records of the leak tests in accordance with 420-3-26-.04(26).
  - 3. Unless a sealed source is accompanied by a certificate from the transferor that shows that it has been leak tested within 6 months before the transfer, it may not be used by the licensee until tested for leakage. Sealed sources that are in storage and not in use do not require leak testing, but must be tested and the test results received before use or transfer to another person if the interval of storage exceeds 6 months.
- (d) Any test conducted pursuant to 420-3-26-.04(9)(b) and (c) that reveals the presence of 185 becquerel (0.005 microcuries) or more of removable radioactive material must be considered evidence that the sealed source is leaking. The licensee shall immediately withdraw the equipment involved from use and shall have it decontaminated and repaired or disposed of in accordance with Agency rules. A report must be filed with the Agency within 5 days of any test with results that exceed the threshold in this paragraph, describing the equipment involved, the test results, and the corrective action taken.

(e) Each exposure device using depleted uranium (DU) shielding and an "S" tube configuration must be tested for DU contamination at intervals not to exceed 12 months. The analysis must be capable of detecting the presence of 185 becquerel (0.005 microcuries) of radioactive material on the test sample and must be performed by a person specifically authorized by the Agency, the Nuclear Regulatory Commission, or another Agreement State to perform the analysis. Should such testing reveal the presence of DU contamination, the exposure device must be removed from use until an evaluation of the wear of the S-tube has been made. Should the evaluation reveal that the S-tube is worn through, the device may not be used again. DU shielded devices do not have to be tested for DU contamination while not in use and in storage. Before using or transferring such a device, however, the device must be tested for DU contamination, if the interval of storage exceeds 12 months. A record of the DU leak-test must be made in accordance with 420-3-26-.04(26).

## (10) **Physical Inventory.**

- (a) Each licensee or registrant shall conduct a physical inventory at intervals not to exceed 3 months to account for all sources of radiation, and for devices containing depleted uranium received and possessed under the license or registration.
- (b) The licensee or registrant shall maintain records of the physical inventory in accordance with 420-3-26-.04(27).

# (11) Inspection and Maintenance of Radiation Machines, Radiographic Exposure Devices, Transport and Storage Containers, Associated Equipment, Source Changers, and Survey Instruments.

- (a) The licensee or registrant shall perform visual and operability checks on survey meters, radiation machines, radiographic exposure devices, transport and storage containers, associated equipment and source changers before each day's use, or work shift, to ensure that:
  - 1. The equipment is in good working condition;
  - 2. The sources are adequately shielded; and
  - 3. Required labeling is present.
- (b) Survey instrument operability must be performed using check sources or other appropriate means.

Chapter 420-3-26

- (c) If equipment problems are found, the equipment must be removed from service until repaired.
- (d) Each licensee or registrant shall have written procedures for and perform inspection and routine maintenance of radiation machines, radiographic exposure devices, source changers, associated equipment, transport and storage containers, and survey instruments at intervals not to exceed 3 months or before the first use thereafter to ensure the proper functioning of components important to safety. If equipment problems are found, the equipment must be removed from service until repaired.
- (e) The licensee's inspection and maintenance program must include procedures to assure that Type B packages are shipped and maintained in accordance with the certificate of compliance or other approval.
- (f) Records of equipment problems and of any maintenance performed under 420-3-26-.04(11) must be made in accordance with 420-3-26-.04(29).

# (12) Permanent Radiographic Installations.

- (a) Each entrance that is used for personnel access to the high radiation area in a permanent radiographic installation must have either:
  - 1. An entrance control of the type described in 420-3-26-.03(19) of these rules that causes the radiation level upon entry into the area to be reduced; or
  - 2. Both conspicuous visible and audible warning signals to warn of the presence of radiation. The visible signal must be actuated by radiation whenever the source is exposed or the machine is energized. The audible signal must be actuated when an attempt is made to enter the installation while the source is exposed or the machine is energized.
- (b) The alarm system must be tested for proper operation with a radiation source each day before the installation is used for radiographic operations. The test must include a check of both the visible and audible signals. Entrance control devices that reduce the radiation level upon entry as designated in 420-3-26-.04(12)(a)1 must be tested monthly. If an entrance control device or an alarm is not operating properly, it must be immediately labeled as defective and repaired within 7 calendar days. The facility may continue to be used during this 7-day period, provided the licensee or registrant implements the continuous surveillance requirements of 420-3-26-.04(21) and uses an alarming ratemeter, unless

otherwise exempted. Test records for entrance controls and audible and visual alarms must be maintained in accordance with 420-3-26-.04(30).

## (13) Labeling, Storage, and Transportation.

(a) The licensee may not use a source changer or a container to store radioactive material unless the source changer or the storage container has securely attached to it a durable, legible, and clearly visible label bearing the standard trefoil radiation caution symbol conventional colors (magenta, purple or black on a yellow background) having a minimum diameter of 25 mm, and the wording:

# CAUTION \* RADIOACTIVE MATERIAL NOTIFY CIVIL AUTHORITIES [or " NAME OF COMPANY"]

## \* --- or "DANGER"

- (b) The licensee may not transport radioactive material unless the material is packaged, and the package is labeled, marked, and accompanied with appropriate shipping papers in accordance with rules set out in Rule 420-3-26-.02.
- (c) Radiographic exposure devices, source changers, storage containers, and radiation machines, must be physically secured to prevent tampering or removal by unauthorized personnel. The licensee shall store radioactive material in a manner that will minimize danger from explosion or fire.
- (d) The licensee shall lock and physically secure the transport package containing radioactive material in the transporting vehicle to prevent accidental loss, tampering, or unauthorized removal.
- (e) The licensee's or registrant's name and city or town where the main business office is located shall be prominently displayed with a durable, clearly visible label(s) on both sides of all vehicles used to transport radioactive material or radiation machines for temporary job site use.

# **Radiation Safety Requirements**

# (14) Conducting Industrial Radiographic Operations.

(a) Whenever radiography is performed at a location other than a permanent radiographic installation, the radiographer must be accompanied by at least one other qualified radiographer or an individual who has at a minimum met the

Chapter 420-3-26

requirements of 420-3-26-.04(16)(c). The additional qualified individual shall observe the operations and be capable of providing immediate assistance to prevent unauthorized entry. Radiography may not be performed if only one qualified individual is present.

- (b) All radiographic operations must be conducted in a permanent radiographic installation unless otherwise specifically authorized by the Agency.
- (c) Except when physically impossible, collimators shall be used in industrial radiographic operations that use radiographic exposure devices that allow the source to be moved out of the device.
- (d) A licensee or registrant may conduct lay-barge, offshore platform, or underwater radiography only if procedures have been approved by the Agency, the Nuclear Regulatory Commission, or by another Agreement State.
- (15) **Radiation Safety Officer.** The radiation safety officer shall ensure that radiation safety activities are being performed in accordance with approved procedures and regulatory requirements in the daily operation of the licensee's or registrant's program.
  - (a) The minimum qualifications, training, and experience for radiation safety officers for industrial radiography are as follows:
    - 1. Completion of the training and testing requirements of 420-3-26-.04(16)(a);
    - 2. 2000 hours of hands-on experience as a qualified radiographer in industrial radiographic operations; and
    - 3. Formal training in the establishment and maintenance of a radiation protection program.
  - (b) The Agency will consider alternatives when the radiation safety officer has appropriate training and experience in the field of ionizing radiation, and in addition, has adequate formal training with respect to the establishment and maintenance of a radiation safety protection program.
  - (c) The specific duties and authorities of the radiation safety officer include:
    - 1. Establishing and overseeing all operating, emergency, and ALARA procedures as required by Rule 420-3-26-.03 of these rules and reviewing them regularly to ensure that they conform to Agency rules and to the

license or registration conditions;

- 2. Overseeing and approving the training program for radiographic personnel to ensure that appropriate and effective radiation protection practices are taught;
- 3. Ensuring that required radiation surveys and leak tests are performed and documented in accordance with the rules, including any corrective measures when levels of radiation exceed established limits;
- 4. Ensuring that personnel monitoring devices are calibrated, if applicable, and used properly; that records are kept of the monitoring results; and that timely notifications are made as required by Rule 420-3-26-.03; and
- 5. Ensuring that operations are conducted safely and for implementing corrective actions including terminating operations.
- (d) Licensees and registrants will have 2 years from the effective date of this rule to meet the requirements of 420-3-26-.04(15)(a) and (b).
- (16) **Training.** 
  - (a) The licensee or registrant may not permit any individual to act as a radiographer until the individual:
    - 1. Has received at least 40 hours of training in the subjects outlined in 420-3-26-.04(16)(g), in addition to on the job training consisting of hands-on experience under the supervision of a radiographer, is certified through a radiographer certification program by a certifying entity in accordance with the criteria specified in Appendix A of this Rule, and has on their person a valid certification ID card issued by a certifying entity. The on the job training shall include a minimum of 320 hours of active participation in the performance of industrial radiography utilizing radioactive material and/or 160 hours of active participation in the performance of industrial radiography utilizing radioactive materials and radiation machines must complete both segments of the on the job training (480 hours); or
    - 2. The licensee or registrant may, until May 25, 2002, allow an individual who has not met the requirements of 420-3-26-.04(16)(a)1, to act as a radiographer provided the individual has received training in an approved

Chapter 420-3-26

training course and successfully completed a written examination that was previously submitted to and approved by the Agency, the Nuclear Regulatory Commission, or another Agreement State, in addition to on the job training consisting of hands-on experience under the supervision of a radiographer. The on the job training shall include a minimum of 320 hours of active participation in the performance of industrial radiography utilizing radioactive material and/or 160 hours of active participation in the performance of industrial radiography utilizing radioactive materials and radiation machines must complete both segments of the on the job training (480 hours).

- (b) In addition, the licensee or registrant may not permit any individual to act as a radiographer until the individual:
  - 1. Has received copies of and instruction in the requirements described in the applicable sections of Rules 420-3-26-.01, 420-3-26-.02, 420-3-26-.03, 420-3-26-.04, and 420-3-26-.10, in the license or registration under which the radiographer will perform industrial radiography, and the licensee's or registrant's operating and emergency procedures;
  - 2. Has demonstrated an understanding of items in 420-3-26-.04(16)(b)1 by successful completion of a written or oral examination;
  - 3. Has received training in the use of the registrant's radiation machines, or the licensee's radiographic exposure devices, sealed sources, in the daily inspection of devices and associated equipment, and in the use of radiation survey instruments; and
  - 4 Has demonstrated understanding of the use of the equipment described in 420-3-26-.04(16)(b)3 by successful completion of a practical examination.
- (c) The licensee or registrant may not permit any individual to act as a radiographer's assistant until the individual:
  - 1. Has received copies of and instruction in the applicable sections of Rules 420-3-26-.01, 420-3-26-.02, 420-3-26-.03, 420-3-26-.04, and 420-3-26-.10, in the license or registration under which the radiographer's assistant will perform industrial radiography, and the licensee's or registrant's operating and emergency procedures;

May 25, 2000

- 2. Has demonstrated an understanding of items in 420-3-26-.04(16)(c)1 by successful completion of a written or oral examination;
- 3. Under the personal supervision of a radiographer, has received training in the use of the registrant's radiation machines, or the licensee's radiographic exposure devices and sealed sources, in the daily inspection of devices and associated equipment, and in the use of radiation survey instruments; and
- 4. Has demonstrated understanding of the use of the equipment described in 420-3-26-.04(16)(c)3 by successful completion of a practical examination.
- (d) The licensee or registrant shall provide annual refresher safety training for each radiographer and radiographer's assistant at intervals not to exceed 12 months.
- (e) Except as provided in 420-3-26-.04(16)(e)4, the radiation safety officer or designee shall conduct an inspection program of the job performance of each radiographer and radiographer's assistant to ensure that the Agency rules, license or registration requirements, and operating and emergency procedures are followed. The inspection program must:
  - 1. Include observation of the performance of each radiographer and radiographer's assistant during an actual industrial radiographic operation, at intervals not to exceed 6 months; and
  - 2. Provide that, if a radiographer or a radiographer's assistant has not participated in an industrial radiographic operation for more than 6 months since the last inspection, the radiographer must demonstrate knowledge of the training requirements of 420-3-26-.04(16)(b)3 and the radiographer's assistant must demonstrate knowledge of the training requirements of 420-3-26-.04(16)(c)3 by a practical examination before these individuals can next participate in a radiographic operation.
  - 3. The Agency may consider alternatives in those situations where the individual serves as both radiographer and radiation safety officer.
  - 4. In those operations where a single individual serves as both radiographer and radiation safety officer, and performs all radiography operations, an inspection program is not required.
- (f) The licensee or registrant shall maintain records of the required training to include

May 25, 2000

#### Chapter 420-3-26

certification documents, written, oral and practical examinations, refresher safety training and inspections of job performance in accordance with 420-3-26-.04(31).

- (g) The licensee or registrant shall include the following subjects required in 420-3-26-.04(16)(a):
  - 1. Fundamentals of radiation safety including:
    - (i) Characteristics of gamma and x-radiation;
    - (ii) Units of radiation dose and quantity of radioactivity;
    - (iii) Hazards of exposure to radiation;
    - (iv) Levels of radiation from sources of radiation; and
    - Methods of controlling radiation dose (time, distance, and shielding);
  - 2. Radiation detection instruments including:
    - (i) Use, operation, calibration, and limitations of radiation survey instruments;
    - (ii) Survey techniques; and
    - (iii) Use of personnel monitoring equipment;
  - 3. Equipment to be used including:
    - (i) Operation and control of radiographic exposure equipment, remote handling equipment, and storage containers, including pictures or models of source assemblies (pigtails);
    - (ii) Operation and control of radiation machines;
    - (iii) Storage, control, and disposal of sources of radiation; and
    - (iv) Inspection and maintenance of equipment.
  - 4. The requirements of pertinent state and federal regulations; and

Chapter 420-3-26

# Radiation Control

- 5. Case histories of accidents in radiography.
- (h) Licensees and registrants will have until May 25, 2001, to comply with the additional training requirements specified in 420-3-26-.04(16)(a)1, 420-3-26-.04(16)(b)1 and 420-3-26-.04(16)(c)1.

# (17) **Operating and Emergency Procedures.**

- (a) Operating and emergency procedures must include, as a minimum, instructions in the following:
  - 1. Appropriate handling and use of sources of radiation so that no person is likely to be exposed to radiation doses in excess of the limits established in Rule 420-3-26-.03;
  - 2. Methods and occasions for conducting radiation surveys;
  - 3. Methods for posting and controlling access to radiographic areas;
  - 4. Methods and occasions for locking and securing sources of radiation;
  - 5. Personnel monitoring and the use of personnel monitoring equipment;
  - 6. Transporting equipment to field locations, including packing of radiographic exposure devices and storage containers in the vehicles, placarding of vehicles when required, and control of the equipment during transportation as described in Rule 420-3-26-02;
  - 7. The inspection, maintenance, and operability checks of radiographic exposure devices, radiation machines, survey instruments, alarming ratemeters, transport containers, and storage containers;
  - 8. Steps that must be taken immediately by radiography personnel in the event a pocket dosimeter is found to be off-scale, an electronic personal dosimeter reads greater than 2 millisieverts (200 mrem), or an alarming ratemeter alarms unexpectedly;
  - 9. The procedure(s) for identifying and reporting defects and noncompliance, as required by 420-3-26-.04(37);
  - 10. The procedure for notifying proper persons in the event of an accident or incident;

Chapter 420-3-26

- 11. Minimizing exposure of persons in the event of an accident or incident, including a source disconnect, a transport accident, or loss of a source of radiation;
- 12. Source recovery procedure if licensee will perform source recoveries; and
- 13. Maintenance of records.
- (b) The licensee or registrant shall maintain copies of current operating and emergency procedures in accordance with 420-3-26-.04(32) and (36).
- (18) Supervision of Radiographer's Assistants. The radiographer's assistant shall be under the personal supervision of a radiographer when using radiographic exposure devices, radiation machines, associated equipment, or a sealed source, or while conducting radiation surveys required by 420-3-26-.04(20)(b) or (c) to determine that the sealed source has returned to the shielded position or the radiation machine is off after an exposure. The personal supervision must include:
  - (a) The radiographer's physical presence at the site where the sources of radiation are being used;
  - (b) The availability of the radiographer to give immediate assistance if required; and
  - (c) The radiographer's direct observation of the assistant's performance of the operations referred to in this section.

#### (19) **Personnel Monitoring**.

- (a) The licensee or registrant may not permit any individual to act as a radiographer or a radiographer's assistant unless, at all times during radiographic operations, each individual wears, on the trunk of the body, a combination of direct reading dosimeter, an alarming ratemeter, and a radiation monitor badge. At permanent radiographic installations where other appropriate alarming or warning devices are in routine use, or during radiographic operations using only radiation machines, the use of an alarming ratemeter is not required.
  - 1. Pocket dosimeters must have a range from zero to 2 millisieverts (200 mrem) and must be recharged at the start of each shift. Electronic personal dosimeters may only be used in place of ion-chamber pocket dosimeters.
  - 2. Each radiation monitor badge must be assigned to and worn by only one

individual.

- 3. Radiation monitor badges must be exchanged at periods not to exceed one month.
- 4. After replacement, each radiation monitor badge must be returned to the supplier for processing within 14 calendar days of the end of the monitoring period, or as soon as practicable. In circumstances that make it impossible to return each radiation monitor badge in 14 calendar days, such circumstances must be documented and available for review by the Agency.
- (b) Direct reading dosimeters such as pocket dosimeters or electronic personal dosimeters, must be read and the exposures recorded at the beginning and end of each shift, and records must be maintained in accordance with 420-3-26-.04(33).
- (c) Pocket dosimeters, or electronic personal dosimeters, must be checked at periods not to exceed 12 months for correct response to radiation, and records must be maintained in accordance with 420-3-26-.04(33). Acceptable dosimeters must read within plus or minus 20 percent of the true radiation exposure.
- (d) If an individual's pocket dosimeter is found to be off-scale, or the electronic personal dosimeter reads greater than 2 millisieverts (200 mrem), the individual's radiation monitor badge must be sent for processing within 24 hours. In addition, the individual may not resume work associated with the use of sources of radiation until a determination of the individual's radiation exposure has been made. This determination must be made by the radiation safety officer or the radiation safety officer's designee. The results of this determination must be included in the records maintained in accordance with 420-3-26-.04(33).
- (e) If a radiation monitor badge is lost or damaged, the worker shall cease work immediately until a replacement radiation monitor badge is provided and the exposure is calculated for the time period from issuance to loss or damage of the radiation monitor badge. The results of the calculated exposure and the time period for which the radiation monitor badge was lost or damaged must be included in the records maintained in accordance with 420-3-26-.04(33).
- (f) Reports received from the radiation monitor badge processor must be retained in accordance with 420-3-26-.04(33).
- (g) Each alarming ratemeter must:

Chapter 420-3-26

- 1. Be checked to ensure that the alarm functions properly before using at the start of each shift;
- 2. Be set to give an alarm signal at a preset dose rate of 5 millisieverts (500 mrem) per hour; with an accuracy of plus or minus 20 percent of the true radiation dose rate;
- 3. Require special means to change the preset alarm function; and
- 4. Be calibrated at periods not to exceed 12 months for correct response to radiation. The licensee shall maintain records of alarming ratemeter calibrations in accordance with 420-3-26-.04(33).
- (20) Radiation Surveys. The licensee or registrant shall:
  - (a) Conduct all surveys with a calibrated and operable radiation survey instrument that meets the requirements of 420-3-26-.04(8);
  - (b) Conduct a survey of the radiographic exposure device and the guide tube after each exposure when approaching the device or the guide tube. The survey must determine that the sealed source has returned to its shielded position before exchanging films, repositioning the exposure head, or dismantling equipment. Radiation machines shall be surveyed after each exposure to determine that the machine is off;
  - (c) Conduct a survey of the radiographic exposure device whenever the source is exchanged and whenever a radiographic exposure device is placed in a storage area as defined in 420-3-26-.04(3), to ensure that the sealed source is in its shielded position; and
  - (d) Maintain records in accordance with 420-3-26-.04(34).
- (21) **Surveillance.** During each radiographic operation, the radiographer shall ensure continuous direct visual surveillance of the operation to protect against unauthorized entry into a radiation area or a high radiation area, as defined in Rule 420-3-26-.01, except at permanent radiographic installations where all entryways are locked and the requirements of 420-3-26-.04(12) are met.
- (22) **Posting.** All areas in which industrial radiography is being performed must be conspicuously posted as required by rule 420-3-26-.03(28). The exceptions listed in rule 420-3-26-.03(29) do not apply to industrial radiographic operations.

# **Recordkeeping Requirements**

(23) **Records for Industrial Radiography**. Each licensee or registrant shall maintain a copy of its license or registration, documents incorporated by reference, and amendments to each of these items until superseded by new documents approved by the Agency, or until the Agency terminates the license or registration.

# (24) Records of Receipt and Transfer of Sources of Radiation.

- (a) Each licensee or registrant shall maintain records showing the receipts and transfers of sealed sources, devices using DU for shielding, and radiation machines, and retain each record for 3 years after transfer or disposal.
- (b) These records must include the date, the name of the individual making the record, radionuclide, number of becquerels (curies) or mass (for DU), and manufacturer, model, and serial number of each source of radiation and/or device, as appropriate.
- (25) **Records of Radiation Survey Instruments**. Each licensee or registrant shall maintain records of the calibrations of its radiation survey instruments that are required under 420-3-26-.04(8) and retain each record for 3 years after it is made.
- (26) **Records of Leak Testing of Sealed Sources and Devices Containing DU**. Each licensee shall maintain records of leak test results for sealed sources and for devices containing DU. The results must be stated in units of becquerels (microcuries). The licensee shall retain each record for 3 years after it is made or until the source in storage is removed whichever is greater.

# (27) Records of Physical Inventory.

- (a) Each licensee or registrant shall maintain records of the physical inventory of all sources of radiation, including devices containing depleted uranium, as required by 420-3-26-.04(10), and retain each record for 3 years.
- (b) The record must include the date of the inventory, name of the individual conducting the inventory, radionuclide, number of becquerels (curies) or mass (for DU) in each device, location of sources of radiation and/or devices, and manufacturer, model, and serial number of each source of radiation and/or device, as appropriate.
- (28) Utilization Logs.

Chapter 420-3-26

- (a) Each licensee or registrant shall maintain utilization logs showing for each source of radiation the following information:
  - 1. A description, including the make, model, and serial number of the radiation machine or the radiographic exposure device, transport, or storage container in which the sealed source is located;
  - 2. The identity and signature of the radiographer to whom assigned;
  - 3. The location and dates of use, including the dates removed and returned to storage; and
  - 4. For permanent radiographic installations, the dates each radiation machine is energized or radiographic exposure device utilized.
- (b) The licensee or registrant shall retain the logs required by 420-3-26-.04(28)(a) for 3 years.

# (29) Records of Inspection and Maintenance of Radiation Machines, Radiographic Exposure Devices, Transport and Storage Containers, Associated Equipment, Source Changers, and Survey Instruments.

- (a) Each licensee or registrant shall maintain records specified in 420-3-26-.04(11) of equipment problems found in daily checks and quarterly inspections of radiation machines, radiographic exposure devices, transport and storage containers, associated equipment, source changers, and survey instruments; and retain each record for 3 years after it is made.
- (b) The record must include the date of check or inspection, name of inspector, equipment involved, any problems found, and what repair and/or maintenance, if any, was performed.
- (30) Records of Alarm System and Entrance Control Checks at Permanent Radiographic Installations. Each licensee or registrant shall maintain records of alarm system and entrance control device tests required by 420-3-26-.04(12) and retain each record for 3 years after it is made.
- (31) **Records of Training and Certification**. Each licensee or registrant shall maintain the following records for 3 years following termination of employment:
  - (a) Records of training of each radiographer and each radiographer's assistant. The record must include radiographer certification documents and verification of

May 25, 2000

certification status, copies of written tests, dates of oral and practical examinations, the names of individuals conducting and receiving the oral and practical examinations, and a list of items tested and the results of the oral and practical examinations; and

- (b) Records of annual refresher safety training and semi-annual inspections of job performance for each radiographer and each radiographer's assistant. The records must list the topics discussed during the refresher safety training, the dates the annual refresher safety training was conducted, and names of the instructors and attendees. For inspections of job performance, the records must also include a list showing the items checked and any non-compliance observed by the radiation safety officer or designee.
- (32) **Copies of Operating and Emergency Procedures.** Each licensee or registrant shall maintain a copy of current operating and emergency procedures until the Agency terminates the license or registration. Superseded material must be retained for 3 years after the change is made.
- (33) **Records of Personnel Monitoring**. Each licensee or registrant shall maintain the following exposure records specified in 420-3-26-.04(19):
  - (a) Direct reading dosimeter readings and yearly operability checks required by 420-3-26-.04(19)(b) and (c) for 3 years after the record is made;
  - (b) Records of alarming ratemeter calibrations for 3 years after the record is made;
  - (c) Reports received from the radiation monitor badge processor until the Agency terminates the license or registration. Upon termination of the license or registration, the licensee or registrant shall permanently store records on Agency Form Y or equivalent, or shall make provision with the Agency for transfer to the Agency; and
  - (d) Records of estimates of exposures as a result of off-scale personal direct reading dosimeters, or lost or damaged, radiation monitor badges until the Agency terminates the license or registration.
- (34) Records of Radiation Surveys. Each licensee shall maintain a record of each exposure device survey conducted before the device is placed in storage as specified in 420-3-26-.04(20)(c). Each record must be maintained for 3 years after it is made.
- (35) Form of Records. Each record required by this Part must be legible throughout the specified retention period. The record may be the original or a reproduced copy or a

microform provided that the copy or microform is authenticated by authorized personnel and that the microform is capable of reproducing a clear copy throughout the required retention period. The record may also be stored in electronic media with the capability for producing legible, accurate, and complete records during the required retention period. Records, such as letters, drawings, and specifications, must include all pertinent information, such as stamps, initials, and signatures. The licensee or registrant shall maintain adequate safeguards against tampering with and loss of records.

## (36) Location Of Documents and Records.

- (a) Each licensee or registrant shall maintain copies of records required by this Rule and other applicable rules at the location identified by the applicant as specified in rule 420-3-26-.02(10)(g).
- (b) Each licensee or registrant shall also maintain current copies of the following documents and records sufficient to demonstrate compliance at each applicable field station and each temporary jobsite;
  - 1. The license or registration authorizing the use of sources of radiation;
  - 2. A copy of Rules 420-3-26-.01, 420-3-26-.02, 420-3-26-.03, 420-3-26-.04, 420-3-26-.05, and 420-3-26-.10;
  - 3. Utilization logs for each source of radiation dispatched from that location as required by 420-3-26-.04(28).
  - 4. Records of equipment problems identified in daily checks of equipment as required by 420-3-26-.04(29)(a);
  - 5. Records of alarm system and entrance control checks required by 420-3-26-.04(30), if applicable;
  - 6. Records of dosimeter readings as required by 420-3-26-.04(33);
  - 7. Operating and emergency procedures as required by 420-3-26-.04(32);
  - 8. Evidence of the latest calibration of the radiation survey instruments in use at the site, as required by 420-3-26-.04(25);
  - 9. Evidence of the latest calibrations of alarming ratemeters and operability checks of dosimeters as required by 420-3-26-.04(33);

- 10 Survey records as required by 420-3-26-.04(34) and 420-3-26-.03(42) as applicable, for the period of operation at the site;
- 11. The shipping papers for the transportation of radioactive materials required by Rule 420-3-26-.02(23) and (24); and
- 12. When operating under reciprocity pursuant to Rule 420-3-26-.02(20) or 420-3-26-.05(6), a copy of the applicable State license or registration, or Nuclear Regulatory Commission license authorizing the use of sources of radiation.

# Notifications

# (37) Notifications.

- (a) In addition to the reporting requirements specified in Rule 420-3-26-.03, each licensee or registrant shall provide a written report to the Agency within 30 days of the occurrence of any of the following incidents involving radiographic equipment:
  - 1. Unintentional disconnection of the source assembly from the control cable;
  - 2. Inability to retract the source assembly to its fully shielded position and secure it in this position;
  - 3. Failure of any component, which is critical to safe operation of the device, to properly perform its intended function; or
  - 4. An indicator on a radiation machine fails to show that radiation is being produced, an exposure switch fails to terminate production of radiation, or a safety interlock fails to terminate x-ray production.
- (b) The licensee or registrant shall include the following information in each report submitted under 420-3-26-.04(37)(a), and in each report of overexposure submitted under Rule 420-3-26-.03(53) which involves failure of safety components of radiography equipment:
  - 1. Description of the equipment problem;
  - 2. Cause of each incident, if known;

Chapter 420-3-26

- 3. Name of the manufacturer and model number of equipment involved in the incident;
- 4. Place, date, and time of the incident;
- 5. Actions taken to establish normal operations;
- 6. Corrective actions taken or planned to prevent recurrence; and
- 7. Names and qualifications of personnel involved in the incident.
- (c) Any licensee or registrant conducting radiographic operations or storing sources of radiation at any location not listed on the license or registration for a period in excess of 90 days in a calendar year, shall notify the Agency prior to exceeding the 90 days.

# **Radiographer Certification**

## (38) Application and Examinations.

- (a) <u>Application</u>
  - 1. An application for taking the examination shall be on forms prescribed and furnished by the Agency.
  - 2. A non-refundable fee of One Hundred Twenty Five Dollars (\$125) shall be submitted with the application to cover certification administrative costs, such as the examination, training documentation review, and issuance of certification.
  - 3. The application and the non-refundable fee shall be submitted to the Agency on or before the dates specified by the Agency.
  - 4. An individual whose certification ID card has been suspended or revoked shall obtain written approval from the Agency to apply to retake the examination.
- (b) <u>Examination</u>. The examination shall be given for the purpose of determining the qualifications of applicants.
  - 1. A written examination shall be held at dates, times, and locations determined by the Agency. The scope of the examination and the

May 25, 2000

methods of procedure, including determination of the passing score, shall be prescribed by the Agency. The examination will assess the applicant's . knowledge to safely use sources of radiation and related equipment and the applicant's knowledge of Rules 420-3-26-.01, 420-3-26-.02, 420-3-26-.03, 420-3-26-.04, and 420-3-26-.10.

- 2. The examination will be administered by the Agency or persons authorized by the Agency.
- 3. A candidate failing an examination may apply for re-examination in accordance with 420-3-26-.04(38)(a) and will be re-examined. A candidate shall not retake the same version of the examination.
- 4. The examination will be in English.
- 5. To take the examination, an individual shall have a picture identification card, such as a driver's license, at the time of the examination.
- 6. Calculators will be permitted during the examination. However, calculators or computers with preprogrammed data or formulas, including exposure calculators, will not be permitted during the examination.
- 7. The examination will be a "closed book" examination.
- 8. Any individual observed by an Agency proctor to be compromising the integrity of the examination shall be required to surrender the examination, the answer sheet, and any work paper. Such individual will not be allowed to complete the examination, will forfeit the examination fee, and will leave the examination site to avoid disturbing other examinees. Such individual must wait 90 days and must resubmit a new application and an additional non-refundable fee of One Hundred Twenty Five Dollars (\$125) before taking a new examination.
- 9. Examination material shall be returned to the Agency at the end of the examination. No photographic or other copying of examination questions or materials shall be permitted. Disclosure by any individual of the contents of any examination prior to its administration is prohibited.
- 10. The names and scores of individuals taking the examination shall be a public record.

Chapter 420-3-26

# (39) Certification Identification (ID) Card.

- (a). A certification ID card shall be issued to each person who successfully completes the requirements of 420-3-26-.04(16)(a)1 and the examination prescribed in 420-3-26-.04(38)(b).
  - 1. Each person's certification ID card shall contain their photograph. The Agency will take the photograph at the time the examination is administered.
  - 2. The certification ID card remains the property of the Agency and may be revoked or suspended.
  - 3. Any individual who wishes to replace their certification ID card shall submit to the Agency a written request for a replacement certification ID card, stating the reason a replacement certification ID card is needed. A non-refundable fee of Twenty Dollars (\$20) shall be paid to the Agency for each replacement of a certification ID card. The prescribed fee shall be submitted with the written request for a replacement certification ID card. The individual shall maintain a copy of the request in their possession while performing industrial radiographic operations until a replacement certification ID card is received from the Agency.
- (b). Each certification ID card is valid for a period of five years, unless revoked or suspended in accordance with 420-3-26-.04(39)(d). Each certification ID card expires at the end of the day, in the month and year stated on the certification ID card.
- (c) Renewal of Certification ID card:.
  - 1. Applications for examination to renew a certification ID card shall be filed in accordance with 420-3-26-.04(38)(a).
  - 2. The examination for renewal of a certification ID card shall be administered in accordance with 420-3-26-.04(38)(b).
  - 3. A renewal certification ID card shall be issued in accordance with 420-3-26-.04(39)(a).
- (d) Revocation or suspension of a certification ID card.
  - 1. Any radiographer who violates these rules or equivalent State or Nuclear

Regulatory Commission regulations, or any applicable statutory requirements may be required to show cause at a formal hearing why their certification ID card should not be revoked or suspended in accordance with 420-3-26-.04(39)(d)2.

2. When an Agency order has been issued for an industrial radiographer to cease and desist from the use of sources of radiation or the Agency revokes or suspends their certification ID card, the industrial radiographer shall surrender the certification ID card to the Agency until the order is changed or the suspension expires.

## (40) **Reciprocity.**

- (a) All reciprocal recognition of licenses and registrations by the Agency will be granted in accordance with rule 420-3-26-.02(20) and 420-3-26-.05(6).
- (b) Reciprocal recognition by the Agency of an individual radiographer certification will be granted provided that:
  - 1. The individual holds a valid certification in the appropriate category issued by a certifying entity, as defined in 420-3-26-.04(3)(i);
  - 2. The requirements and procedures of the certifying entity issuing the certification affords the same or comparable certification standards as those afforded by 420-3-26-.04(16)(a);
  - 3. The applicant presents the certification to the Agency prior to entry into the state; and
  - 4. No escalated enforcement action is pending with the Nuclear Regulatory Commission or in any other state.
- (c) Certified individuals who are granted reciprocity by the Agency shall maintain the certification upon which the reciprocal recognition was granted, or prior to the expiration of such certification, shall meet the requirements of 420-3-26-.04(16)(a).

# (41) Specific Requirements for Radiographic Personnel Performing Industrial Radiography.

(a) At a job site, the following shall be supplied by the licensee or registrant:

Chapter 420-3-26

- 1. At least one operable, calibrated survey instrument for each exposure device or radiation machine in use;
- 2. A current radiation monitor badge for each person performing radiographic operations;
- 3. An operable, calibrated direct reading dosimeter for each person performing radiographic operations ;
- 4. An operable, calibrated, alarming ratemeter for each person performing radiographic operations using a radiographic exposure device; and
- 5. The appropriate barrier ropes and signs.
- (b) Each radiographer at a job site shall have on their person a valid certification ID card issued by a certifying entity.
- (c) Industrial radiographic operations shall not be performed if any of the items in 420-3-26-.04(41)(a) and (b) are not available at the job site or are inoperable.
- (d) During an inspection, the Agency may terminate an operation if any of the items in 420-3-26-.04(41)(a) and (b) are not available or operable, or if the required number of radiographic personnel are not present. Operations shall not be resumed until all required conditions are met.
- Authority: §§22-14-4, 22-14-7, and 22-14-8, Code of Alabama, 1975.
- History: New 6-15-66, Revised 3-18-70,3-17-71; Repromulgated 8-21-74; Revised 5-21-75, 1-18-78; Revised 11-21-79; Revised and Repromulgated 10-21-81; Revised and Repromulgated effective 12-31-83; Revised and Repromulgated effective 1-31-90; Revised and Repromulgated effective 4-22-94; Revised and Repromulgated effective May 25, 2000.
- Author: Kirksey E. Whatley, Director, Office of Radiation Control, Alabama Department of Public Health

#### 420-3-26-.04

## APPENDIX A

#### I. Requirements for an Independent Certifying Organization.

An independent certifying organization shall:

- 1. Be an organization such as a society or association, whose members participate in, or have an interest in, the field of industrial radiography;
- 2. Make its membership available to the general public nationwide. Membership shall not be restricted because of race, color, religion, sex, age, national origin or disability;
- 3. Have a certification program open to nonmembers, as well as members;
- 4. Be an incorporated, nationally recognized organization, that is involved in setting national standards of practice within its fields of expertise;
- 5. Have an adequate staff, a viable system for financing its operations, and a policy and decision-making review board;
- 6. Have a set of written organizational by-laws and policies that provide adequate assurance of lack of conflict of interest and a system for monitoring and enforcing those by-laws and policies;
- 7. Have a committee, whose members can carry out their responsibilities impartially, to review and approve the certification guidelines and procedures, and to advise the organization's staff in implementing the certification program;
- 8. Have a committee, whose members can carry out their responsibilities impartially, to review complaints against certified individuals and to determine appropriate sanctions;
- 9. Have written procedures describing all aspects of its certification program, maintain records of the current status of each individual's certification and the administration of its certification program;
- 10. Have procedures to ensure that certified individuals are provided due process with respect to the administration of its certification program, including the

Chapter 420-3-26

process of becoming certified and any sanctions imposed against certified individuals;

- 11. Have procedures for proctoring examinations, including qualifications for proctors. These procedures must ensure that the individuals proctoring each examination are not employed by the same company or corporation (or a wholly-owned subsidiary of such company or corporation) as any of the examinees;
- 12. Exchange information about certified individuals with the Nuclear Regulatory Commission and other independent certifying organizations and/or Agreement States and allow periodic review of its certification program and related records; and
- 13. Provide a description to the Nuclear Regulatory Commission of its procedures for choosing examination sites and for providing an appropriate examination environment.

# **II. Requirements for Certification Programs.**

All certification programs must:

- 1. Require applicants for certification to (a) receive training in the topics set forth in 420-3-26-.04(16)(g) or equivalent State or Nuclear Regulatory Commission regulations, and (b) satisfactorily complete a written examination covering these topics;
- 2. Require applicants for certification to provide documentation that demonstrates that the applicant has:
  - (a) received training in the topics set forth in 420-3-26-.04(16)(g) or equivalent State or Nuclear Regulatory Commission regulations;
  - (b) satisfactorily completed a minimum period of on-the-job training as specified in 420-3-26-.04(16)(a); and
  - (c) received verification by a State licensee or registrant or a Nuclear Regulatory Commission licensee that the applicant has demonstrated the capability of independently working as a radiographer.
- 3. Include procedures to ensure that all examination questions are protected from disclosure;

- 4. Include procedures for denying an application and revoking, suspending, and reinstating a certification;
- 5. Provide a certification period of not less than 3 years nor more than 5 years;
- 6. Include procedures for renewing certifications and, if the procedures allow renewals without examination, require evidence of recent full-time employment and annual refresher training; and
- 7. Provide a timely response to inquiries, by telephone or letter, from members of the public, about an individual's certification status.

# **III.** Requirements for Written Examinations

All examinations must be:

- 1. Designed to test an individual's knowledge and understanding of the topics listed in 420-3-26-.04(16)(g) or equivalent State or Nuclear Regulatory Commission requirements;
- 2. Written in a multiple-choice format;
- 3. Have test items drawn from a question bank containing psychometrically valid questions based on the material in 420-3-26-.04(16)(g).

Chapter 420-3-26

#### 420-3-26-.05

# **REGISTRATION OF X-RAY PRODUCING MACHINES**

## GENERAL

## (1) **Registration Requirement**.

- (a) This Rule 420-3-26-.05 provides for the registration of radiation machines capable of producing x-rays of less than 0.9 meV. Every person possessing an x-ray producing machine shall register in accordance with the provisions of this rule. Except as specifically exempted in Section 420-3-26-.05(4), each person who receives, possesses, uses, or services a radiation machine shall register such machines with the Agency in accordance with the requirements of this Rule 420-3-26-.05.<sup>1</sup>
- (b) In addition to the requirements of this Rule 420-3-26-.05, all registrants are subject to the requirements of Rules 420-3-26-.01, 420-3-26-.10, and 420-3-26-.11. Registrants using radiation machines for the performance of industrial radiography are also subject to the requirements of Rule 420-3-26-.04 and registrants using radiation machines in the healing arts are also subject to the requirements of Rule 420-3-26-.06 of these rules.

#### DEFINITIONS

## (2) General Definitions.

- (a) "Person" means any individual, corporation, partnership, firm, association, trust, estate, public or private institution, group, agency, political subdivision or agency thereof, and any legal successor, representative, agent, or agency of the foregoing, other than the U. S. Nuclear Regulatory Commission and other Federal Government agencies.
- (b) "Possessing an x-ray producing machine" means using, operating, storing manufacturing, or otherwise having control of an x-ray producing machine in the State of Alabama.

<sup>&</sup>lt;sup>1</sup> See Rule 420-3-26-.08 for the registration requirements for particle accelerators.

- (c) "Radiation producing machine" means any machine or device capable of producing radiation, but excluding devices which produce radiation only by the use of radio- active material.
- (d) "Registrant" means any person who is registering or who has registered with the Agency pursuant to this rule.
- (e) "Services" means the installation, calibrating, repairing, maintaining, or performing a radiation protection survey of an x-ray producing machine or an associated x-ray component.

## (3) **Registration Procedure**.

#### (a) Initial Registration.

Every person who possesses an x-ray producing machine shall register the machine with the Agency by June 1, 1965. Every person not already registered who acquires possession of an x-ray producing machine subsequent to June 1, 1965, shall register with the Agency prior to acquiring an x-ray machine.

#### (b) Renewal of Registration

Every person possessing an x-ray producing machine shall renew such registration with the agency at such times as the Agency shall deem necessary.

## (c) **Registration Form**.

Registration and renewal of registration shall be made on a form furnished by the Agency (Alabama State Board of Health). The registration shall set forth all information called for by the form.

## (d) **Report of Change**.

Within thirty (30) days of change, the registrant shall report to the Agency of any change in the name or address of the registrant or location of the installation; receipt, sale, or disposal of any reportable source of radiation.

## (e) **Report of Discontinuance**.

Every registrant who permanently discontinues the use of, or permanently disposes of all his x-ray producing machines at an installation, shall notify the Agency within thirty (30) days of such action.

## (f) Registration Shall Not Imply Approval.

No person, in any advertisement, shall refer to the fact that an x-ray producing machine is registered with the Agency and no person shall state or imply that any activity so registered has been approved by the Agency.

## (g) **Registration of Services**.

Each person who commercially services an x-ray producing machine in this State, to an Agency registrant, shall apply for the registration of such services with the Agency not later than October 1, 1974, thereafter prior to furnishing or offering to furnish any such services. Such registration shall indicate the training of each individual in the subjects listed in Appendix A. Such registration is also subject to the requirements of paragraphs (b), (c), (d), (e), and (f) of this section.

- (4) **Exclusion from Registration**. The following materials and devices do not require registration:
  - (a) Electrical equipment that is not primarily intended to produce radiation and that does not produce a radiation level greater than 0.5 mr/hr at any readily accessible point 5 centimeters from the surface. Such equipment shall not be exempt if it is used or handled in such a manner that any individual might receive a radiation dose exceeding the limits specified in these rules.
  - (b) All radioactive material.
  - (c) Radiation producing machines while in transit or storage incident thereto.

## (5) Vendor Obligations.

- (a) Any person who sells, leases, transfers, or lends x-ray producing machines in this State shall notify the Agency (Alabama State Board of Health) within thirty (30) days after the end of each calendar quarter of:
  - 1. (i) The name and address of persons who have received these machines.

## 318

Chapter 420-3-26

- (ii) The manufacturer and model of each machine transferred;
- (iii) The date of transfer of each x-ray machine.
- 2. Negative reports shall be furnished to the Agency (Alabama State Board of Health) within thirty (30) days after the end of each calendar quarter.
- (b) No person shall sell, lease, transfer, or install x-ray equipment or the accessories used in connection with such equipment unless such accessories and equipment, when properly placed in operation and properly used, will meet the requirements of these rules. This includes responsibility for the delivery of cones or collimators, filters, adequate timers, and fluoroscopic shutters. Further, no person shall sell, lease, deliver, install, or place in operation any x-ray equipment at any facility or for any person not registered with the Agency.
- (6) Out-of-State X-ray Producing Machines. Whenever any x-ray machine is brought into the State for any temporary use the person proposing to bring such machine into the state shall give written notice to the Agency (Alabama State Board of Health) at least two (2) days before such machine enters the State. The notice shall include the type of X-ray producing machine; the nature, duration, and scope of use; and the exact location where the x-ray producing machine is to be used. If for a specific case the two (2) day period would impose an undue hardship on the person, he may upon application to the Agency (Alabama State Board of Health) obtain permission to proceed sooner. In addition, the out-of-state person must:
  - (a) Comply with all applicable rules of the Agency (Alabama State Board of Health); and,
  - (b) Supply the Agency (Alabama State Board of Health) with such other information as the Agency (Alabama State Board of Health) may reasonable request.
- (7) Plan Review.
  - (a) Prior to construction, the floor plans and equipment of all installations (new modification of existing installations after January 1, 1977) utilizing x-rays for diagnostic or therapeutic purposes shall be submitted to the Agency for review and approval. The required information is denoted in Appendices B and C of this Rule.

- (b) The Agency may require the applicant to utilize the services of a qualified expert to determine the shielding requirements prior to the plan review and approval.
- (c) The approval of such plans shall not preclude the requirement of additional modifications should a subsequent analysis of operating conditions indicate the possibility of an individual receiving a dose in excess of the limits prescribed in 420-3-26-.03(2), 420-3-26-.03(5), and 420-3-26-.03(6).

# (8) Modification, Suspension, and Termination of a Registration or Activities Registered

- (a) A registration or activity registered shall be subject to amendment, revision, or modification or such activities may be suspended or terminated by reason of amendment to the Act, or by reason of rule, regulations, and orders issued by the Agency.
- (b) Any registration or activity registered may be terminated, suspended, or modified in whole, or part, for any material false statement in the application, or because of conditions revealed by such application or statement of fact or any report, records, or inspection or other means which would warrant the Agency to refuse to grant a registration on an original application, or for violation of, or failure to observe any of the terms and conditions of the Act, or the regulations, or of any rule, regulation, or order of the Agency.
- (c) Except in case of willfulness or those in which the public health interest or safety requires otherwise, no registration or activity registered shall be modified, suspended, or terminated, unless prior to the institution of proceedings therefore, facts or conduct which may warrant such action shall have been called to the attention of the registrant in writing and the registrant shall have been accorded an opportunity to demonstrate or achieve compliance with all lawful requirements.
- Authority: §§22-14-4, 22-14-6, 22-14-7, 22-14-8, 22-14-9, 22-14-11, 22-14-12, 22-14-13, and 22-14-14, also 22-2-1, 22-2-2, 22-2-5, and 22-2-6, Code of Alabama, 1975.
- History: New, 6-15-66; Revised, 3-18-70, 3-17-71; Repromulgated 8-21-74; Revised 9-15-76; Recodified 6-11-78; Revised and Repromulgated 10-21-81; Repromulgated effective 12-31-83. Revised effective 12-31-86. Revised and

320

Repromulgated effective 1-31-90.

Chapter 420-3-26

# 420-3-26-.05

# APPENDIX A

### **INSTRUCTION OF SERVICERS OF X-RAY EQUIPMENT**

- I. Fundamentals of radiation safety
  - A. Characteristics of x-radiation
  - B. Units of radiation dose (mrem)
  - C. Hazards of excessive exposure to radiation
  - D. Levels of radiation from sources of radiation
  - E. Methods of controlling radiation dose
    - 1. Working time
    - 2. Working distances
    - 3. Shielding

# II. Radiation detection instrumentation to be used

- A. Use of radiation survey instruments
  - 1. Operations
  - 2. Calibration
  - 3. Limitations
- B. Survey techniques
- C. Use of personnel monitoring equipment
  - 1. Film Badges and/or Thermoluminescence Dosimeters (TLD's)
  - 2. Pocket Dosimeters
  - 3. Pocket Chambers
- III. Operation and control of x-ray equipment
  - A. Effects of collimation and filtration

Chapter 420-3-26

B. Film processing techniques

IV. The requirements of pertinent Federal and State regulations.

January 31, 1990

### 420-3-26-.05

### APPENDIX B

# INFORMATION ON RADIATION SHIELDING REQUIRED FOR PLAN REVIEWS

In order for the Agency to provide an evaluation, technical advice and official approval on shielding requirements for a radiation installation, the following information is needed.

- 1. The plans should show, as a minimum, the following:
  - a. The normal location of the radiation producing equipment's radiation port; the port's travel and traverse limits; general direction(s) of the radiation beam; locations of any windows; the location of the operator's booth; the location of the equipment's control console.
  - b. Structural composition and thickness of all walls, doors, partitions, floor, and ceiling of the rooms(s) concerned.
  - c. Height, floor to floor, of the room(s) concerned.
  - d. The type of occupancy of all adjacent areas inclusive of space above and below the room(s) concerned. If there is an exterior wall, show distance to the closest existing occupied area(s).
  - e. The make and model of the radiation producing equipment including the maximum energy output (for x-ray machines this is the kilovolt peak potential).
  - f. The type of examination(s) or treatment(s) which will be performed with the equipment (e.g., dental, orthodontal, chest, gastrointestinal, fluoroscopic, podiatry, fixed therapy, rotational therapy, etc.).
- 2. Information on the anticipated workload used in shielding calculations will be provided by the registrant.
- 3. If the services of a qualified radiation expert have been utilized, a copy of his report shall be submitted with the plans. This report must show all basic assumptions (i.e., workload, occupancy and use factors, distance, etc.) used to determine the shielding requirements.

324

January 31, 1990

Chapter 420-3-26

#### 420-3-26-.05

#### APPENDIX C

# MINIMUM DESIGN REQUIREMENTS FOR AN X-RAY MACHINE OPERATOR'S BOOTH

### 1. Space Requirements.

The operator shall be allotted not less than 7.5 square feet of unobstructed floor space in the booth.

- (1) The minimum space as indicated above may be any geometric configuration with no dimension of less than 2 feet.
- (2) The space shall be allotted excluding any encumbrance by the console, such as overhang or cables, or other similar encroachments.
- (3) The operator's station at the control shall be behind a protective barrier, either in a separate room, in a protected booth, or behind a shield which will intercept the useful beam and any radiation which has been scattered only once.
- (4) The booth walls shall be at least 7 feet high and shall be permanently fixed to the floor or other structure as may be necessary.
- (5) When a door or movable panel is used as an integral part of the booth structure, it must have a permissive device which will prevent an exposure when the door or panel is not closed (this type of booth structure is not recommended).

### 2. Switch Placement.

The operator's switch for the radiographic machine shall be fixed within the booth and:

- (1) Shall be at least 30 inches from any open edge of the booth wall which is proximal to the examining table.
- (2) Shall allow the operator to use the majority of the available viewing windows.

January 31, 1990

# 3. Viewing System Requirements.

Each booth shall have at least one viewing device which will:

- (1) Be so placed that the operator can view the patient during any exposure, and
- (2) The device shall be so placed that he can have full view of any occupant of the room and should be so placed that he can view any entry into the room. If any door, which allows access to the room, cannot be seen from the booth, then that door must have a permissive device controlling the exposure which will prevent the exposure if the door is not closed.
- (3) When the viewing system is a window, the following requirements also apply:
  - (a) It shall have a visible area of at least 1 square foot the base of which is at least 4.5 feet above the floor.
  - (b) The distance between the proximal edge of the window and the open edge of the booth shall not be less than 13 inches.
  - (c) The glass shall have the same lead equivalence as that required in the booth's wall in which it is to be mounted.
- (4) When viewing system is by mirrors, the mirror(s) shall be located as to accomplish the general requirements as in (1) above.
- (5) When the viewing system is by electronic means (e.g., TV, etc.):
  - (a) The camera shall be so located as to accomplish the general requirements in (1) above, and
  - (b) There shall be an alternate viewing system as a back up for electronic failure.

Chapter 420-3-26

### 420-3-26-.06

# RADIATION SAFETY REQUIREMENTS FOR USERS OF X-RAY IN HEALING ARTS OR SERVICERS OF X-RAY EQUIPMENT

(1) Scope. Rule 420-3-26-.03 establishes standards for use of x-rays in the healing arts including but not limited to medicine, dentistry, osteopathy, chiropractic, podiatry, and veterinary medicine or servicers of x-ray equipment. The provisions of this Rule 420-3-26-.06 are written in addition to, and not in substitution for, other applicable provisions of these regulations. Periodic inspections will be performed of all registrants. The inspection frequency will depend upon available personnel and work load, but every x-ray unit ideally should be inspected not less than once every two years.

## (2) **Definitions**.

- (a) "Agency" means the State Board of Health.
- (b) "ARCR" means the Alabama Regulations for Control of Radiation.
- (c) "Aluminum Equivalent" means the thickness of aluminum affording the same attenuation, under specified conditions, as the material in question.
- (d) "Dead Man Switch" means a switch so constructed that a circuit closing contact can only be maintained by continuous pressure by the operator.
- (e) "Diagnostic Tube Housing" means an x-ray tube housing so constructed that the leakage radiation with the port closed at a distance of one (1) meter in any direction from the target cannot exceed one hundred (100) milliroentgens in one (1) hour when the tube is operated at any of its specified ratings.
- (f) "Filter" means material placed in the useful beam to absorb preferentially the less penetrating radiations.
- (g) "Half-Value Layer (hvl)" means the thickness of absorber required to reduce a beam of radiation to one-half (1/2) its incident exposure rate.
- (h) "High Radiation Area" means any area in which there exists radiation or such

levels that a major portion of the body could receive in any one (1) hour a dose in excess of 100 Millirems.

- (i) "Inherent Filtration" means the filtration in the useful beam due to the window of the x-ray tube and any permanent tube enclosure.
- (j) "Interlock" means a device for precluding access to an area of radiation hazard either by preventing entry or by automatically removing the hazard.
- (k) "Kilovolts Peak (kVp)" means the crest value in kilovolts of the potential of a pulsating potential generator.
- (1) "Lead Equivalent" means the thickness of lead affording the same attenuation under specified conditions as the material in question.
- (m) "Leakage Radiation" means all radiation coming from within the tube housing except the useful beam.
- (n) "Mobile X-Ray Unit" means a unit that is not permanently fixed to a definite location in a building or vehicle.
- (o) "Personnel Monitoring Equipment" means devices designed to be worn or carried by an individual for the purpose of measuring the dose received (film badges, pocket dosimeters).
- (p) "Primary Protective Barrier" means a barrier sufficient to attenuate the useful beam to the required degree.
- (q) "Protective Apron" means a barrier of attenuating materials, used to reduce radiation exposure.
- (r) "Protective Barrier" means a barrier of attenuating materials, used to reduce radiation exposure.
- (s) "Protective Glove" means a glove made of attenuating materials used to reduce radiation exposure.
- (t) "Radiation." The word radiation shall mean ionizing radiation, that is any electromagnetic or particulate radiation capable of producing ions directly or indirectly in its passage through matter.

#### Chapter 420-3-26

- (u) "Radiation Area" means any area in which there exists radiation at such levels that a major portion of the body could receive in any one (1) hour a dose in excess of 5 millirems, or in any five (5) consecutive days a dose in excess of 100 millirems.
- (v) "Restricted Area" means any area to which access is controlled by the registrant for purposes of protection of individuals from exposure to radiation.
   "Restricted area" shall not include any areas used for residential quarters, although upon authorization by the Agency a separate room or rooms in a residential building may be set apart as a restricted area.
- (w) "Scatter Radiation" means secondary radiation or radiation that, during passage through matter has been deviated in direction.
- (x) "Secondary Protective Barrier" means a barrier sufficient to attenuate stray radiation to the required degree.
- (y) "Shutter" means a device, generally of lead, fixed to an x-ray housing to intercept the useful beam.
- (z) "Stray Radiation" means radiation not serving any useful purpose. It includes leakage and scattered radiation.
- (aa) "Therapeutic Type Tube Housing" means an x-ray tube housing so constructed that the leakage radiation with the port closed at a distance of one (1) meter in any direction from the target cannot exceed one (1) roentgen in one (1) hour and at a distance of five (5) centimeters from any point of the surface of the housing accessible to the patient, cannot exceed thirty (30) roentgens in one (1) hour when the tube is operated at any of its specified ratings.
- (bb) "Useful Beam" means that part of the radiation which passes through the window, aperture, cone, or other collimating device of the tube housing.
- (cc) "Services" means the installation, calibrating, repairing, maintaining or performing a radiation protection survey of an x-ray producing machine or associated x-ray component.
- (dd) "Healing Arts" means the practice of medicine, dentistry, osteopathy, chiropractic, podiatry, and for non-humans, veterinary medicine.

- (ee) "Portable" means x-ray equipment designed to be hand-held.
- (ff) "Stationary" means x-ray equipment which is installed in a fixed location.
- (gg) "Gonad shield" means a primary protective barrier for the testes or ovaries.
- (hh) "Image receptor" means any device, such as a fluorescent screen or radiographic film, which transforms incident x-ray photons either into a visible image or into another form which can be made into a visible image by further electronic or chemical transformations.

### (3) General Safety Provisions.

- (a) The Agency may waiver compliance with the specific requirements of this Rule 420-3-26-.06 by an existing machine or installation if (1) such compliance would require replacement or substantial modification of the machine or installation and (2) the registrant demonstrates, to the Agency's satisfaction, achievement through other means of radiation protection equivalent to that required by these rules.
- (b) Persons shall not be exposed to the useful beam except for healing arts purposes, each exposure of which has been authorized by a licensed practitioner of the healing arts. This provision specifically prohibits deliberate exposure for the following purposes:
  - Exposure of an individual for training, demonstration, or other purposes unless (a) there are also healing arts requirements and proper prescription has been provided, (b) the radiographs are made for the student's own training, (c) the radiographs are made only once with no more than two retakes and if only a small tissue volume (e.g. less than a skull) is exposed per radiograph, and (d) the films are properly interpreted and are made a part of the dental or medical record.
  - 2. Exposure of an individual for the purpose of healing arts screening without prior written approval of the Agency. (Screening means an exposure of a person without prior examination or a determination of a specific individual need by a licensed practitioner).
- (c) **Personnel Monitoring**. Each registrant shall provide personnel monitoring devices which shall be used by:

#### Chapter 420-3-26

- 1. Each individual who receives, or is likely to receive, whole body dose in excess of 25 milliroentgens per week;
- 2. Each individual who enters a high radiation area;
- 3. Each individual who operates mobile x-ray equipment;
- 4. Each individual who operates photofluoroscopic equipment;
- 5. Each individual while he services an operable x-ray producing machine.
- (d) Use.
  - 1. The registrant shall be responsible for assuring that all requirements of Rule 420-3-26-.03 are met.
  - 2. The registrant shall assure that all x-ray equipment under his control is operated only by individuals adequately instructed in safe operating procedures and competent in safe use of the equipment.
  - 3. After October 1, 1974, no registrant who services x-ray producing equipment shall permit any person to service such equipment, when operable, until such person has been appropriately instructed in the subjects outlined in Appendix A of Rule 420-3-26-.05 of these rules and shall have demonstrated an understanding thereof.
  - 4. The speed of film or screen and film combinations shall be the fastest speed consistent with the diagnostic objectives of the examination.
  - 5. Portable or mobile x-ray equipment shall be used only for examinations where it is impractical to transfer the patient to a stationary radiographic installation.

### (e) Shielding.

1. Each installation shall be provided with such primary barriers and/or secondary barriers as are necessary to assure compliance with 420-3-26-.03(2), 420-3-26-.03(5), and 420-3-26-.03(6). This requirement shall be deemed to be met if the thickness of such barriers

1

Chapter 420-3-26

is equivalent to those as computed in accordance with National Council on Radiation Protection and Measurements Report No. 49.<sup>1</sup>

- (f) **Darkroom Requirements**. To reduce unnecessary re-exposures of patients resulting from film processing problems:
  - 1. The darkroom shall be light-proof.
  - 2. The area in which undeveloped films are handled for processing shall be devoid of light, during handling and processing, with the exception of light in the wave lengths having no specific effects on the radiographic film.
  - 3. A thermometer and timer operable and appropriate to the type of film processing shall be in use in the darkroom. The use of properly maintained automatic film processing equipment shall meet this requirement for all film so processed.

# (4) Fluoroscopic Installations.

- (a) Equipment.
  - 1. The tube housing shall be of diagnostic type.
  - 2. The target-to-panel or target-to-table top distance of equipment installed before the effective date of these rules shall not be less than twelve (12) inches, and shall not be less than fifteen (15) inches in equipment installed thereafter.
  - 3. The total filtration permanently in the useful beam shall not be less than 2.5 millimeters aluminum equivalent. This requirement may be assumed to have been met if the half-value layer is not less than 2.5 millimeters aluminum at normal operating voltages.
  - 4. The equipment shall be so constructed that the entire cross section of

Available from NCRP Publications, 7910 Woodmont Avenue, Suite 1016 Bethesda, Md. 20814

Chapter 420-3-26

the useful beam is attenuated by a primary barrier. This barrier is usually the viewing device, either a conventional fluoroscopic screen or an image intensification mechanism.

(i) For equipment installed before the effective date of the rules,<sup>2</sup> the required lead equivalent of the barrier shall not be less than 1.5 millimeters for 100 kVp, shall not be less than 1.8 millimeters for 125 kVp or shall not be less than 2.0 millimeters for 150 kVp.

For equipment installed or re-installed after the effective date of these rules, the required lead equivalent of the barrier shall not be less than 2.0 millimeters for 125 kVp, or shall not be less than 2.7 millimeters for 150 kVp.

For conventional fluoroscopes the requirements of paragraph (i) may be assumed to have been met if the exposure rate measured at the viewing surface of the fluorescent screen does not exceed fifty (50) milliroentgens per hour with the screen in the primary beam of the fluoroscope without a patient, under normal operating conditions.

- (ii) Collimators shall be provided to restrict the size of the useful beam to less that the area of the barrier. For conventional fluoroscopes this requirement is met if, when the adjustable diaphragm is opened to its fullest extent, an unilluminated margin is left on the fluorescent screen with the screen centered in the beam at a distance of fourteen (14) inches from the panel or table top. The margin requirement does not apply to installations where image intensifiers are use, but a protective shield shall be provided in these installations so that the useful beam may not exceed the viewing area by more than 2% of the source to image receptor distance for any dimension.
- (iii) The tube mounting and the barrier shall be so linked together

<sup>2</sup> June 15, 1966

Chapter 420-3-26

that under conditions of fluoroscopic use, the barrier always intercepts the useful beam.

- (iv) Collimators and adjustable diaphragms or shutters to restrict the size of the useful beam to the area of clinical interest and shall provide a minimum of 2.0 millimeters lead-equivalent protection for 100 kVp, 2.4 millimeters for 125 kVp, or 2.7 millimeters for 150 kVp.
- 5. The exposure switch shall be of the dead-man type.
- 6. A manual-reset, cumulative timing device shall be used which will either indicate elapsed time by an audible signal or turn off the apparatus when the total exposure exceeds a predetermined limit in one or a series of exposures. The device shall have a maximum time range of five minutes.
- 7. For fluoroscopy, the exposure rate measured at the panel or table top shall not exceed ten (10) roentgens per minute. This does not apply during cinegraphic procedures.
- 8. Unless measurements indicate otherwise, protective aprons of at least a quarter millimeter lead equivalent shall be worn by all persons in the fluoroscopic room except the patient.
- 9. Protective gloves of at least a quarter millimeter lead equivalent shall be worn by the fluoroscopist during every examination.
- 10. Mobile fluoroscopic equipment shall meet the requirements of this Rule where applicable, except that:
  - (i) In the absence of a table top, a cone or spacer frame shall limit the target-to-skin distance to not less than 20 centimeters.
  - (ii) Image intensification shall always be provided. Conventional fluoroscopic screens shall not be used.

Chapter 420-3-26

- (iii) It shall be impossible to operate a machine when the collimating cone or diaphragm is not in place.
- (iv) The exposure rate measured at the 30 cm from image receptor shall not exceed ten (10) roentgens per minute.
- (b) Structural Shielding. Ordinarily, only secondary barriers are necessary except for combined fluoroscopic-radiographic installations.

# (5) Radiographic Installations Other than Dental and Veterinary Medicine.

- (a) Equipment.
  - 1. The tube housing shall be of a diagnostic type.
  - 2. (i) Diaphragms or cones shall be provided for collimating the useful beam. When round collimators are used, the diameter of the beam at the film location shall be no greater than the diagonal dimension of the film plus three percent of the source to image receptor distance. For rectangular collimators, the beam size shall be no greater than the film dimension plus three percent of the source to image receptor distance. The diaphragms or cones shall provide the same degree of protection as the tube housing.
    - (ii) Adjustable collimators installed after the effective date of this rule<sup>3</sup> shall incorporate light beams to define the projected dimensions of the useful beam.
  - 3. (i) Except when contraindicated for a particular purpose, for equipment operation at seventy (70) kVp, and below, the total filtration permanently in the useful beam shall be equivalent to at least 1.5 mm of aluminum. This requirement may be assumed to have been met if the half-value layer is not less than 1.5 mm aluminum at normal operating voltages.
    - (ii) Except when contraindicated for a particular medical purpose,

<sup>3</sup> March 18, 1970

Chapter 420-3-26

for equipment capable of operating above seventy (70) kVp the total filtration permanently in the useful beam shall be equivalent to at least 2.5 mm of aluminum. This requirement may be assumed to have been met if the half-value layer is not less than 2.5 mm aluminum at normal operating voltages.

- 4. A device shall be provided to terminate the exposure after a preset time interval, preset product of current and time (mAs), a preset number of pulses, or a preset radiation exposure to the image receptor. It shall not be possible to make an exposure when the timer is set to a zero or off position, if either position is provided.
- 5. A dead-man type of exposure switch shall be so arranged that it cannot be conveniently operated out of a shielded area. Exposure switches for "spot-film" devices used in conjunction with fluoroscopic tables are exempted from this shielding requirement.

# (b) Structural Shielding.

- 1. All wall, floor and ceiling areas exposed to the useful beam shall have primary barriers. Primary barriers in walls shall extend to a minimum height of eighty-four (84) inches above the floor of the area being shielded.
- 2. Secondary barriers shall be provided in all wall, floor, and ceiling areas not having primary barriers or where the primary barrier's requirements are lower than the secondary barrier's requirements.
- 3. The operator's station at the control shall be behind a protective barrier, either in a separate room, in a protected booth, or behind a shield which will intercept the useful beam and any radiation which has been scattered only once.
- 4. A window of lead-equivalent glass equal to that required by the adjacent barrier or a mirror system shall be provided large enough and so placed that the operator can see the patient without having to leave the protected area during exposure, and shall meet the requirements of 420-3-26-.05, Appendix C.3.
- (c) Operating Procedures.

- 1. No individual exposed to occupational radiation shall hold patients during exposures except during emergencies, nor shall any individual be regularly used for this service. If the patient must be held by an individual, that individual shall be protected with appropriate shielding devices such as protective gloves and apron and he shall be so positioned that no part of his body will be struck by the useful beam.
- 2. Only the operators of radiographic equipment, other required individuals, and the patient shall be present during exposures. No unprotected parts of the operator's body shall be in the useful beam.
- 3. The useful beam shall be restricted to the area of clinical interest.

# (6) Mobile Diagnostic Radiographic Equipment.

### (a) Equipment.

- 1. All requirements of 420-3-26-.06(5)(a) apply except 420-3-26-.06(5)(a)5.
- 2. The exposure control switch shall be of the dead-man type and shall be so arranged that the operator can stand at least six (6) feet from the patient and well away from the useful beam.

# (b) Structural Shielding.

1. When a mobile unit is used routinely in one location, it shall be considered a fixed installation subject to shielding requirements specified in 420-3-26-.06(3)(d) and 420-3-26-.06(5)(b).

# (c) **Operating Procedures**.

- 1. All provisions of 420-3-26-.06(5)(c) apply, except 420-3-26-.06(5)(c)2.
- 2. The target-to-skin distance shall not be less than twelve (12) inches.

Chapter 420-3-26

# (7) Chest Photofluorographic Installations.

- (a) Equipment.
  - 1. All provisions of 420-3-26-.06(5)(a) apply.
  - 2. A collimator shall restrict the useful beam to the area of the photofluorographic screen.

# (b) Structural Shielding.

1. All provisions of 420-3-26-.06(3)(d) and 420-3-26-.05(5)(b) apply.

# (c) Operating Procedures.

- 1. All provisions of 420-3-26-.06(5)(c) apply.
- 2. All individuals except the patient being examined shall be in shielded positions during exposures.

# (8) Dental Radiographic Installations.

# (a) Equipment.

- 1. The tube housing shall be of diagnostic type.
- 2. Diaphragms or cones shall be used for collimating the useful beam and shall provide the same degree of protection as the housing. The diameter of the useful beam at the cone tip shall not be more than three (3) inches.
- A cone or spacer frame shall provide a target-to-skin distance of not less than seven (7) inches with apparatus operating above fifty (50) kVp or four (4) inches with apparatus operating at fifty (50) kVp or below.
- 4. (i) For equipment operating up to seventy (70) kVp, the total filtration permanently in the useful beam shall be equivalent to at least 1.5 mm of aluminum. This requirement may be assumed to have been met if the half-value layer is not less

Chapter 420-3-26

than 1.5 mm aluminum at normal operating voltages.

- (ii) For equipment operating above seventy (70) kVp, the total filtration permanently in the useful beam shall be equivalent to at least 2.5 mm of aluminum. This requirement may be assumed to have been met if the half-value layer is not less than 2.5 mm of aluminum at the normal operating voltages.
- 5. A device shall be provided to terminate the exposure after a preset time interval, preset product of current and time (mAs), a preset number of pulses, or a preset radiation exposure to the image receptor. It shall not be possible to make an exposure when the timer is set at a zero or off position, if either position is provided. Except for dental panoramic systems, termination of exposure shall cause automatic resetting of the time to its initial setting or to zero.
- 6. The exposure control switch shall be of the dead-man type.
- Each installation shall be provided with a protective barrier for the operator or shall be so arranged that the operator can stand at least six
  (6) feet from the patient and well away from the useful beam.

# (b) Structural Shielding.

- 1. Dental rooms containing x-ray machines shall be provided with primary barriers for all areas struck by the useful beam.
- 2. When dental x-ray units are installed, the rooms adjacent will be adequately protected.
  - NOTE: In most cases structural materials or ordinary walls suffice as a protective barrier without addition of special shielding material.

# (c) Operating Procedures.

1. Neither the dentist nor his assistant shall be permitted to hold patients or films during exposure, nor shall any individual be regularly used for this service.

- 2. During each exposure, the operator shall stand at six (6) feet from the patient or behind a protective barrier.
- 3. Only the patient shall be in the useful beam.
- 4. Neither the tube housing nor the pointer cone shall be hand-held during exposure.
- 5. Fluoroscopy shall not be used in dental examinations.

# (9) Therapeutic X-ray Installations.

- (a) Equipment.
  - 1. The tube housing shall be of therapeutic type.
  - 2. Permanent diaphragms or cones used for collimating the useful beam shall afford the same degree of protection as the tube housing. Adjustable or removable beam-defining diaphragms or cones shall transmit not more than five (5) percent of the useful beam obtained at the maximum kilovoltage and with maximum treatment filter.
  - 3. Filters shall be secured in place to prevent them from dropping out during treatment. The filter slot shall be so constructed that the radiation escaping through it does not exceed one (1) roentgen per hour at one (1) meter, or if the radiation from the slot is accessible to the patient, thirty (30) roentgens per hour at five (5) centimeters from the external opening.
  - 4. The x-ray tube shall be so mounted that it cannot turn or slide with respect to the aperture.
  - 5. Means shall be provided to immobilize the tube housing during stationary portal treatment.
  - 6. A timer shall be provided to terminate the exposure after a preset time regardless of what other exposure limiting devices are present.

- 7. Equipment utilizing shutters to control the useful shall have a shutter position indicator on the control.
- 8. There shall be on the control panel an easily discernible indicator which will give positive information as to whether or not the x-ray tube is energized.

# (b) Structural Shielding.

- 1. All wall, floor, and ceiling areas that can be struck by the useful beam, plus a border of one foot, shall be provided with primary protective barriers.
- 2. All wall, floor, and ceiling areas that cannot be struck by the useful beam shall be provided with secondary barriers.
- 3. With equipment operating above one hundred and twenty-five (125) kVp, the required barriers shall be an integral part of the building.
- 4. With equipment operating above one hundred and fifty (150) kVp, the control panel shall be within a protective booth equipped with an interlocked door, or outside the treatment room.
- 5. Interlocks shall be provided for x-ray therapy equipment capable of operating above 150 kVp so that, when any door of the treatment room is opened, either the machine will shut off automatically or the radiation level within the room will be reduced to an average of not more than two milliroentgens per hour and a maximum of ten milliroentgens per hour at a distance of one (1) meter in any direction from the target. After such shut off or reduction in output, it shall be possible to restore the machine to full operation only from the control panel.
- 6. Provisions shall be made to permit continuous observation of patients during irradiation.
- 7. Windows, mirror systems, or closed-circuit television viewing screens used for observing the patient shall be so located that the operator may see the patient and the control panel from the same position.

# (c) Operating Procedures.

- 1. All new installations shall have a protection survey made by, or under the direction of, a qualified expert. This shall also be done after any change in the installation which might produce a radiation hazard. The expert shall report his findings in writing to the person in charge of the installation and to the Agency (State Board of Health).
  - NOTE: Paragraph (c)1. of 420-3-26-.06(9), Rule 420-3-26-.06 was revised by the State Board of Health on March 19, 1979.
- 2. The installation shall be operated in compliance with any limitations indicated by the protection survey.
- 3. No individual who works with radiation, unless he is the patient, shall be in the treatment room during exposure. No other individual shall be there except when it is clinically necessary. If any individual is required to be in the treatment room with the patient during exposure, he shall be protected as much as possible from scattered radiation, and shall not be in the useful beam.
- 4. Records of surveys required by subparagraph (4) of this paragraph shall be maintained for two years after the facility has ceased to be used as described in the survey. If the survey was used to determine an individual's exposure, the record must be maintained until disposal is authorized by the Agency.
- (d) All provisions of this Section apply to therapeutic veterinary installations.
- (e) The output of each therapeutic x-ray machine shall be calibrated by, or under the direction of, a qualified expert. The calibration shall be repeated after any change in or replacement of components of the x-ray generating equipment which could cause a change in x-ray output. Check calibrations shall be made at least one a year thereafter. Records of calibration shall be maintained by the registrant.
- (10) X-ray Therapy Equipment Operated at Potentials of Sixty (60) KV and Below.

# (a) Equipment.

- 1. All provisions of 420-3-26-.06(9)(a) apply, except for equipment used for "contact therapy", 420-3- 26-.06(9)(a) in which instance the leakage radiation at the surface of the tube housing shall not exceed 0.1 roentgen per hour.
- 2. There shall be on the control panel some easily discernible device which will give positive indication as to whether or not the tube is energized.

# (b) **Operating Procedures.**

- 1. Automatic timers shall be provided which will permit accurate presetting and determination of exposures as short as one second.
- 2. In the therapeutic application of apparatus constructed with beryllium or other low-filtration windows, the registrant shall insure that the unfiltered radiation reaches only the part intended and that the useful beam is blocked at all times except when actually being used.
- 3. Machines having an output of more than 1,000 roentgens per minute at any accessible place shall not be left unattended without the power being shut off at the primary disconnecting means.
- 4. If the tube is hand-held during irradiation, the operator shall wear protective gloves and apron.

# (11) Veterinary Medicine Radiographic Installations.

### (a) Equipment.

- 1. The tube housing shall be of diagnostic type.
- 2. Diaphragms or cones shall be provided for collimating the useful beam to the area of clinical interest and shall provide the same degree of protection as required of the housing, as indicated in 420-3-26-.06(5)(a)2.(i) and (ii).

3.

- Except when contraindicated for a particular radiographic purpose, the total filtration permanently in the useful beam shall not be less than 1.5 millimeters aluminum-equivalent for equipment operating up to seventy (70) kVp and 2.0 millimeters aluminum-equivalent for machines operated in excess of seventy (70) kVp.
- 4. A device shall be provided to terminate the exposure after a preset time interval, preset product of current and time (mAs), a preset number of pulses, or a preset radiation exposure to the image receptor. It shall not be possible to make an exposure when the timer is set at a zero or off position, if either position is provided.
- 5. A dead-man type of exposure switch shall be provided, together with an electrical cord of sufficient length so that the operator can stand out of the useful beam at least six (6) feet from the animal during all x-ray exposures.

# (b) Structural Shielding.

1. All wall, floor, and ceiling areas shall be provided with applicable protective barriers as required in 420-3-26-.06(5)(b).

# (c) Operating Procedures.

- 1. The operator shall stand well away from the tube housing and the animal during radiographic exposures. Provisions shall be made so that it will not be necessary for the operator to stand in the useful beam. Hand-held fluoroscopic screens shall not be used. The tube housing shall not be held by the operator. No individual other than the persons involved in the operation shall be in the x-ray room while exposures are being made.
- 2. In any application in which the operator or an assistant is not located behind a protective barrier, a protective apron having a lead-equivalent of not less than 0.5 millimeter shall be worn
- 3. No individual shall be regularly employed to hold or support animals or hold film during radiation exposures. Occupationally exposed individuals shall not perform this service except in cases in which no other method is available. Any individual holding or supporting an

Chapter 420-3-26

animal during radiation exposure shall wear protective gloves and apron having a lead-equivalent of not less than 0.5 millimeter.

Authority: §§ 22-14-4, 22-14-7, 22-14-8, Code of Alabama, 1975.

Author: Aubrey V. Godwin, Director, Division of Radiation Control.

History: New 6-15-66; Revised 6-17-68, 3-18-70, Repromulgated 8-21-74, Revised 9-15-76, 1-18-78; Recodified 6-11-78; Revised 11-21-79; Revised and Repromulgated 10-21-81; Revised and Repromulgated effective 12-31-83. Revised effective 12-31-86. Revised and Repromulgated effective 1-31-90. Revised effective 9-30-90.

# 420-3-26-.07

# **USE OF RADIONUCLIDES IN THE HEALING ARTS**

# (1) **Purpose and Scope.**

This rule establishes requirements and provisions for the production, preparation, compounding and use of radionuclides in the healing arts and for issuance of licenses authorizing the medical use of this material. These requirements and provisions provide for the protection of the public health and safety. The requirements and provisions of this rule are in addition to, and not in substitution for, others in these rules. The requirements and provisions of these rules apply to applicants and licensees subject to this rule unless specifically exempted.

# (2) **Definitions**.

- (a) "Address of use" means the building or buildings that are identified on the license and where radioactive material may be received, used, or stored.
- (b) "Area of use" means a portion of a physical structure that has been set aside for the purpose of receiving, using, or storing radioactive material.
- (c) "As low as is reasonably achievable" (ALARA) means making every reasonable effort to maintain exposures to radiation as far below the dose limits as is practical, consistent with the purpose for which the licensed or registered activity is undertaken, taking into account the state of technology, the economics of improvements in relation to the state of technology, the economics of improvements in relation to the public health and safety, and other societal and socioeconomic considerations, and in relation to utilization of nuclear energy and licensed or registered sources of radiation in the public interests.
- (d) "Authorized nuclear pharmacist" means a pharmacist who:
  - 1. Has been approved to practice nuclear pharmacy by the Alabama State Board of Pharmacy; and
    - a. Is identified as an authorized nuclear pharmacist on an Agency specific license that authorizes the use of radioactive material in the practice of nuclear pharmacy; or
    - b. Is identified as an authorized nuclear pharmacist on a permit issued

December 18, 1996

by an Agency specific licensee of broad scope that is authorized to permit the use of radioactive material in the practice of nuclear pharmacy.

(e) "Authorized user" means a practitioner of the healing arts who is identified as an authorized user on an Agency license that authorizes the medical use of radioactive material.

(f) "Brachytherapy" means a method of radiation therapy in which sealed sources are utilized to deliver a radiation dose at a distance of up to a few centimeters, by surface, intracavitary, or interstitial application.

(g) "Brachytherapy source" means an individual sealed source or a manufacturerassembled source train that is not designed to be disassembled by the user.

(h) "Dedicated check source" means a radioactive source that is used to assure the constant operation of a radiation detection or measurement device over several months or years. This source may also be used for other purposes.

- (i) "Diagnostic clinical procedures manual" means a collection of written procedures that describes each method (and other instructions and precautions) by which the licensee performs diagnostic clinical procedures; where each diagnostic clinical procedure has been approved by the authorized user and includes the radiopharmaceutical, desage, and route of administration.
- (j) "Management" means the chief executive officer or that individual's designee.
- (k) "Medical institution" means an organization in which several medical disciplines are practiced.
- (1) "Medical use" means the intentional internal or external administration of radioactive material, or the radiation therefrom, to humans in the practice of the healing arts in accordance with a license issued by the Agency.
- (m) "Misadministration" means the administration of:
  - 1. A radiopharmaceutical dosage greater than 30 uCi (1.11 MBq) of either sodium iodide I-125 or I-131:
    - a. Involving the wrong patient or wrong radiopharmaceutical, or
    - b. When both the administered dosage differs from the prescribed dosage by more than 20 percent of the prescribed dosage and the difference between the administered dosage and prescribed dosage exceeds 30

December 18,1996

Chapter 420-3-26

### uCi (1.11 MBq).

- 2. A therapeutic radiopharmaceutical dosage, other than sodium iodide I-125 or I-131:
  - a. Involving the wrong patient, wrong radiopharmaceutical, or wrong route of administration; or
  - b. When the administered dosage differs from the prescribed dosage by more than 20 percent of the prescribed dosage.
- 3. A gamma stereotactic radiosurgery radiation dose:
  - a. Involving the wrong patient or wrong treatment site; or
  - b. When the calculated total administered dose differs from the total prescribed dose by more than 10 percent of the total prescribed dose.
- 4. A teletherapy radiation dose:
  - a. Involving the wrong patient, wrong mode of treatment, or wrong treatment site;
  - b. When the treatment consists of 3 or fewer fractions and the calculated total administered dose differs from the total prescribed dose by more than 10 percent of the total prescribed dose;
  - c. When the calculated weekly administered dose is 30 percent or more greater than the weekly prescribed dose; or
  - d. When the calculated total administered dose differs from the total prescribed dose by more than 20 percent of the total prescribed dose.
- 5. A brachytherapy radiation dose:
  - a. Involving the wrong patient, wrong radioisotope, or wrong treatment site (excluding, for permanent implants, seeds that were implanted in the correct site but migrated outside the treatment site);
  - b. Involving a sealed source that is leaking;
  - c. When, for a temporary implant, one or more sealed sources are not

348

Chapter 420-3-26

removed upon completion of the procedure; or

- d. When the calculated administered dose differs from the prescribed dose by more than 20 percent of the prescribed dose.
- 6. A diagnostic radiopharmaceutical dosage, other than quantities greater than 30 uCi (1.11 MBq) of either sodium iodine I-125 or I-131, both:
  - a. Involving the wrong patient, wrong radiopharmaceutical, wrong route of administration, or when the administered dosage differs from the prescribed dosage; and
  - b. When the dose to the patient exceeds 5 rem (0.05 Sv) effective dose equivalent or 50 rem (0.5 Sv) dose equivalent to any individual organ.
- (n) "Mobile nuclear medicine service" means the transportation and medical use of radioactive material.
- (o) "Output" means the exposure rate, dose rate, or a quantity related in a known manner to these rates from a teletherapy unit for a specified set of exposure conditions.
- (p) "Prescribed dosage" means the quantity of radiopharmaceutical activity as documented:
  - 1. In a written directive; or
  - 2. Either in the diagnostic clinical procedures manual or in any appropriate record in accordance with the directions of the authorized user for diagnostic procedures.
- (q) "Prescribed dose" means:
  - 1. For gamma stereotactic radiosurgery, the total dose as documented in the written directive;
  - 2. For teletherapy, the total dose and dose per fraction as documented in the written directive; or
  - 3. For brachytherapy, either the total source strength and exposure time, or the total dose, as documented in the written directive.
- (r) "Recordable event" means the administration of:

December 18, 1996

- 1. A radiopharmaceutical or radiation without a written directive where a written directive is required;
- 2. A radiopharmaceutical or radiation where a written directive is required without daily recording of each administered radiopharmaceutical dosage or radiation dose in the appropriate record;
- 3. A radiopharmaceutical dosage greater than 30 uCi (1.11 MBq) of either sodium iodine I-125 or I-131 when both the administered dosage differs from the prescribed dosage by more than 10 percent of the prescribed dosage, and the difference between the administered dosage and the prescribed dosage exceeds 15 uCi (555 kBq);
- 4. A therapeutic radiopharmaceutical dosage, other than sodium iodine I-125 or I-131, when the administered dosage differs from the prescribed dosage by more than 10 percent of the prescribed dosage;
- 5. A teletherapy radiation dose when the calculated weekly administered dose is 15 percent or more greater than the weekly prescribed dose; or
- 6. A brachytherapy radiation dose when the calculated administered dose differs from the prescribed dose by more than 10 percent of the prescribed dose.
- (s) "Teletherapy physicist" means the individual identified as the qualified teletherapy physicist on an Agency license.
- (t) "Teletherapy" means therapeutic irradiation in which the source of radiation is at a distance from the body.
- (u) "Visiting authorized nuclear pharmacist" means a nuclear pharmacist who is not identified on the license of the licensee being visited.
- (v) "Visiting authorized user" means an authorized user who is not identified on the license of the licensee being visited.
- (w) "Written directive" means an order in writing for a specific patient, dated and signed by an authorized user prior to the administration of a radiopharmaceutical or radiation, except as specified in (6) of this definition, containing the following information:
  - 1. For any administration of quantities greater than 30 uCi (1.11 MBq) of either sodium iodine I-125 or I-131: the dosage;

- 2. For a therapeutic administration of a radiopharmaceutical other than sodium iodine I-125 or I-131: the radiopharmaceutical, dosage, and route of administration;
- 3. For gamma stereotactic radiosurgery: target coordinates, collimator size, plug pattern and total dose;
- 4. For teletherapy: the total dose, dose per fraction, treatment site, and overall treatment period;
- 5. For high-dose-rate remote afterloading brachytherapy: the radioisotope, treatment site, and total dose; or
- 6. For all other brachytherapy:
  - a. prior to implantation: the radioisotope, number of sources, and source strengths; and
  - b. after implantation but prior to completion of the procedure: the radioisotope, treatment site, and total source strength and exposure time (or, equivalently, the total dose).

# (3) License Required.

- (a) No person shall manufacture, produce, acquire, receive, possess, use, or transfer radioactive material for medical use except in accordance with a specific or general license issued pursuant to this rule or as otherwise provided in this rule.
- (b) Unless prohibited by license condition an individual may receive, possess, use, or transfer radioactive material in accordance with the rules in this rule under the supervision of an authorized user as provided in 420-3-26-.07(10).

# (4) License Amendments.

A licensee shall apply for and shall receive a license amendment:

- (a) Before using radioactive material for a method or type of medical use not permitted by the license issued under this part;
- (b) Before permitting anyone, except a visiting authorized user described in 420-3-26-.07(12), to work as an authorized user under the license;
- (c) Before changing the Radiation Safety Officer or Teletherapy Physicist(s);

- (d) Before receiving radioactive material in excess of the amount authorized on the license;
- (e) Before adding to or changing the area of use or address of use identified on the license; and
- (f) Before changing statements, representations, and procedures which are incorporated into the license.

# (5) **Notifications.**

A licensee shall notify the Agency by letter within 30 days when an authorized user, Radiation Safety Officer, or Teletherapy Physicist, permanently discontinues performance of duties under the license.

# General Administrative Requirements.

# (6) ALARA Program.

- (a) Each licensee shall develop and implement a written program to maintain radiation doses and releases of radioactive material in effluents to unrestricted areas as low as reasonably achievable in accordance with 420-3-26-.03(5)(b) of these rules.
- (b) To satisfy the requirement of 420-3-26-.07(6)(a):
  - 1. The management, Radiation Safety Officer and all authorized users shall participate in the establishment, implementation, and operation of the program as required by these regulations or required by the Radiation Safety Committee.
  - 2. For licensees that are not medical institutions, management and all authorized users shall participate in the program as requested by the Radiation Safety Officer.
- (c) The ALARA program shall include an annual review, by the Radiation Safety Committee for licensees that are medical institutions, or management and the Radiation Safety Officer for licensees that are not medical institutions, of summaries of the types and amounts of radioactive material used, occupational dose reports, and continuing education and training for all personnel who work with or in the vicinity of radioactive material.
- (d) The purpose of the review is to ensure that individuals make every reasonable effort to maintain occupational doses, doses to the general public, and releases of radioactive material as low as reasonably achievable, taking into account the state

Chapter 420-3-26

of technology, and the cost of improvements in relation to benefits.

(e) The licensee shall retain a current written description of the ALARA program for the duration of the license.

The written description must include:

- 1. A commitment by management to keep occupational doses as low as reasonably achievable;
- 2. A requirement that the Radiation Safety Officer brief management once each year on the radiation safety program;
- 3. Personnel exposure action levels that, when exceeded, will initiate an investigation by the Radiation Safety Officer of the cause of the exposure; and
- 4. Personnel exposure investigational levels that, when exceeded, will initiate a prompt investigation by the Radiation Safety Officer of the cause of the exposure and a consideration of actions that might be taken to reduce the probability of recurrence.

# (7) Radiation Safety Officer.

- (a) A licensee shall appoint a Radiation Safety Officer responsible for implementing the radiation safety program. The licensee, through the Radiation Safety Officer, shall ensure that radiation safety activities are being performed in accordance with approved procedures and regulatory requirements in the daily operation of the licensee's radioactive material program.
- (b) The Radiation Safety Officer shall:
  - 1. Investigate overexposures, misadministrations, accidents, spills, losses, thefts, unauthorized receipts, uses, transfers, disposals, and other deviations from approved radiation safety practice and implement corrective actions as necessary;
  - 2. Implement written policy and procedures for:
    - (i) Authorizing the purchase of radioactive material;
    - (ii) Receiving and opening packages of radioactive material;
    - (iii) Storing radioactive material;

- (iv) Keeping an inventory record of radioactive material;
- (v) Using radioactive material safely;
- (vi) Taking emergency action if control of radioactive material is lost;
- (vii) Performing periodic radiation surveys;
- (viii) Performing checks of survey instruments and other safety equipment;
- (ix) Disposing of radioactive material;
- (x) Training personnel who work in or frequent areas where radioactive material is used or stored; and
- (xi) Keeping a copy of all records and reports required by the Agency rules, a copy of these rules, a copy of each licensing request and license and amendments, and the written policy and procedures required by the rules.
- 3. For medical use not sited at a medical institution, approve or disapprove radiation safety program changes with the advice and consent of management prior to submittal to the Agency for licensing action.
- 4. For medical use sited at a medical institution, assist the Radiation Safety Committee in the performance of its duties.

# (8) Radiation Safety Committee.

Each medical institution licensee shall establish a Radiation Safety Committee to oversee the use of radioactive material.

- (a) The Committee shall meet the following administrative requirements:
  - 1. Membership must consist of at least three individuals and shall include an authorized user of each type of use permitted by the license, the Radiation Safety Officer, a representative of the nursing service, and a representative of management who is neither an authorized user nor a Radiation Safety Officer. Other members may be included as the licensee deems appropriate.
  - 2. The Committee shall meet a least once each Calendar quarter.
  - 3. To establish a quorum and to conduct business, one-half of the Committee's membership shall be present, including the Radiation Safety Officer and the

# Chapter 420-3-26

management's representative.

- 4. The minutes of each Radiation Safety Committee meeting shall include:
  - (i) The date of the meeting;
  - (ii) Members present;
  - (iii) Members absent;
  - (iv) Summary of deliberations and discussions;
    - (v) Recommended actions and the numerical results of all ballots; and
    - (vi) Documentation of any reviews required in 420-3-26-.07(6)(b) and 420-3-26-.07(8)(b).
- 5. The Committee shall provide each member with a copy of the meeting minutes, and retain one copy for the duration of the license.
- (b) To oversee the use of licensed material, the Committee shall:
  - 1. Be responsible for monitoring the institutional program to maintain individual and collective doses as low as reasonably achievable;
  - 2. Review, on the basis of safety and with regard to the training and experience standards of this rule, and approve or disapprove any individual who is to be listed as an authorized user, the Radiation Safety Officer, or Teletherapy Physicist before submitting a license application or request for amendment or renewal;
  - 3. Review on the basis of safety and approve or disapprove each proposed method of use of radioactive material;
  - 4. Review on the basis of safety, and approve with the advice and consent of the Radiation Safety Officer and the management representative, or disapprove procedures and radiation safety program changes prior to submittal to the Agency for licensing action;
  - 5. Review quarterly, with the assistance of the Radiation Safety Officer, occupational radiation exposure records of all personnel working with radioactive material;
  - 6. Review quarterly, with the assistance of the Radiation Safety Officer, all

incidents involving radioactive material with respect to cause and subsequent actions taken;

- 7. Review annually, with the assistance of the Radiation Safety Officer, the radioactive material program; and
- 8. Establish a table of investigational and action levels for occupational dose that, when exceeded, will initiate investigations and/or considerations of action by the Radiation Safety Officer.

# (9) Statement of Authorities and Responsibilities.

- (a) A licensee shall provide the Radiation Safety Officer, and at a medical institution the Radiation Safety Committee, sufficient authority, management prerogative, and organizational freedom to:
  - 1. Identify radiation safety problems;
  - 2. Initiate, recommend, or promote corrective actions; and
  - 3. Verify implementation of corrective actions.
- (b) A licensee shall establish in writing the authorities, duties, responsibilities, and radiation safety activities of the Radiation Safety Officer, and at a medical institution the Radiation Safety Committee.

# (10) Supervision.

- (a) A licensee who permits the receipt, possession, production, preparation, compounding, use, or transfer of radioactive material by an individual under the supervision of an authorized user as allowed by 420-3-26-.07(3) shall:
  - 1. Instruct the supervised individual in the principles of radiation safety appropriate to that individual's use of radioactive material;
  - 2. Periodically review the supervised individual's use of radioactive material, the records kept to reflect this use, and provide reinstruction as needed;
  - 3. Require an authorized user to be immediately available to communicate with the supervised individual;
  - 4. Require an authorized user to be able to be physically present and available

to the supervised individual on one hours notice;1 and

- 5. Require that only those individuals specifically trained, and designated by an authorized user, be permitted to administer radionuclides or radiation to patients.
- (b) A licensee shall require the supervised individual receiving, possessing, producing, preparing, compounding, using or transferring radioactive material under 420-3-26-.07(3) to:
  - 1. Follow the instructions of the supervising authorized user;
  - 2. Follow written radiation safety procedures established by the licensee; and
  - 3. Comply with these rules and the license conditions with respect to the use of radioactive material.

### (11) Authorized User

A licensee shall assure that only authorized users of radioactive material:

- (a) Select the patients to receive radioactive material or radiation therefrom;
- (b) Prescribe the radiopharmaceutical dosage and/or dose to be administered through the issuance of a written directive or reference to the diagnostic clinical procedures manual; and
- (c) Interpret the results of tests, studies, or treatments.

(NOTE: If, because of the patient's condition, a delay in order to provide a written revision to an existing written directive would jeopardize the patient's health, an oral revision to an existing written directive will be acceptable, provided that the oral revision is documented immediately in the patient's record and a revised written directive is signed by the authorized user within 48 hours of the oral revision. Also, a written revision to an existing written directive may be made for any diagnostic or therapeutic procedure provided that the revision is dated and signed by an authorized user prior to the administration of the

<sup>&</sup>lt;sup>1</sup> The supervising authorized user need not be present for each use of radioactive material.

radiopharmaceutical dosage, the brachytherapy dose, the gamma stereotactic radiosurgery dose, the teletherapy dose, or the next teletherapy fractional dose. If, because of the emergent nature of the patient's condition, a delay in order to provide a written directive would jeopardize the patient's health, an oral directive will be acceptable, provided that the information contained in the oral directive is documented immediately in the patient's record and a written directive is prepared within 24 hours of the oral directive.)

### (12) Visiting Authorized User.

- (a) A licensee may permit any visiting authorized user to use licensed material for medical use under the terms of the licensee's license for 60 days each year if:
  - 1. The visiting authorized user has the prior written permission of the licensee's management and, if the use occurs on behalf of an institution, the institution's Radiation Safety Committee;
  - 2. The licensee has a copy of an Agency license that identifies the visiting authorized user by name as an authorized user for medical use; and
  - 3. Only those procedures for which the visiting authorized user is specifically authorized by an Agency license are performed by that individual.
- (b) A licensee need not apply for a license amendment in order to permit a visiting authorized user to use licensed material as described in 420-3-26-.07(11).
- (c) A licensee shall retain copies of the records specified in 420-3-26-.07(12) for 5 years from the date of the last use by the visiting authorized user, but the records may be discarded if the visiting authorized user has been listed as an authorized user on the licensee's license.

### (13) Visiting Authorized Nuclear Pharmacist.

- (a) A licensee may permit any visiting authorized nuclear pharmacist to use licensed material for nuclear pharmacy use under the terms of the licensee's license for 60 days each year if:
  - 1. The visiting authorized nuclear pharmacist has the prior written permission of the licensee's management and, if the use occurs on behalf of an institution, the institution's Radiation Safety Committee; and
  - 2. The licensee has a copy of an Agency license that identifies the visiting authorized nuclear pharmacist, by name, as an authorized user for nuclear pharmacy use.

- (b) A licensee need not apply for a license amendment in order to permit a visiting authorized nuclear pharmacist to use licensed material as described in 420-3-26-.07(13)(a).
- (c) A licensee shall retain copies of the records specified in 420-3-26-.07(13) for 5 years from the date of the last use by the visiting authorized nuclear pharmacist, but the records may be discarded if the visiting authorized nuclear pharmacist has been listed as an authorized user on the licensee's license.

## (14) Mobile Nuclear Medicine Service Administrative Requirements.

- (a) The Agency will only license mobile nuclear medicine services and/or clients of such services in accordance with this rule and other applicable requirements of these rules. The mobile nuclear medicine service shall be licensed if the service receives, uses or possesses radioactive material. The client of the mobile nuclear medicine service shall be licensed if the client receives or possesses radioactive material to be used by a mobile nuclear medicine service.
- (b) Mobile nuclear medicine service licensees shall retain for three years after the duration of service a letter signed by the management of each location where services are rendered that authorizes use of radioactive material. If the client is licensed, the letter shall document procedures for notification, receipt, storage and documentation of transfer of radioactive material delivered to the client's location for use by the mobile nuclear medicine service.
- (c) A mobile nuclear medicine service may not have radioactive material delivered directly from the manufacturer or the distributor to the client's address of use, unless the client has a license. Radioactive material delivered to the client's address of use shall be received and handled in conformance with the client's license.
- (d) A mobile nuclear medicine service shall inform a responsible individual, such as a member of management or their designee, who is on site at each client's address of use at the time that radiopharmaceuticals are being administered.

### (15) Quality Management Program.

- (a) Each licensee or applicant shall establish and maintain a written quality management program to provide assurance that radioactive material or radiation therefrom will be administered as directed by the authorized user. The quality management program shall include written policies and procedures to meet the following specific objectives:
  - 1. That, prior to administration, a written directive is prepared for:

359

(i) Any teletherapy radiation dose;

- (ii) Any gamma stereotactic radiosurgery radiation dose;
- (iii) Any brachytherapy radiation dose;
- (iv) Any administration of quantities greater than 30 uCi (1.11 MBq) of either sodium iodine I-125 or I-131; or
- (v) Any therapeutic administration of a radiopharmaceutical, other than sodium iodine I-125 or I-131;

(NOTE: If, because of the patient's condition, a delay in order to provide a written revision to an existing written directive would jeopardize the patient's health, an oral revision to an existing written directive will be acceptable, provided that the oral revision is documented immediately in the patient's record and a revised written directive is signed by the authorized user within 48 hours of the oral revision. Also, a written revision to an existing written directive may be made for any diagnostic or therapeutic procedure provided that the revision is dated and signed by an authorized user prior to the administration of the radiopharmaceutical dosage, the brachytherapy dose, the gamma stereotactic radiosurgery dose, the teletherapy dose, or the next teletherapy fractional dose. If, because of the emergent nature of the patient's condition, a delay in order to provide a written directive would jeopardize the patient's health, an oral directive will be acceptable, provided that the information contained in the oral directive is documented immediately in the patient's record and a written directive is prepared within 24 hours of the oral directive.)

- 2. That, prior to each administration, the patient's identity is verified by more than one method as the individual named in the written directive;
- 3. That final plans of treatment and related calculations for brachytherapy, teletherapy, and gamma stereotactic radiosurgery are in accordance with the respective written directives;
- 4. That each administration is in accordance with the written directive; and
- 5. That any unintended deviation from the written directive is identified and evaluated, and appropriate action is taken.
- (b) Each licensee shall;
  - 1. Develop procedures for and conduct a review of the quality management program including, since the last review, an evaluation of:
    - (i) A representative sample of patient administrations;
    - (ii) All recordable events, and

December 18, 1996

360

### (iii) All misadministrations

to verify compliance with all aspects of the quality management program; these reviews shall be conducted at intervals no greater than 12 months;

- 2. Evaluate each of these reviews to determine the effectiveness of the quality management program and, if required, make modifications to meet the objectives of 420-3-26(15)(a); and
- 3. Retain records of each review, including the evaluations and findings of the review, in an auditable form for 3 years.
- (c) The licensee shall evaluate and respond to each recordable event, within 30 days after discovery of the recordable event, by:
  - 1. Assembling the relevant facts including the cause;
  - 2. Identifying what, if any, corrective action is required to prevent recurrence; and
  - 3. Retaining a record, in an auditable form, for 3 years, of the relevant facts and what corrective action, if any, was taken.
- (d) Each licensee shall retain:
  - 1. Each written directive; and
  - 2. A record of each administered radiation dose or radiopharmaceutical dosage where a written directive is required in 420-3-26-.03(15)(a)1., in an auditable form, for 3 years after the date of administration.
- (e) The licensee may make modifications to the quality management program to increase the program's efficiency provided the program's effectiveness is not decreased. Such modifications must be in writing, and shall be made available for review by the Agency during the next amendment request, license renewal or inspection, whichever occurs first.
- (f) Each applicant for a new license, as applicable, shall submit to the Agency a written quality management program as part of the application for a license, and shall implement the program upon issuance of the license by the Agency.
- (g) Each existing licensee, as applicable, shall submit to the Agency a written certification that the quality management program has been implemented, and shall make the quality management program available for review by the Agency during the next

amendment request, license renewal or inspection, whichever occurs first.

# (16) Records, Notifications, and Reports of Misadministrations and Recordable Events.

- (a) For a misadministration:
  - 1. The licensee shall notify the Agency by telephone no later than 24 hours after discovery of the misadministration.
  - 2. The licensee shall submit a written report to the Agency within 15 days after discovery of the misadministration. The written report must include;
    - (i) The licensee's name;
    - (ii) The prescribing physician's name;
    - (iii) A brief description of the event;
    - (iv) Why the event occurred;
    - (v) The effect on the patient;
    - (vi) What improvements are needed to prevent recurrence;
    - (vii) Actions taken to prevent recurrence;
    - (viii) Whether the licensee notified the patient, or the patient's responsible relative or guardian (this person will be subsequently referred to as "the patient"), and if not, why not, and
    - (ix) If the patient was notified, what information was provided to the patient.

The report must not include the patient's name or other information that could lead to identification of the patient.

3. The licensee shall notify the referring physician and also notify the patient of the misadministration not later than 24 hours after its discovery, unless the referring physician personally informs the licensee either that he or she will inform the patient or that, based on medical judgement, telling the patient would be harmful. The licensee is not required to notify the patient without first consulting the referring physician. If the referring physician or patient cannot be reached within 24 hours, the licensee shall notify the patient as soon

as possible thereafter. The licensee may not delay any appropriate medical care for the patient, including any necessary remedial care as a result of the misadministration, because of any delay in notification.

- 4. If the patient was notified, the licensee shall also furnish, within 15 days after discovery of the misadministration, a written report to the patient by sending either;
  - (i) a copy of the report that was submitted to the Agency, or
  - a brief description of both the event and the consequences, as they may affect the patient, provided a statement is included that the report submitted to the Agency can be obtained from the licensee.
- (b) For any recordable event:
  - 1. The Radiation Safety Officer shall promptly (within 15 days) investigate its cause, make a record for Agency review, and retain the record as directed in 420-3-26-.07 (16) (e).
- (c) The licensee shall also notify the referring physician and the Agency in writing within 15 days if the the following occurs:

### The administration of:

- (i) A radioactive material not intended for medical use;
- (ii) A dosage five-fold different from the intended dosage; or
- (iii) A radioactive material such that the patient is likely to receive an organ dose greater than 2 rem (0.02 Sv) or a whole body dose greater than 500 mrems (5 mSv).

(Note: Licensees may use dosimetry tables in package inserts, corrected only for the amount of radioactivity administered, to determine whether a report is required.)

- (d) Each licensee shall retain a record of reports required in 420-3-26-.07(16)(a) through (c) for 5 years. The record must contain:
  - 1. The names of all individuals involved (including the prescribing physician, allied health personnel, the patient, and the patient's referring physician);
  - 2. The patient's social security number or identification number if one has been

Chapter 420-3-26

assigned;

- 3. A brief description of the event, and why it occurred;
- 4. The effect on the patient;
- 5. What improvements are needed to prevent recurrence; and
- 6. The action taken to prevent recurrence.
- (e) Aside from the notification requirement, nothing in 420-3-26-.07(16)(a) through
   (e) shall affect any rights or duties of licensees and physicians in relation to each other, patients, or the patient's responsible relatives or guardians.

### (17) Suppliers.

A licensee may use for medical use only:

- (a) Radioactive material manufactured, labeled, packaged, and distributed in accordance with a license issued pursuant to these rules or the equivalent regulations of another Agreement State, a Licensing State or the U.S. Nuclear Regulatory Commission; and
- (b) Reagent kits that have been manufactured, labeled, packaged, and distributed in accordance with an approval issued by the U.S. Department of Health and Human Services, Food and Drug Administration.

### **General Technical Requirements**

### (18) Quality Control of Imaging Equipment.

Each licensee shall establish written quality control procedures for all equipment used to obtain images from radionuclide studies. As a minimum the procedures shall include quality control procedures recommended by equipment manufacturers or procedures which have been approved by the Agency. The licensee shall conduct quality control procedures in accordance with written procedures.

### (19) Possession, Use, Calibration, and Check of Dose Calibrators.

(a) A medical use licensee authorized to administer radiopharmaceuticals shall possess a dose calibrator and use it to measure the amount of activity administered to each patient.

- (b) A licensee shall:
  - 1. Check each dose calibrator for constancy with a dedicated check source at the beginning of each day of use. To satisfy the requirement of this section, the check must be done on a frequently used setting with a sealed source of not less than 100 uCi (3700 kBq) for any photon-emitting radio-nuclide with a half-life greater than 90 days;
  - 2. Test each dose calibrator for accuracy upon installation and at intervals not to exceed 12 months thereafter by assaying at least 2 sealed sources containing different radionuclides, the activity of which the manufacturer has determined within 5 percent of the stated activity, with minimum activity of 100 uCi (3700 kBq) for any photon-emitting radionuclide, and at least one of which has a principal photon energy between 100 keV and 500 keV;
  - 3. Test each dose calibrator for linearity upon installation and at intervals not to exceed three months thereafter over the range of use between 30 uCi (1.1 MBq) and the highest dosage that will be administered; and
  - 4. Test each dose calibrator for geometry dependence upon installation over the range of volumes and volume configurations for which it will be used. The licensee shall keep a record of this test for the duration of the use of the dose calibrator.
- (c) A licensee shall mathematically correct dosage readings for any geometry or linearity error that exceeds 10 percent if the dosage is greater than 30 uCi (1.1 MBq) and shall repair or replace the dose calibrator if the accuracy or constancy error exceeds 10 percent.
- (d) A licensee shall also perform checks and tests required by 420-3-26-.07(19) following adjustment or repair of the dose calibrator.
- (e) A licensee shall retain a record of each check and test required by this 420-3-26-.07(19) for 5 years. The records required by this section shall include:
  - 1. For 420-3-26-.07(19)(b)(1);
    - (i) The model and serial number of the dose calibrator,
    - (ii) The identity and calibrated activity of the radionuclide contained in the check source,
    - (iii) The date of the check,

Chapter 420-3-26

- (iv) The activity measured,
- (v) The instrument settings,
- (vi) The percentage error from the decay corrected value for each source, and
- (vii) The initials of the individual who performed the check;
- 2. For 420-3-26-.07(19)(b)(2);
  - (i) The model and serial number of the dose calibrator,
  - (ii) The model and serial number of each source used,
  - (iii) The identity of the radionuclide contained in the source and its activity,
  - (iv) The date of the test,
  - (v) The results of the test,
  - (vi) The instrument settings, and
  - (vii) The signature of the Radiation Safety Officer;
- 3. For 420-3-26-.07(19)(b)(3);
  - (i) The model and serial number of the dose calibrator,
  - (ii) The calculated activities,
  - (iii) The measured activities,
  - (iv) The date of the test, and
  - (v) The signature of the Radiation Safety Officer; and
- 4. For 420-3-26-.07(19)(b)(4);
  - (i) The model and serial number of the dose calibrator,
  - (ii) The configuration and calibrated activity of the source measured,

Chapter 420-3-26

- (iii) The activity of the source,
- (iv) The activity measured and the instrument setting for each volume measured,
- (v) The date of the test, and
- (vi) The signature of the Radiation Safety Officer.

### (20) Calibration and Check of Survey Instruments.

- (a) A licensee shall ensure that the survey instruments used to show compliance with this part have been calibrated before first use, annually, and following repair.
- (b) To satisfy the requirements of 420-3-26-.07(20)(a) the licensee shall:
  - 1. Calibrate all required scale readings up to 1000 mrem (10 mSv) per hour with a radiation source;
  - 2. For each scale that shall be calibrated, calibrate two readings separated by at least 50% of scale reading; and
  - 3. Conspicuously note on the instrument the apparent exposure rate from a dedicated check source as determined at the time of calibration, and the date of calibration.
- (c) To satisfy the requirements of 420-3-26-.07(20)(a) the licensee shall:
  - 1. Consider a point as calibrated if the indicated exposure rate differs from the calculated exposure rate by not more than 10 percent; and
  - 2. Consider a point as calibrated if the indicated exposure rate differs from the calculated exposure rate by not more than 20 percent if a correction chart or graph is conspicuously attached to the instrument.
- (d) A licensee shall check each survey instrument for proper operation with the dedicated check source before each use. The licensee is not required to keep records of these checks.
- (e) The licensee shall retain a record of each calibration required in 420-3-26-.07(20)(a) for 5 years. The record shall include:
  - 1. A description of the calibration procedure; and

- 2. A description of;
  - (i) The source used and the certified exposure rates from the source,
  - (ii) The exposure rates indicated by the instrument being calibrated,
  - (iii) The correction factors deduced from the calibration data,
  - (iv) The signature of the individual who performed the calibration, and
  - (v) The date of calibration.
- (f) To meet the requirements of 420-3-26-.07(20)(a), (b), and (c), the licensee may obtain the services of individuals licensed by the Agency, the U. S. Nuclear Regulatory Commission, an Agreement State or a Licensing State to perform calibrations of survey instruments. Records of calibrations which contain information required by 420-3-26-.07(20)(e), shall be maintained by the licensee.

### (21) Assay of Radiopharmaceutical Dosages.

A licensee shall:

- (a) Assay, within 30 minutes before medical use, the activity of each radiopharmaceutical dosage that contains more than 30 uCi (1.1 MBq) of a photon-emitting radionuclide;
- (b) Assay, before medical use, the activity of each radiopharmaceutical dosage with a desired activity of 30 uCi (1.1 MBq) or less of a photon-emitting radionuclide to verify that the dosage does not exceed 30 uCi (1.1 MBq); and
- (c) Retain a record of the assays required by 420-3-26-.07(21)(a) and (b) for 5 years. To satisfy this requirement, the record shall contain the:
  - 1. Generic name, trade name, or abbreviation of the radiopharmaceutical, its lot number, and expiration dates and the radionuclide;
  - 2. Patient's name, and identification number if one has been assigned;
  - 3. Prescribed dosage and activity of the dosage at the time of assay, or a notation that the total activity is less than 30 uCi (1.1 MBq);
  - 4. Date and time of the assay and administration; and
  - 5. Initials of the individual who performed the assay.

### (22) Authorization for Calibration and Reference Sources.

Any person authorized by 420-3-26-.07(3) for medical use of radioactive material may receive, possess, and use the following radioactive material for check, calibration and reference use:

- (a) Sealed sources manufactured and distributed by persons specifically licensed pursuant to 420-3-26-.02 of these rules or equivalent provisions of the U.S. Nuclear Regulatory Commission, Agreement State or Licensing State and that do not exceed 15 mCi (555 MBq) each;
- (b) Any radioactive material listed in 420-3-26-.07(33) or (35) with a half-life of 100 days or less in individual amounts not to exceed 15 mCi (555 MBq);
  - (c) Any radioactive material listed in 420-3-26-.07(33) or 420-3-26-.07(35) with a half life greater than 100 days in individual amounts not to exceed 200 uCi (7.4 MBq) each; and
  - (d) Technetium-99m in individual amounts not to exceed 50 mCi (1.85 GBq).

## (23) Requirements for Possession of Sealed Sources and Brachytherapy Sources.

- (a) A licensee in possession of any sealed source or brachytherapy source shall follow the radiation safety and handling instructions supplied by the manufacturer or equivalent instructions approved by the Agency, and shall maintain the instructions for the duration of source use in a legible form convenient to users.
- (b) A licensee in possession of a sealed source shall assure that:
  - 1. The source is tested for leakage before its first use unless the licensee has a certificate from the supplier indicating that the source was tested within 6 months before transfer to the licensee; and
  - 2. The source is tested for leakage at intervals not to exceed 6 months or at intervals approved by the Agency, another Agreement State, a Licensing State or the U.S. Nuclear Regulatory Commission.
- (c) To satisfy the leak test requirements of this section, the licensee shall assure that:
  - 1. Leak tests are capable of detecting the presence of  $0.005 \ \mu\text{Ci}$  (185 Bq) of radioactive material on the test sample, or in the case of radium, the escape of radon at the rate of  $0.001 \ \mu\text{Ci}$  (37 Bq) per 24 hours;

- 2. Test samples are taken from the source or from the surfaces of the device in which the source is mounted or stored on which radioactive contamination might be expected to accumulate; and
- 3. Test samples are taken when the source is in the "off" position.
- (d) A licensee shall retain leak test records for 5 years. The records shall contain;
  - 1. The model number and serial number, if assigned, of each source tested,
  - 2. The identity of each source radionuclide and its estimated activity,
  - 3. The measured activity of each test sample expressed in microcuries (Bq),
  - 4. A description of the method used to measure each test sample,
  - 5. The date of the test, and
  - 6. The signature of the Radiation Safety Officer.
- (e) If the leak test reveals the presence of 0.005 μCi (185 Bq) or more of removable contamination, or in the case of radium, the escape of radon at the rate of 0.001 microcuries (37 Bq) per 24 hours, the licensee shall:
  - 1. Immediately withdraw the sealed source from use and store it in accordance with the requirements of these rules; and
  - 2. File a report within 5 days of receiving the leak test results with the Agency describing the equipment involved, the test results, and the action taken.
- (f) A licensee need not perform a leak test on the following sources:
  - 1. Sources containing only radioactive material with a half-life of less than 30 days;
  - 2. Sources containing only radioactive material as a gas;
  - Sources containing 100 μCi (3.7 MBq) or less of beta or photon-emitting material or 10 μCi (370 kBq) or less of alpha-emitting material;
  - 4. Seeds of iridium-192 encased in nylon ribbon; and
  - 5. Sources stored and not being used. The licensee shall, however, test each such source for leakage before any use or transfer unless it has been tested for

leakage within 6 months before the date of use or transfer.

- (g) A licensee in possession of a sealed source or brachytherapy source shall conduct a physical inventory of all such sources quarterly. The licensee shall retain each inventory record for 5 years. The inventory records must contain;
  - 1. The model number of each source and serial number if one has been assigned.
  - 2. The identity of each source radionuclide and its estimated activity,
  - 3. The location of each source,
  - 4. Date of the inventory, and
  - 5. The signature of the Radiation Safety Officer.
- (h) A licensee in possession of a sealed source or brachytherapy source shall survey with a radiation survey instrument at quarterly intervals all areas where such sources are stored. This does not apply to teletherapy sources in teletherapy units or sealed sources in diagnostic devices.
- (i) A licensee shall retain a record of each survey required in 420-3-26-.07(23)(h) for 5 years. The record must include;
  - 1. The date of the survey,
  - 2. A sketch of each area that was surveyed,
  - 3. The measured dose rate at several points in each area expressed in mrem  $(\mu Sv)$  per hour,
  - 4. The model number and serial number of the survey instrument used to make the survey, and
  - 5. The signature of the Radiation Safety Officer.

### (24) Syringe Shields.

- (a) A licensee shall keep syringes that contain radioactive material to be administered in a radiation shield.
- (b) A licensee shall require each individual who prepares or administers radiopharmaceuticals to use a syringe radiation shield unless the use of the shield is contraindicated for that patient.

### (25) Syringe Labels.

Unless utilized immediately a licensee shall conspicuously label each syringe, or syringe radiation shield that contains a syringe with a radiopharmaceutical;

- (a) With the radiopharmaceutical name or its abbreviation,
- (b) The type of diagnostic study or therapy procedure to be performed or the patient's name.

### (26) Vial Shields.

A licensee shall require each individual preparing or handling a vial that contains a radiopharmaceutical to keep the vial in a vial radiation shield.

### (27) Vial Shield Labels.

A licensee shall conspicuously label each vial radiation shield that contains a vial of a radiopharmaceutical with the radiopharmaceutical name or its abbreviation.

## (28) Surveys for Contamination and Ambient Radiation Dose Rate.

- (a) A licensee shall survey with a radiation detection survey instrument at the end of each day of use all areas where radiopharmaceuticals are routinely prepared for use or administered.
- (b) A licensee shall survey with a radiation detection survey instrument at least once each week all areas where radiopharmaceuticals or radioactive wastes are stored.
- (c) A licensee shall conduct the surveys required by 420-3-26-.07(28)(a) and (b) so as to be able to measure dose rates as low as 0.1 mrem (1 μSv) per hour.
- (d) A licensee shall establish dose rate action levels for the surveys required by 420-3-26-.07(28)(a) and (b) and shall require that the individual performing the survey immediately notify the Radiation Safety Officer if a dose rate exceeds an action level.
- (e) A licensee shall survey for removable contamination each day of use all areas where radiopharmaceuticals are routinely prepared for use or administered and each week where radioactive materials are stored.
- (f) A licensee shall conduct the surveys required by 420-3-26-.07(28)(e) so as to be able

to detect contamination on each wipe sample of 2000 disintegrations per minute (33.3 Bq).

- (g) A licensee shall establish removable contamination action levels for the surveys required by 420-3-26-.07(28)(e) and shall require that the individual performing the survey notify the Radiation Safety Officer if contamination exceeds action levels.
- (h) A licensee shall retain a record of each survey required by 420-3-26-.07(28)(a), (b) and (e) for 5 years. The record must include;
  - 1. The date of the survey,
  - 2. A sketch of each area surveyed,
  - 3. Action levels established for each area,
  - The measured dose rate at several points in each area expressed in mrem (μSv) per hour or the removable contamination in each area expressed in disintegrations (Bq) per minute per 100 square centimeters,
  - 5. The serial number and the model number of the instrument used to make the survey or analyze the samples, and
  - 6. The initials of the individual who performed the survey.
  - 7. A record of contamination surveys required by 420-3-26-.07(28)(e) shall be made at least once a week.

## (29) Release of Patients Containing Radiopharmaceuticals or Permanent Implants.

- (a) A licensee shall not authorize release from confinement for medical care any patient administered a radiopharmaceutical until either:
  - 1. The dose rate from the patient is less than 5 mrem (50  $\mu$ Sv) per hour at a distance of 1 meter; or
  - 2. The activity in the patient is less than 30 mCi (1.11 GBg).
- (b) A licensee shall not authorize release from confinement for medical care any patient administered a permanent implant until the dose rate from the patient is less than 5 mrem (50 μSv) per hour at a distance of 1 meter.
- (c) Prior to the release from confinement for medical care any patient meeting the requirements of 420-3-26-.07(27)(a) or (b), the licensee shall provide verbal and

written instructions to the patient on how to maintain radiation exposures to family members and the general public as low as reasonably achievable (ALARA). In the case of permanent implant patients who may be released immediately after surgery, the instructions should be given to the patient prior to surgery.

# (30) Mobile Nuclear Medicine Service Technical Requirements.

A licensee providing mobile nuclear medicine service shall:

- (a) Transport to each address of use only syringes or vials containing prepared radiopharmaceuticals or radiopharmaceuticals that are intended for reconstitution of radiopharmaceutical kits;
- (b) Bring into each location of use all radioactive material to be used and, before leaving, remove all unused radioactive material and associated radioactive waste;
- (c) Secure or keep under constant surveillance and immediate control all radioactive material when in transit or at a location of use;
- (d) Check survey instruments and dose calibrators as required in 420-3-26-.07(19)(b)(1), 420-3-26-.07(19)(d), 420-3-26-.07(19)(e) and 420-3-26-.07(20)(d), and check all other transported equipment for proper function before medical use at each location of use;

(e) Carry a calibrated survey meter in each vehicle that is being used to transport radioactive material, and, before leaving a client location of use, survey all areas of radiopharmaceutical use with a radiation detection survey instrument to ensure that all radiopharmaceuticals and all associated radioactive waste have been removed; and

- (f) Retain a record of each survey required by 420-3-26-.07(30)(e) for 5 years. The record must include;
  - 1. The date of the survey,
  - 2. A plan of each area that was surveyed,
  - 3. The measured dose rate at several points in each area of use expressed in mrem  $(\mu Sv)$  per hour,
  - 4. The model and serial number of the instrument used to make the survey, and
  - 5. The initials of the individual who performed the survey.

#### Chapter 420-3-26

### (31) Storage of Volatiles and Gases.

- (a) A licensee shall store volatile radiopharmaceuticals and radioactive gases in the shipper's radiation shield and container.
- (b) A licensee shall store and use a multidose container in a properly functioning fume hood.

### (32) Decay-In-Storage.

- (a) A licensee shall hold radioactive material for decay-in-storage before disposal in ordinary trash and is exempt from the requirements of 420-3-26-.03(33) of these rules if the licensee:
  - 1. Holds radioactive material for decay a minimum of 10 half-lives;
  - 2. Monitors radioactive material at the container surface before disposal as ordinary trash and determines that its radioactivity cannot be distinguished from the background radiation level with a radiation detection survey instrument set on its most sensitive scale and with no interposed shielding;
  - 3. Removes or obliterates all radiation labels; and
  - 4. Separates and monitors each generator column individually with all radiation shielding removed to ensure that its contents have decayed to background radiation level before disposal.
- (b) For radioactive material disposed in accordance with 420-3-26-.07(32)(a), the licensee shall retain a record of each disposal for 5 years. The record must include;
  - 1. The date of the disposal,
  - 2. The date on which the radioactive material was placed in storage,
  - 3. The model and serial number of the survey instrument used,
  - 4. The background dose rate,
  - 5. The radiation dose rate measured at the surface of each waste container, and
  - 6. The name of the individual who performed the disposal.

### Uptake, Dilution, and Excretion